NZ722405B2 - Compounds for treating patients with ros1 mutant cancer cells - Google Patents
Compounds for treating patients with ros1 mutant cancer cells Download PDFInfo
- Publication number
- NZ722405B2 NZ722405B2 NZ722405A NZ72240515A NZ722405B2 NZ 722405 B2 NZ722405 B2 NZ 722405B2 NZ 722405 A NZ722405 A NZ 722405A NZ 72240515 A NZ72240515 A NZ 72240515A NZ 722405 B2 NZ722405 B2 NZ 722405B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- indazolyl
- benzamide
- methyl
- piperazinyl
- cancer
- Prior art date
Links
- 101710027587 ROS1 Proteins 0.000 title claims abstract description 277
- 201000011510 cancer Diseases 0.000 title claims abstract description 178
- 150000001875 compounds Chemical class 0.000 title abstract description 202
- 102100002050 ROS1 Human genes 0.000 claims abstract description 291
- 101700054115 ROS1A Proteins 0.000 claims abstract description 275
- 101700043017 NTRK1 Proteins 0.000 claims abstract description 177
- 108060005033 NTRK2 Proteins 0.000 claims abstract description 151
- 150000003839 salts Chemical class 0.000 claims abstract description 92
- 239000011780 sodium chloride Substances 0.000 claims abstract description 91
- 102100016102 NTRK1 Human genes 0.000 claims abstract description 27
- 108010064892 trkC Receptor Proteins 0.000 claims abstract description 24
- 102100016106 NTRK2 Human genes 0.000 claims abstract description 23
- 102100016105 NTRK3 Human genes 0.000 claims abstract description 23
- 230000004077 genetic alteration Effects 0.000 claims abstract description 17
- 231100000118 genetic alteration Toxicity 0.000 claims abstract description 17
- -1 N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl) (tetrahydro-2H-pyranylamino) benzamide Chemical compound 0.000 claims description 611
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 58
- 201000002528 pancreatic cancer Diseases 0.000 claims description 58
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 42
- 201000011231 colorectal cancer Diseases 0.000 claims description 37
- 206010029260 Neuroblastoma Diseases 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 30
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 28
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 23
- 206010039491 Sarcoma Diseases 0.000 claims description 11
- 208000001602 Mammary Analogue Secretory Carcinoma Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 104
- 102000001253 Protein Kinases Human genes 0.000 abstract description 71
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract description 64
- 201000010099 disease Diseases 0.000 abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 28
- 108060006633 Protein Kinases Proteins 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 230000002074 deregulated Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 210000004027 cells Anatomy 0.000 description 157
- 108060005034 NTRK3 Proteins 0.000 description 123
- 108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 description 119
- 102000005906 Anaplastic Lymphoma Kinase Human genes 0.000 description 119
- 239000000203 mixture Substances 0.000 description 108
- 230000002401 inhibitory effect Effects 0.000 description 71
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 61
- 230000000051 modifying Effects 0.000 description 59
- 230000035772 mutation Effects 0.000 description 59
- 108091000081 Phosphotransferases Proteins 0.000 description 55
- 230000003827 upregulation Effects 0.000 description 50
- 230000003828 downregulation Effects 0.000 description 49
- 239000003112 inhibitor Substances 0.000 description 48
- 125000000623 heterocyclic group Chemical group 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 38
- 239000002246 antineoplastic agent Substances 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 30
- 125000003118 aryl group Chemical group 0.000 description 29
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 28
- 239000001257 hydrogen Substances 0.000 description 25
- 229910052739 hydrogen Inorganic materials 0.000 description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 23
- 108091006028 chimera Proteins 0.000 description 21
- 229910052736 halogen Inorganic materials 0.000 description 20
- 150000002367 halogens Chemical class 0.000 description 20
- 150000002431 hydrogen Chemical group 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 19
- 101700035808 TRK1 Proteins 0.000 description 18
- 239000002775 capsule Substances 0.000 description 18
- 101710019688 COR4 Proteins 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 229960004117 Capecitabine Drugs 0.000 description 14
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 14
- 239000003937 drug carrier Substances 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 13
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 13
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 description 13
- 108010025020 Nerve Growth Factor Proteins 0.000 description 13
- 229940053128 Nerve Growth Factor Drugs 0.000 description 13
- 102000015336 Nerve Growth Factor Human genes 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 230000019491 signal transduction Effects 0.000 description 13
- 230000001225 therapeutic Effects 0.000 description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 201000009030 carcinoma Diseases 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 12
- 125000004193 piperazinyl group Chemical group 0.000 description 12
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 11
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 11
- 239000004037 angiogenesis inhibitor Substances 0.000 description 11
- 125000005418 aryl aryl group Chemical group 0.000 description 11
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 230000036961 partial Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 10
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 10
- 238000009825 accumulation Methods 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 208000009956 Adenocarcinoma Diseases 0.000 description 9
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 9
- 206010027476 Metastasis Diseases 0.000 description 9
- 229920001850 Nucleic acid sequence Polymers 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 210000003169 Central Nervous System Anatomy 0.000 description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 8
- 208000005017 Glioblastoma Diseases 0.000 description 8
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 8
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- 206010025650 Malignant melanoma Diseases 0.000 description 8
- 101700079360 NTF4 Proteins 0.000 description 8
- 102100016138 NTF4 Human genes 0.000 description 8
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 239000006184 cosolvent Substances 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 229960003668 docetaxel Drugs 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 229960001796 sunitinib Drugs 0.000 description 8
- 101710027366 ACVRL1 Proteins 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- 208000001258 Hemangiosarcoma Diseases 0.000 description 7
- 101700009327 NTF3 Proteins 0.000 description 7
- 102100015697 NTF3 Human genes 0.000 description 7
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 7
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 7
- 206010025310 Other lymphomas Diseases 0.000 description 7
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000002730 additional Effects 0.000 description 7
- 201000003076 angiosarcoma Diseases 0.000 description 7
- 230000002354 daily Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 230000000670 limiting Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010003549 Asthenia Diseases 0.000 description 6
- 229940120638 Avastin Drugs 0.000 description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 6
- 108010005144 Bevacizumab Proteins 0.000 description 6
- 210000000988 Bone and Bones Anatomy 0.000 description 6
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 6
- 208000006168 Ewing Sarcoma Diseases 0.000 description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 6
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 6
- 101710041325 MAPKAPK2 Proteins 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 229940053867 Xeloda Drugs 0.000 description 6
- 231100000494 adverse effect Toxicity 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 229960000397 bevacizumab Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 229960002411 imatinib Drugs 0.000 description 6
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001603 reducing Effects 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 229960003787 sorafenib Drugs 0.000 description 6
- 230000004083 survival Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 5
- UUSZLLQJYRSZIS-LXNNNBEUSA-N Aplidine Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 5
- 229940120655 Eloxatin Drugs 0.000 description 5
- 229960001433 Erlotinib Drugs 0.000 description 5
- 229960002949 Fluorouracil Drugs 0.000 description 5
- 101700040665 IGF Proteins 0.000 description 5
- 102100014231 IGF1 Human genes 0.000 description 5
- 101700074337 IGF1 Proteins 0.000 description 5
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010061289 Metastatic neoplasm Diseases 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 229960001592 Paclitaxel Drugs 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 210000002307 Prostate Anatomy 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 229940034785 Sutent Drugs 0.000 description 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 5
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 230000002209 hydrophobic Effects 0.000 description 5
- 201000003803 inflammatory myofibroblastic tumor Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229960004768 irinotecan Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960004891 lapatinib Drugs 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000009251 multiple myeloma Diseases 0.000 description 5
- 150000002829 nitrogen Chemical group 0.000 description 5
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 5
- 229960001756 oxaliplatin Drugs 0.000 description 5
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 5
- 239000000546 pharmaceutic aid Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000002062 proliferating Effects 0.000 description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- 230000002459 sustained Effects 0.000 description 5
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 4
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 101700006234 AKT1 Proteins 0.000 description 4
- 102100010552 AURKA Human genes 0.000 description 4
- 101700007619 AURKA Proteins 0.000 description 4
- 206010000599 Acromegaly Diseases 0.000 description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 101700052211 BDNF Proteins 0.000 description 4
- 102100015985 BDNF Human genes 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 4
- 229940088954 Camptosar Drugs 0.000 description 4
- 108010022830 Cetuximab Proteins 0.000 description 4
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- 229940080856 Gleevec Drugs 0.000 description 4
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 4
- 229940084651 Iressa Drugs 0.000 description 4
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 101700067074 MAPK Proteins 0.000 description 4
- 208000000172 Medulloblastoma Diseases 0.000 description 4
- 206010027191 Meningioma Diseases 0.000 description 4
- 210000000214 Mouth Anatomy 0.000 description 4
- 102100020079 NPM1 Human genes 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 108010008267 Nerve Growth Factors Proteins 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004063 Propylene glycol Drugs 0.000 description 4
- 206010038932 Retinopathy Diseases 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 229960001603 Tamoxifen Drugs 0.000 description 4
- 229940063683 Taxotere Drugs 0.000 description 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 4
- 229960003433 Thalidomide Drugs 0.000 description 4
- 210000001685 Thyroid Gland Anatomy 0.000 description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 4
- 229950000578 Vatalanib Drugs 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 229960000928 clofarabine Drugs 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 229960000255 exemestane Drugs 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- 125000005842 heteroatoms Chemical group 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010025568 nucleophosmin Proteins 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 229960005079 pemetrexed Drugs 0.000 description 4
- 108010049948 plitidepsin Proteins 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 201000004681 psoriasis Diseases 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000000582 retinoblastoma Diseases 0.000 description 4
- 101710024887 rl Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 101700045897 spk-1 Proteins 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229930003347 taxol Natural products 0.000 description 4
- 229960000235 temsirolimus Drugs 0.000 description 4
- 229960000303 topotecan Drugs 0.000 description 4
- 210000004881 tumor cells Anatomy 0.000 description 4
- 229960000241 vandetanib Drugs 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- QXRSDHAAWVKZLJ-PVYNADRNSA-N (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 3
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1R,2R)-1,2-dimethanidylcyclohexane;5-fluoro-1H-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 3
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1V8X590XDP Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 3
- OUAGJGIFBVGMSU-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=CC=C1C(N)=O OUAGJGIFBVGMSU-UHFFFAOYSA-N 0.000 description 3
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 3
- 229940110282 Alimta Drugs 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 229960004562 Carboplatin Drugs 0.000 description 3
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 3
- 101700025368 ERBB2 Proteins 0.000 description 3
- 229950001287 Edotecarin Drugs 0.000 description 3
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 229940082789 Erbitux Drugs 0.000 description 3
- 101710009074 FLT3 Proteins 0.000 description 3
- 102100004573 FLT3 Human genes 0.000 description 3
- 206010016629 Fibroma Diseases 0.000 description 3
- 206010017758 Gastric cancer Diseases 0.000 description 3
- 229940020967 Gemzar Drugs 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 229960002913 Goserelin Drugs 0.000 description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 3
- 208000002125 Hemangioendothelioma Diseases 0.000 description 3
- 206010020718 Hyperplasia Diseases 0.000 description 3
- 102100014263 IGF1R Human genes 0.000 description 3
- 101700025802 IGF1R Proteins 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- 206010024190 Leiomyosarcomas Diseases 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 208000009856 Lung Disease Diseases 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 229960004857 Mitomycin Drugs 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 102100018369 NF1 Human genes 0.000 description 3
- 101700072759 NF1 Proteins 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 description 3
- 208000009905 Neurofibromatosis Diseases 0.000 description 3
- 229940080607 Nexavar Drugs 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 108010061219 Panitumumab Proteins 0.000 description 3
- 206010033775 Paraesthesia Diseases 0.000 description 3
- 229950006299 Pelitinib Drugs 0.000 description 3
- 229940068968 Polysorbate 80 Drugs 0.000 description 3
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 3
- 101700007719 RAF1 Proteins 0.000 description 3
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 229940120982 Tarceva Drugs 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 208000001608 Teratocarcinoma Diseases 0.000 description 3
- 229940058865 Vectibix Drugs 0.000 description 3
- 229960003048 Vinblastine Drugs 0.000 description 3
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 3
- 229960002184 abarelix Drugs 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 230000001174 ascending Effects 0.000 description 3
- 201000001320 atherosclerosis Diseases 0.000 description 3
- 229960003005 axitinib Drugs 0.000 description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960001467 bortezomib Drugs 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 229960003603 decitabine Drugs 0.000 description 3
- 201000008286 diarrhea Diseases 0.000 description 3
- 235000019564 dysgeusia Nutrition 0.000 description 3
- 230000029578 entry into host Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 201000008808 fibrosarcoma Diseases 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 230000002452 interceptive Effects 0.000 description 3
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000001394 metastastic Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 201000004931 neurofibromatosis Diseases 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000002246 oncogenic Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrugs Drugs 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 3
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 200000000008 restenosis Diseases 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- 201000010208 seminoma Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 3
- 108010064884 trkA Receptor Proteins 0.000 description 3
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 3
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 2
- NECZZOFFLFZNHL-XVGZVFJZSA-N (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 description 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 2
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4aS,5aR,12aR)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
- NFIXBCVWIPOYCD-UHFFFAOYSA-N 2-(4-benzylphenoxy)-N,N-diethylethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 2
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-Methoxyestradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- SETFNECMODOHTO-UHFFFAOYSA-N 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 2
- QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 2
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- HZXSQIHZPVCLDJ-LMOVPXPDSA-N 5-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]pentoxy-methylphosphinic acid;sodium Chemical compound [Na].COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCOP(C)(O)=O HZXSQIHZPVCLDJ-LMOVPXPDSA-N 0.000 description 2
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 2
- 108060006693 ABL Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 2
- 101700037792 AURKB Proteins 0.000 description 2
- 102100010553 AURKB Human genes 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 210000004100 Adrenal Glands Anatomy 0.000 description 2
- 206010064930 Age-related macular degeneration Diseases 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 108060006672 BUB1 Proteins 0.000 description 2
- 229960000190 Bacillus Calmette–Guérin vaccine Drugs 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 108060006674 CDC7 Proteins 0.000 description 2
- 101710015564 CHEK1 Proteins 0.000 description 2
- 108060006647 CHEK2 Proteins 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 201000003884 Chagas disease Diseases 0.000 description 2
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 206010073251 Clear cell renal cell carcinoma Diseases 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 102000016736 Cyclins Human genes 0.000 description 2
- 108050006400 Cyclins Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 101700005454 DDR2 Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- 229960000605 Dexrazoxane Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- BNFRJXLZYUTIII-UHFFFAOYSA-N Efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 2
- AXRCEOKUDYDWLF-UHFFFAOYSA-N Enzastaurin Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 2
- 229950002189 Enzastaurin Drugs 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
- MVGSNCBCUWPVDA-MFOYZWKCSA-N Exisulind Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 2
- 229950011548 FADROZOLE Drugs 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- 206010018404 Glucagonoma Diseases 0.000 description 2
- 229940015001 Glycerin Drugs 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 206010058490 Hyperoxia Diseases 0.000 description 2
- 102100015972 IL2 Human genes 0.000 description 2
- 101700083088 ILK Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 2
- 229950003909 Iguratimod Drugs 0.000 description 2
- 229950009881 Indisulam Drugs 0.000 description 2
- 229960000905 Indomethacin Drugs 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 206010022498 Insulinoma Diseases 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 101700016050 JAK2 Proteins 0.000 description 2
- 102100019516 JAK2 Human genes 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- 210000000088 Lip Anatomy 0.000 description 2
- 229940002661 Lipitor Drugs 0.000 description 2
- DHMTURDWPRKSOA-RUZDIDTESA-N Lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 101710027479 MAP2K1 Proteins 0.000 description 2
- 102100006473 MAP2K1 Human genes 0.000 description 2
- 101700028785 MEK1 Proteins 0.000 description 2
- 101700053443 MKK1 Proteins 0.000 description 2
- 101700052154 MPK1 Proteins 0.000 description 2
- 208000002780 Macular Degeneration Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229950010895 Midostaurin Drugs 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N Motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 2
- VAZLWPAHMORDGR-UHFFFAOYSA-L Motexafin gadolinium Chemical compound C1=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=C1[N]1=CC3=[N]4[Gd]11(N56)(OC(=O)C)(OC(=O)C)[N]2=CC(C(C)=C2CCCO)=[N]1C2=CC6=C(CC)C(CC)=C5C=C4C(CCCO)=C3C VAZLWPAHMORDGR-UHFFFAOYSA-L 0.000 description 2
- ZTFBIUXIQYRUNT-MDWZMJQESA-N Mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 2
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
- 229950007221 Nedaplatin Drugs 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 208000004296 Neuralgia Diseases 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 108009000578 Oxidative Stress Proteins 0.000 description 2
- 101700058955 PAK4 Proteins 0.000 description 2
- 102100008311 PAK4 Human genes 0.000 description 2
- 101700078689 PAK5 Proteins 0.000 description 2
- 102100008312 PAK5 Human genes 0.000 description 2
- 101700021228 PAK6 Proteins 0.000 description 2
- 101700036247 PARP1 Proteins 0.000 description 2
- 102100014579 PARP1 Human genes 0.000 description 2
- 108091007929 PDGF receptors Proteins 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- SZFPYBIJACMNJV-UHFFFAOYSA-N Perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 230000037289 Plasma half life Effects 0.000 description 2
- 230000037240 Plasma half-life Effects 0.000 description 2
- 229950008499 Plitidepsin Drugs 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 102100016115 RAF1 Human genes 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Resveratrol Natural products C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- VHXNKPBCCMUMSW-FQEVSTJZSA-N Rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 2
- 229950009213 Rubitecan Drugs 0.000 description 2
- 101710009384 SRC Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
- 229950000055 Seliciclib Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960001567 Sodium stibogluconate Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960000894 Sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 229950007967 Tesmilifene Drugs 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 108010010691 Trastuzumab Proteins 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 229960004824 Triptorelin Drugs 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229940035504 Tromethamine Drugs 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 210000004291 Uterus Anatomy 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 101700009925 WNK1 Proteins 0.000 description 2
- 208000008383 Wilms Tumor Diseases 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 108010023617 abarelix Proteins 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 229960005339 acitretin Drugs 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001833 anti-estrogenic Effects 0.000 description 2
- 230000003388 anti-hormone Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- JUPMBRMEHSUGLE-UHFFFAOYSA-N butenyl Chemical compound CCC=[CH] JUPMBRMEHSUGLE-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 230000002759 chromosomal Effects 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 229930013349 epothilone B Natural products 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 229960004945 etoricoxib Drugs 0.000 description 2
- 229950000484 exisulind Drugs 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 230000003176 fibrotic Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000003054 hormonal Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 230000000222 hyperoxic Effects 0.000 description 2
- 230000001969 hypertrophic Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000005969 isothiazolinyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 125000003971 isoxazolinyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 230000000626 neurodegenerative Effects 0.000 description 2
- 201000004404 neurofibroma Diseases 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229960000435 oblimersen Drugs 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000000790 osteoblast Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229960004662 parecoxib Drugs 0.000 description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
- 108010042024 pertuzumab Proteins 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 101710039033 pkbA Proteins 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- HUCXKZBETONXFO-AJDZVAQLSA-N teprenone Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)=CCCC(C)=O HUCXKZBETONXFO-AJDZVAQLSA-N 0.000 description 2
- 229950006156 teprenone Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
- 229960000977 trabectedin Drugs 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 102000015533 trkA Receptor Human genes 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000005969 uveal melanoma Diseases 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000004066 vascular targeting agent Substances 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 201000006083 xeroderma pigmentosum Diseases 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- QXOPTIPQEVJERB-JQWIXIFHSA-N (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C1=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)SC(CC[C@H]2CC=3C(=O)N=C(N)NC=3NC2)=C1C QXOPTIPQEVJERB-JQWIXIFHSA-N 0.000 description 1
- OJLHWPALWODJPQ-QNWVGRARSA-N (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- GTXSRFUZSLTDFX-HRCADAONSA-N (2S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- OLCWFLWEHWLBTO-HSZRJFAPSA-N (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 description 1
- MAVDNGWEBZTACC-HNNXBMFYSA-N (3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C1=CC=C(OCC#CCO)C=C1 MAVDNGWEBZTACC-HNNXBMFYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VVKMHTWFAUCCOD-UHFFFAOYSA-N 1-(3-aminopropyl)-8-[3-[2-(dimethylamino)-2-oxoethyl]anilino]-N-[(2-methylpyridin-4-yl)methyl]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide Chemical group CN(C)C(=O)CC1=CC=CC(NC=2N=C3C=4N(CCCN)N=C(C=4CCC3=CN=2)C(=O)NCC=2C=C(C)N=CC=2)=C1 VVKMHTWFAUCCOD-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- KUFRQPKVAWMTJO-LMZWQJSESA-N 17-Dimethylaminoethylamino-17-demethoxygeldanamycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- NKZTZAQIKKGTDB-QPLCGJKRSA-N 2-[2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethoxy]ethanol Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 1
- PJKVJJYMWOCLIJ-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1H-quinazolin-4-one;hydron;dichloride Chemical compound Cl.Cl.CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 PJKVJJYMWOCLIJ-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M 2-chloroethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- ZUDXUNPSRMREOJ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2H-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C(COC1=CC(O)=CC=C11)=C1CC(C=C1)=CC=C1OCCN1CCCCC1 ZUDXUNPSRMREOJ-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-Aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2R,3R,4S,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
- STWODXDTKGTVCJ-UHFFFAOYSA-N 4-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1C1CCNCC1 STWODXDTKGTVCJ-UHFFFAOYSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-Methylenetetrahydrofolate Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N 5-chloro-4-hydroxy-1H-pyridin-2-one Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- NKGPJODWTZCHGF-KQYNXXCUSA-N 6-Thioinosinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(S)=C2N=C1 NKGPJODWTZCHGF-KQYNXXCUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-Hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 229950004810 ATAMESTANE Drugs 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000002718 Adenomatoid Tumor Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229940034653 Advicor Drugs 0.000 description 1
- 229950003105 Afimoxifene Drugs 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N Afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940060515 Aleve Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229950010817 Alvocidib Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N Amonafide Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 1
- 229960004701 Amonafide Drugs 0.000 description 1
- 229920002287 Amplicon Polymers 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N Annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 229950002465 Apaziquone Drugs 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 229950002842 Apratastat Drugs 0.000 description 1
- 229940087620 Aromasin Drugs 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N Arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 Arzoxifene Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N BBR-2778 Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229950001429 Batabulin Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N Bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N Belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 Belotecan Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940110331 Bextra Drugs 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N Bicalutamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 description 1
- RXOVOXFAAGIKDQ-UHFFFAOYSA-N Brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
- 229950004271 Brostallicin Drugs 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- 229940022418 Caduet Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 206010058019 Cancer pain Diseases 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- 229950002826 Canertinib Drugs 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N Canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 229950000772 Canfosfamide Drugs 0.000 description 1
- 229950007296 Cantuzumab mertansine Drugs 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 229940047495 Celebrex Drugs 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N Cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229940103380 Clolar Drugs 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229940066901 Crestor Drugs 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N Cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N DHA-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000003350 DNA copy number gain Effects 0.000 description 1
- 229940059359 Dacogen Drugs 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 229940070230 Daypro Drugs 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N Deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- LFQCJSBXBZRMTN-OAQYLSRUSA-N Diflomotecan Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC(F)=C(F)C=C3N=C21 LFQCJSBXBZRMTN-OAQYLSRUSA-N 0.000 description 1
- 229940072701 Dolobid Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N Dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000005135 EC 1.3.3.4 Human genes 0.000 description 1
- 108020001991 EC 1.3.3.4 Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 101700039191 EGFR Proteins 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 108091007936 ERK family Proteins 0.000 description 1
- 102100016692 ESR1 Human genes 0.000 description 1
- 101700054316 ETR1 Proteins 0.000 description 1
- 210000000959 Ear, Middle Anatomy 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000003372 Endocrine Glands Anatomy 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 229950011487 Enocitabine Drugs 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 229950009537 Epristeride Drugs 0.000 description 1
- 229950006835 Eptaplatin Drugs 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N Exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N FOLFIRI regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- 229940065410 Feldene Drugs 0.000 description 1
- 229940087476 Femara Drugs 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229950004684 Fispemifene Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960002258 Fulvestrant Drugs 0.000 description 1
- 229950011325 Galarubicin Drugs 0.000 description 1
- 210000003594 Ganglia, Spinal Anatomy 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 210000000260 Genitalia, Male Anatomy 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N Gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
- 229950009073 Gimatecan Drugs 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 229950011595 Glufosfamide Drugs 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N Halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 Halofuginone Drugs 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 208000006359 Hepatoblastoma Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- XJYNBZQTAZDMHZ-UHFFFAOYSA-N Imidacrine Chemical compound O.Cl.Cl.O=C1C2=CC(O)=CC=C2N2C=NC3=CC=C(NCCN(CC)CC)C1=C32 XJYNBZQTAZDMHZ-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229950004983 Incyclinide Drugs 0.000 description 1
- 229940089536 Indocin Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
- 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- 101710033922 KRAS Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 210000001117 Keloid Anatomy 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 108010044023 Ki-1 Antigen Proteins 0.000 description 1
- 210000000244 Kidney Pelvis Anatomy 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N Lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229940095570 Lescol Drugs 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 206010024627 Liposarcoma Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229940063718 Lodine Drugs 0.000 description 1
- 229950001750 Lonafarnib Drugs 0.000 description 1
- 229940076783 Lucentis Drugs 0.000 description 1
- 229940087857 Lupron Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700043292 MECR Proteins 0.000 description 1
- 102100014728 MECR Human genes 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 229940092110 Macugen Drugs 0.000 description 1
- 229950000547 Mafosfamide Drugs 0.000 description 1
- PBUUPFTVAPUWDE-HSLMEMBISA-N Mafosfamide Chemical compound OS(=O)(=O)CCS[C@@H]1CCOP(=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-HSLMEMBISA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229950001869 Mapatumumab Drugs 0.000 description 1
- 229950008001 Matuzumab Drugs 0.000 description 1
- 230000036676 Maximum tolerable dose Effects 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 210000001370 Mediastinum Anatomy 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229940090004 Megace Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000002418 Meninges Anatomy 0.000 description 1
- 206010070665 Mesoblastic nephroma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027459 Metastases to lymph node Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229940099246 Mevacor Drugs 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 229940072709 Motrin Drugs 0.000 description 1
- 239000005462 Mubritinib Substances 0.000 description 1
- 229950002212 Mubritinib Drugs 0.000 description 1
- 208000010492 Mucinous Cystadenocarcinoma Diseases 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 208000009091 Myxoma Diseases 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N N,N-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 1
- MAVDNGWEBZTACC-UHFFFAOYSA-N N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide Chemical compound ONC(=O)C1C(C)(C)SCCN1S(=O)(=O)C1=CC=C(OCC#CCO)C=C1 MAVDNGWEBZTACC-UHFFFAOYSA-N 0.000 description 1
- WDRDJIKPKBUQOY-UHFFFAOYSA-N N1N=C(C2=CC=CC=C12)[NH-] Chemical class N1N=C(C2=CC=CC=C12)[NH-] WDRDJIKPKBUQOY-UHFFFAOYSA-N 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 229940090008 Naprosyn Drugs 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 210000001989 Nasopharynx Anatomy 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229950010159 Nemorubicin Drugs 0.000 description 1
- 208000010021 Nerve Compression Syndromes Diseases 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 229940063708 Neutrexin Drugs 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 229940099637 Nilandron Drugs 0.000 description 1
- 229950010203 Nimotuzumab Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N Nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N Nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 Nolatrexed Drugs 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N Ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
- 229940099216 Oncaspar Drugs 0.000 description 1
- 241001644482 Onyx Species 0.000 description 1
- XZEUAXYWNKYKPL-URLMMPGGSA-N Ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 229950001094 Ortataxel Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N Ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N Osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 Osaterone Drugs 0.000 description 1
- LUMKNAVTFCDUIE-VHXPQNKSSA-N Ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000003388 Osteoid Osteoma Diseases 0.000 description 1
- 208000008798 Osteoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 210000003101 Oviducts Anatomy 0.000 description 1
- LXCWYTUKZXZSAJ-AUHBJGJSSA-N PCK 3145 Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 LXCWYTUKZXZSAJ-AUHBJGJSSA-N 0.000 description 1
- 102100004939 PDGFRB Human genes 0.000 description 1
- 101710018346 PDGFRB Proteins 0.000 description 1
- 229940099511 POLYSORBATE 65 Drugs 0.000 description 1
- 101710040930 PTGS2 Proteins 0.000 description 1
- 102100015381 PTGS2 Human genes 0.000 description 1
- 201000001146 Paget's disease of bone Diseases 0.000 description 1
- 210000003254 Palate Anatomy 0.000 description 1
- 210000002741 Palatine Tonsil Anatomy 0.000 description 1
- 229960004390 Palbociclib Drugs 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 210000003681 Parotid Gland Anatomy 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229950003819 Pelitrexol Drugs 0.000 description 1
- 210000003899 Penis Anatomy 0.000 description 1
- 229950010632 Perifosine Drugs 0.000 description 1
- 210000004303 Peritoneum Anatomy 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 229960004403 Pixantrone Drugs 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 210000004224 Pleura Anatomy 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229940089484 Pravachol Drugs 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- YSQDQEOIFWWVHA-UHFFFAOYSA-A ProMune Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 YSQDQEOIFWWVHA-UHFFFAOYSA-A 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 210000003065 Pyriform Sinus Anatomy 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 101700016196 RNP30 Proteins 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 229950007649 Ranpirnase Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N Rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 229950005950 Rebimastat Drugs 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 229940087462 Relafen Drugs 0.000 description 1
- 210000000574 Retroperitoneal Space Anatomy 0.000 description 1
- 229940120975 Revlimid Drugs 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 210000003079 Salivary Glands Anatomy 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 208000004548 Serous Cystadenocarcinoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig Cell Tumor Diseases 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- DZMVCVHATYROOS-ZBFGKEHZSA-N Soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 208000005250 Spontaneous Fracture Diseases 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 102100016327 TEK Human genes 0.000 description 1
- 101710037124 TEK Proteins 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229950003999 Tafluposide Drugs 0.000 description 1
- 229940099419 Targretin Drugs 0.000 description 1
- 229950004186 Telatinib Drugs 0.000 description 1
- 229940061353 Temodar Drugs 0.000 description 1
- 229940034915 Thalomid Drugs 0.000 description 1
- 108010091299 TheraCIM Proteins 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940019127 Toradol Drugs 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N Torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 Torcetrapib Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229940100411 Torisel Drugs 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 1
- 229940032510 Trelstar Drugs 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 229940094060 Tykerb Drugs 0.000 description 1
- AHXICHPPXIGCBN-GPWPDEGDSA-N UQC681JJIV Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 AHXICHPPXIGCBN-GPWPDEGDSA-N 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 102100015313 VIP Human genes 0.000 description 1
- 101700003320 VIP Proteins 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N Vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229940099039 Velcade Drugs 0.000 description 1
- 229940065658 Vidaza Drugs 0.000 description 1
- 208000009540 Villous Adenoma Diseases 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229940087652 Vioxx Drugs 0.000 description 1
- 208000009311 Vipoma Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940063674 Voltaren Drugs 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- 210000003905 Vulva Anatomy 0.000 description 1
- 229940100445 WHEAT STARCH Drugs 0.000 description 1
- RLQVKDVIBJCQGE-WDUCDQOOSA-N Win-25540 Chemical compound O=C1C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 RLQVKDVIBJCQGE-WDUCDQOOSA-N 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- ZPUHVPYXSITYDI-HEUWMMRCSA-N Xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Yamafur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 229940004212 Yondelis Drugs 0.000 description 1
- 101700069422 ZHX2 Proteins 0.000 description 1
- 229940099232 Zinecard Drugs 0.000 description 1
- 229940072168 Zocor Drugs 0.000 description 1
- 229940033942 Zoladex Drugs 0.000 description 1
- 229940061261 Zolinza Drugs 0.000 description 1
- 229940002005 Zometa Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N Zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 Zotarolimus Drugs 0.000 description 1
- GXJABQQUPOEUTA-NVXWUHKLSA-N [(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-NVXWUHKLSA-N 0.000 description 1
- RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2R,4aR,6R,7R,8S,8aR)-6-[[(5S,5aR,8aR,9R)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4R,5R)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(E)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 229940045988 antineoplastic drugs Protein kinase inhibitors Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 201000010781 bone remodeling disease Diseases 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 108010016799 cantuzumab mertansine Proteins 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 201000005262 chondroma Diseases 0.000 description 1
- 201000009047 chordoma Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 231100000466 common adverse event Toxicity 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000002559 cytogenic Effects 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 201000009051 embryonal carcinoma Diseases 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- ISJSHQTWOHGCMM-NDEPHWFRSA-N ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NS(=O)(=O)C=1C(=CC(=CC=1C(C)C)C(C)C)C(C)C)CC1=CC=CC(C(N)=N)=C1 ISJSHQTWOHGCMM-NDEPHWFRSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229940044168 geranylgeranylacetone Drugs 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 201000010915 glioblastoma multiforme Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101710030209 lin-45 Proteins 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 108010021856 mapatumumab Proteins 0.000 description 1
- 108010029633 matuzumab Proteins 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229930014694 morphine Natural products 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 101700077936 ncsA Proteins 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108010043585 nimotuzumab Proteins 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- YVPOTNAPPSUMJX-UHFFFAOYSA-N octadecanoic acid;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCCCC(O)=O YVPOTNAPPSUMJX-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000010133 oligodendroglioma Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229960003327 ormeloxifene Drugs 0.000 description 1
- 229960003969 ospemifene Drugs 0.000 description 1
- 230000000010 osteolytic Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010048400 p80(NPM-ALK) protein Proteins 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 230000004977 physiological function Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 200000000025 progressive disease Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000003197 protein kinase b inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 201000001722 pulmonary large cell neuroendocrine carcinoma Diseases 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000026749 regulation of bone remodeling Effects 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 210000004176 reticulum cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000001483 serenoa repens Nutrition 0.000 description 1
- 231100000247 serious adverse effect Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 201000001839 skull cancer Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 200000000009 stenosis Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- QQILXENAYPUNEA-UHFFFAOYSA-M tolmetin sodium dihydrate Chemical compound O.O.[Na+].C1=CC(C)=CC=C1C(=O)C1=CC=C(CC([O-])=O)N1C QQILXENAYPUNEA-UHFFFAOYSA-M 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. Specifically, the treatment of cancer in a patient known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3. ds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. Specifically, the treatment of cancer in a patient known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3.
Description
COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Nos.
61/942287, filed on February 20, 2014; 62/052994, filed on September 19, 2014; 62/055450, filed
on September 25, 2014; 62/069999, filed on October 29, 2014; each of which are incorporated
herein by reference in their entirety; including any drawings.
PARTIES OF JOINT RESEARCH AGREEMENT
The compositions and methods disclosed herein are subject to a joint research
agreement between Ignyta, Inc. and Nerviano Medical Sciences s.r.l., executed October 10, 2013.
FIELD OF THE INVENTION
The present invention relates to certain substituted indazole compounds, which
modulate the activity of protein kinases. The compounds of this invention are therefore useful in
treating diseases caused by deregulated protein kinase activity. The present invention also provides
methods for preparing these compounds, pharmaceutical compositions comprising these
compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising
these compounds.
BACKGROUND OF THE INVENTION
The malfunctioning of protein kinases (PKs) is the hallmark of numerous
diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers encode for
PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases, such as
benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis,
vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis
glomerulonephritis and post-surgical stenosis and restenosis.
PKs are also implicated in inflammatory conditions and in the multiplication of
viruses and parasites. PKs may also play a major role in the pathogenesis and development of
neurodegenerative disorders.
For a general reference to PKs malfunctioning or deregulation see, for instance,
Current Opinion in Chemical Biology 1999, 3:459-465.
A subset of PK is a group of membrane receptors with intrinsic protein-tyrosine
kinase activity (RPTK). Upon binding of grow factors, RPTKs become activated and phosphorylate
17426518_1 (GHMatters) P41939NZ00
themselves and a series of substrates in the cytoplasm. Through this mechanism, they can transduce
intracellular signalings for proliferation, differentiation or other biological changes. Structural
abnormalities, over-expression and activation of RTPKs are frequently observed in human tumors,
suggesting that constitutive ignition of the signal transduction leading to cell proliferation can result
in malignant transformation. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor
belonging to the insulin receptor subfamily of RTKs: the ALK gene is located on chromosome 2 and
is expressed mainly in neuronal cells, especially during development. The ALK gene is involved in a
balanced chromosomal translocation with the Nucleophosmin (NPM) gene on chromosome 5 in a
large subset of Anaplastic Large Cell Lymphomas (ALCL). In the ALK+ ALCL, as a result of the
translocation, the NPM ubiquitous promoter drives an ectopic expression of the fusion protein in
which the NPM moiety dimerizes and the ALK kinase domain undergoes auto-phosphorylation and
becomes constitutively active.
Many data from the literature have demonstrated that the NPM-ALK fusion
protein has a strong oncogenic potential and its ectopic expression is responsible for cellular
transformation. Moreover, the constitutive expression of human NPM-ALK in mouse T-cell
lymphocytes is sufficient for the development of lymphoid neoplasia in transgenic animals with a
short period of latency.
ALCL is a defined disease characterized by the surface expression of the CD30
antigen (Ki-1), and accounts for 2% of adult and 13% of pediatric non-Hodgkin's lymphomas,
affecting predominantly young male patients. ALK+ ALCL accounts for 70% of all ALCLs and is an
aggressive disease with systemic signs, and frequent extranodal involvement (bone marrow, skin,
bone, soft tissues).
About 15-20% of ALK-expressing ALCLs were found to bear a different
chromosomal translocation, involving the cytoplasmic portion of ALK, with different N-terminal
moieties, all resulting in constitutive activation of the ALK kinase domain.
Moreover, cell lines established from solid tumors of ectodermal origin like
melanomas, breast carcinomas, as well as neuroblastomas, glioblastomas, Ewings sarcomas,
retinoblastomas, were found to express the ALK receptor.
ROS1 belongs to the insulin-receptor superfamily. Like other tyrosine kinase
receptor molecules, it plays a role in relaying growth signals from the environment outside the cell
into the cell’s nucleus. It is 1 of 2 orphan receptor tyrosine kinase family members with no known
17426518_1 (GHMatters) P41939NZ00
binding ligand. Genetic changes in ROS1, such as gene rearrangements, mutations, or copy number
increases, create oncogenes, which can lead to cancer (Stumpfova and Janne, 2012). ROS1 was
discovered in NSCLC patients in the form of a fusion protein (6 different partners for ROS1) and is
found in approximately 2% of patients with NSCLC (Bergethon et al., 2012; Davies et al, 2012).
Two other ROS1 gene rearrangements have been detected in a variety of other cancers, including
glioblastoma multiforme, cholangiocarcinoma, ovarian cancer, gastric adenocarcinoma, colorectal
cancer, inflammatory myofibroblastic tumor, angiosarcoma, and epitheloid hemangioendothelioma
(Lee et al., 2013; Davies and Doebele, 2013; Davies, et al., 2012; Shaw et al., 2013).
ROS1 gene rearrangements create fusion proteins with constitutively active
kinase domains that activate downstream signaling pathways leading to oncogenic properties in
cells, including uncontrolled proliferation and resistance to cell death with prolonged tumor cell
survival. These pathways include Ras-ERK for cellular proliferation and the JAK-STAT and
PI3K/AKT pathways, which regulate cell survival (anti-apoptosis) and proliferation. ROS1 fusion
proteins may also activate the mTOR pathway, which is critical for the regulation of protein
translation. Cancers that have these pathways activated tend to be more aggressive, with invasion
and metastasis leading to poor survival of the patients (Davies and Doebele, 2013).
Trk's are the high affinity receptor tyrosine kinases activated by a group of
soluble growth factors called neurotrophins (NT). The Trk receptor family has three members--
TrkA, TrkB and TrkC. Among the neurotrophins are (i) nerve growth factor (NGF) which activates
TrkA, (ii) brain-derived neurotrophic factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3
which activates TrkC. Trk's are widely expressed in neuronal tissue and are implicated in the
maintenance, signaling and survival of neuronal cells (Patapoutian, A. et al., Current Opinion in
Neurobiology, 2001, 11, 272-280). NTRK1 encodes the TrkA receptor tyrosine kinase. TrkA
activates the PI3K/AKT, PKC and ERK1/2 pathways which promote cell growth and survival.
Inhibitors of the Trk/neurotrophin pathway have been demonstrated to be
effective in numerous pre-clinical animal models of pain. For example, antagonistic NGF and TrkA
antibodies (for example, RN-624) have been shown to be efficacious in inflammatory and
neuropathic pain animal models and in human clinical trials (Woolf, C. J. et al. (1994)
Neuroscience 62, 327-331; Zahn, P. K. et al. (2004) J. Pain 5, 157-163; McMahon, S. B. et al.,
(1995) Nat. Med. 1, 774-780; Ma, Q. P. and Woolf, C. J. (1997) Neuroreport 8, 807-810; Shelton,
D. L. et al. (2005) Pain 116, 8-16; Delafoy, L. et al. (2003) Pain 105, 489-497; Lamb, K. et al.
17426518_1 (GHMatters) P41939NZ00
(2003) Neurogastroenterol. Motil. 15, 355-361; Jaggar, S. I. et al. (1999) Br. J. Anaesth. 83, 442-
448). Additionally, recent literature indicates after inflammation, BDNF levels and TrkB signaling
is increased in the dorsal root ganglion (Cho, L. et al. Brain Research 1997, 749, 358) and several
studies have show antibodies that decrease signaling through the BDNF/TrkB pathway inhibit
neuronal hypersensitization and the associated pain (Chang-Qi, L et al. Molecular Pain 2008, 4:27).
In addition, it has been shown that tumor cell sand tumor invading macrophages
directly stimulates TrkA located on peripheral pain fibers. Using various tumor models in both mice
and rats it was demonstrated that neutralizing NGF with a monoclonal antibody inhibits cancer
related pain to a degree similar or superior to the highest tolerated dose of morphine. In addition,
activation of the BDNF/TrkB pathway has been implicated in numerous studies as a modulator of
various types of pain including inflammatory pain (Matayoshi, S., J. Physiol. 2005, 569:685-95),
neuropathic pain (Thompson, S. W., Proc. Natl. Acad. Sci. USA 1999, 96:7714-18) and surgical
pain (Li, C.-Q. et al., Molecular Pain, 2008, 4(28), 1-11). Because TrkA and TrkB kinases may serve
as a mediator of NGF driven biological responses, inhibitors of TrkA and/or other Trk kinases may
provide an effective treatment for chronic pain states.
Recent literature has also shown that overexpression, activation, amplification
and/or mutation of Trk's are associated with many cancers including neuroblastoma (Brodeur, G.
M., Nat. Rev. Cancer 2003, 3, 203-216), ovarian cancer (Davidson. B., et al., Clin. Cancer Res.
2003, 9, 2248-2259), breast cancer (Kruettgen et al, Brain Pathology 2006, 16: 304-310), prostate
cancer (Dionne et al, Clin. Cancer Res. 1998, 4(8): 1887-1898), pancreatic cancer (Dang et al,
Journal of Gastroenterology and Hepatology 2006, 21(5): 850-858), multiple myeloma (Hu et al,
Cancer Genetics and Cytogenetics 2007, 178: 1-10), astrocytoma and medulloblastoma (Kruettgen
et al, Brain Pathology 2006, 16: 304-310) glioma (Hansen et al, Journal of Neurochemistry 2007,
103: 259-275), melanoma (Truzzi et al, Journal of Investigative Dermatology 2008, 128(8): 2031-
2040, thyroid carcinoma (Brzezianska et al, Neuroendocrinology Letters 2007, 28(3), 221-229.),
lung adenocarcinoma (Perez-Pinera et al, Molecular and Cellular Biochemistry 2007, 295(1&2), 19-
26), large cell neuroendocrine tumors (Marchetti et al, Human Mutation 2008, 29(5), 609-616), and
colorectal cancer (Bardelli, A., Science 2003, 300, 949). In preclinical models of cancer, Trk
inhibitors are efficacious in both inhibiting tumor growth and stopping tumor metastasis. In
particular, non-selective small molecule inhibitors of Trk A, B and C and Trk/Fc chimeras were
efficacious in both inhibiting tumor growth and stopping tumor metastasis (Nakagawara, A. (2001)
17426518_1 (GHMatters) P41939NZ00
Cancer Letters 169:107-114; Meyer, J. et al. (2007) Leukemia, 1-10; Pierottia, M. A. and Greco A.,
(2006) Cancer Letters 232:90-98; Eric Adriaenssens, E. et al. Cancer Res (2008) 68:(2) 346-351)
(Truzzi et al, Journal of Investigative Dermatology 2008, 128(8): 2031-2040. Therefore, an inhibitor
of the Trk family of kinases is expected to have utility in the treatment of cancer.
Various gene rearrangements of the Trk gene have been implicated in human
malignancies. For example, the MPRIP-NRTK1 and CD74-NRTK1 gene rearrangements have been
implicated in the development of non-small cell lung cancer. Gene rearrangements TPM3-NRTK1,
TGF-NTRK1 and TPR-NTRK1 have been implicated in the development of papillary thyroid
cancer. The TPM3-NTRK1 gene rearrangement has been implicated in the development of
colorectal cancer. NTRK1, NTRK2 or NTRK3 gene rearrangements have also been identified in
glioblastoma, AML and secretory breast cancer. In 2013, Vaishnavi et al. reported novel NTRK1
fusions in 3/91 pan-negative patients with lung adenocarcinoma using NGS and FISH (Vaishnavi et
al. Nat Med. 2013 Nov:19(11):1469-72).
In addition, inhibition of the neurotrophin/Trk pathway has been shown to be
effective in treatment of pre-clinical models of inflammatory diseases. For example, inhibition of
the neurotrophin/Trk pathway has been implicated in preclinical models of inflammatory lung
diseases including asthma (Freund-Michel, V; Frossard, N.; Pharmacology & Therapeutics (2008),
117(1), 52-76), interstitial cystitis (Hu Vivian Y; et. al. The Journal of Urology (2005), 173(3),
1016-21), inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Di Mola, F.
F, et. al., Gut (2000), 46(5), 670-678) and inflammatory skin diseases such as atopic dermatitis
(Dou, Y.-C.; et. al. Archives of Dermatological Research (2006), 298(1), 31-37), eczema and
psoriasis (Raychaudhuri, S. P.; et. al. Journal of Investigative Dermatology (2004), 122(3), 812-
819).
The neurotrophin/Trk pathway, particularly BDNF/TrkB, has also been
implicated in the etiology of neurodegenerative diseases including multiple sclerosis, Parkinson's
disease and Alzheimer's disease (Sohrabji, Farida; Lewis, Danielle K. Frontiers in
Neuroendocrinology (2006), 27(4), 404-414). Modulation of the neutrophin/Trk pathway may have
utility in treatment of these and related diseases.
The TrkA receptor is also thought to be critical to the disease process in the
infection of the parasitic infection of Typanosoma cruzi (Chagas disease) in human hosts (de Melo-
17426518_1 (GHMatters) P41939NZ00
Jorge, M. et al. Cell Host & Microbe (2007), 1(4), 251-261). Thus, TrkA inhibition my have utility
in treating Chagas disease and related protozoan infections.
Trk inhibitors may also find use in treating disease related to an imbalance of the
regulation of bone remodeling, such as osteoporosis, rheumatoid arthritis, and bone metastases.
Bone metastases are a frequent complication of cancer, occurring in up to 70 percent of patients
with advanced breast or prostate cancer (1) and in approximately 15 to 30 percent of patients with
carcinoma of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney. Osteolytic
metastases can cause severe pain, pathologic fractures, life-threatening hypercalcemia, spinal cord
compression, and other nerve-compression syndromes. For these reasons, bone metastasis is a
serious and costly complication of cancer. Therefore, agents that can induce apoptosis of
proliferating osteoblasts would be highly advantageous. Expression of TrkA and TrkC receptors has
been observed in the bone forming area in mouse models of bone fracture (K. Asaumi, et al., Bone
(2000) 26(6) 625-633). In addition, localization of NGF was observed in almost all bone forming
cells (K. Asaumi, et al.). Recently, it was demonstrated that a pan-Trk inhibitor inhibits the tyrosine
signaling activated by neurotrophins binding to all three of the Trk receptors in human hFOB
osteoblasts (J. Pinski, et al., (2002) 62, 986-989). These data support the rationale for the use of Trk
inhibitors for the treatment of bone remodeling diseases, such as bone metastases in cancer patients.
In conclusion, interfering with ALK or ROS1 signaling likely represents a
specific and effective way to block tumor cell proliferation in ALCL and possibly other indications.
The insulin-like growth factor 1 receptor (IGF-1R, IGF1R) is also a member of the insulin receptor
subfamily of RTKs.
In addition, interfering with TrkA, TrkB and/or TrkC signaling, or a combination
thereof, represents a specific and effective way to block tumor cell proliferation in various cancers,
including, but not limited to, non-small cell lung cancer, papillary thyroid cancer, neuroblastoma,
pancreatic cancer and colorectal cancer.
There exist several lines of evidence suggesting that IGF-1R signaling can
contribute to tumorigenesis, and that interfering with IGF-1R function represents a valid therapeutic
option in cancer. For an overview of IGFs and IGF-1R signaling, physiological function, and
detailed description of the evidence supporting involvement of this system in human cancer that is
summarized above, as well as in other pathologies, the reader is directed to the many reviews on the
subject and references contained therein, for example Baserga R. et al, Biochim Biophys Acta vol.
17426518_1 (GHMatters) P41939NZ00
1332, pages F105-F126, 1997; Khandwala H. M. et al, Endocr Rev vol. 21, pages 215-44, 2000; Le
Roith D. et al, Endocr Rev vol. 22, pages 53-74, 2001; Valentinis B. et al, Mol Pathol vol. 54, pages
133-7, 2001; Wang Y. et al, Curr Cancer Drug Targets vol. 2, pages 191-207, 2002; Laron, Z. J Clin
Endocrinol Metab vol. 89, pages 1031-1044, 2004; Hofmann F et al, Drug Discov Today vol. 10,
pages 1041-7, 2005.
SUMMARY OF THE INVENTION
3-Amino and 3-acylamino indazole derivatives for the treatment of
neurodegenerative diseases, cerebrovascular accidents, obesity, cardiovascular diseases and cancer
are disclosed in WO2006003276, WO2004022544 and WO 2003078403 in the name of Aventis
Pharma SA.
17426518_1 (GHMatters) P41939NZ00
Indazolylamide derivatives for the treatment of diabetes, neurodegenerative
conditions such as Alzheimer's disease and Parkinson's disease are disclosed in WO2003051847 in
the name of SmithKline Beecham P.L.C.
Indazole derivatives for the treatment of tumor disease, viral disease,
immunosuppression in transplantation, cystic fibrosis and diseases associated with angiogenesis are
disclosed in WO2008003396 in the name of Merck GMBH.
Despite these developments, there is still a need for more effective agents for the
treatment of such diseases.
We have now discovered that a series of indazoles are potent protein kinase
inhibitors and are thus useful in anticancer therapy.
Accordingly, the present invention attempts to provide a substituted indazole
compound represented by formula (I), or formula 2.(I).
[0031a] In accordance with one embodiment of the present invention, there is provided
use of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof, for preparing a
medicament for treating cancer in a patient, wherein said patient is known to possess at least one
genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3.
[0031b] In accordance with another embodiment of the present invention, there is
provided use of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof, for
preparing a medicament for treating sarcoma in a patient, wherein said patient is known to possess
at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and
NTRK3.
More particularly, the present invention attempts to provide a substituted
indazole compound represented by formula (I),
17426518_1 (GHMatters) P41939NZ00
wherein:•X is —CH2—, —CH(OH)—, —CH(OR′)— or —C(R′R″)—, wherein: ◦R′ is an
optionally further substituted straight or branched C1-C6 alkyl and R″ is hydrogen or an optionally
further substituted straight or branched C1-C6 alkyl; •Ar is aryl or heteroaryl optionally substituted
with one or more substituents independently selected from halogen, C2-C6 alkenyl, C2-C6 alkynyl,
cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10,
NHSO2R10, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an
17426518_1 (GHMatters) P41939NZ00
optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl
and heteroaryl, wherein: ◦R4 is hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, NR5R6, OR7, SR7,
R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched
C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl; R5 and R6 are independently
hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, R8R9N—C2-C6 alkyl, R8O—C2-C6 alkyl, an optionally
further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl or
heteroaryl, or R5 and R6, taken together with the nitrogen atom to which they are bonded, may form
an optionally substituted heterocyclyl group;
◦R7 is hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, COR4, SOR10, SO2R10, R8R9N—C2-C6
alkyl, R8O—C2-C6 alkyl, an optionally further substituted straight or branched C1-C6 alkyl, C3-C6
cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein R4 is as defined above;
◦R8 and R9 are independently hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, COR4, an
optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl
or heteroaryl, or R8 and R9, taken together with the nitrogen atom to which they are bonded, may
form an optionally substituted heterocyclyl group, wherein R4 is as defined above;
◦R10 is hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, NR5R6, OR7, R8R9N—C1-C6 alkyl,
R8O—C1-C6 alkyl, an optionally further substituted straight or branched C1-C6 alkyl, C3-C6
cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein R5, R6, R7, R8 and R9 are as defined above;
•R is an optionally substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl,
heterocyclyl, aryl or heteroaryl;
•R1, R2 and R3 are independently hydrogen, halogen, nitro, an optionally substituted straight
or branched C1-C6 alkyl, NR5R6, or OR7, wherein R5, R6 and R7 are as defined above; or isomers,
tautomers, prodrugs or pharmaceutically acceptable salt thereof.
Several indazole derivatives useful for the therapy of a variety of diseases such as
cancer, neurodegenerative, cardiovascular, metabolic and of the central nervous system, have been
disclosed in WO2007075847 in the name of Takeda Pharmaceutical, in WO2006003276,
WO2004062662, WO2004022544 and WO2003078403 all in the name of Aventis, in
WO2006080450 in the name of Kyowa Hakko Kogyo and in WO2006003276 in the name of
University of Connecticut.
17426518_1 (GHMatters) P41939NZ00
Despite these developments, there is still need for effective agents for said
diseases. The present inventors have now discovered that compounds of formula 2.(I), described
below, are kinase inhibitors and are thus useful in therapy as antitumor agents.
More particularly, a second object of the present invention is to provide a
substituted indazole compound represented by formula 2.(I),
Wherein Ar is aryl optionally substituted with one or more substituents independently
selected from halogen, alkenyl, alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7,
SR7, SOR10, SO2R10, NHSOR10, NHSO2R10, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an
optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl and
aryl, wherein:
R4 is hydrogen, alkenyl, alkynyl, NR5R6, OR7, SR7, R8R9N—C1-C6 alkyl, R8O—C1-C6
alkyl, an optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl,
heterocyclyl or aryl;
R5 and R6 are independently hydrogen, alkenyl, alkynyl, R8R9N—C2-C6 alkyl, R8O—C2-
C6 alkyl, an optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl,
heterocyclyl or aryl, or R5 and R6, taken together with the nitrogen atom to which they are bonded,
may form an optionally substituted heterocyclyl group;
17426518_1 (GHMatters) P41939NZ00
R7 is hydrogen, alkenyl, alkynyl, COR4, SOR10, SO2R10, R8R9N—C2-C6 alkyl, R8O—
C2-C6 alkyl, an optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl,
heterocyclyl or aryl, wherein R4 is as defined above;
R8 and R9 are independently hydrogen, alkenyl, alkynyl, COR4, an optionally further
substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl or aryl, or R8 and R9,
taken together with the nitrogen atom to which they are bonded, may form an optionally substituted
heterocyclyl group, wherein R4 is as defined above;
R10 is hydrogen, alkenyl, alkynyl, NR5R6, OR7, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl,
an optionally further substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl or
aryl, wherein R5, R6, R7, R8 and R9 are as defined above; R is an optionally further substituted
straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl or aryl; R1, R2 and R3 are
independently hydrogen, halogen, nitro, an optionally further substituted straight or branched C1-C6
alkyl, NR5R6 or OR7, wherein R5, R6 and R7 are as defined above; and pharmaceutically
acceptable salt thereof.
The present invention also provides a method for treating diseases caused by
and/or associated with deregulated protein kinase activity, particularly PLK family, protein kinase C
in different isoforms, Met, PAK-4, PAK-5, ZC-1, STLK-2, DDR-2, Aurora 1, Aurora 2, Bub-1,
Chk1, Chk2, HER2, raf1, MEK1, MAPK, EGF-R, PDGF-R, FGF-R, FLT3, JAK2, IGF-R, ALK,
PI3K, weel kinase, Src, Abl, Akt, MAPK, ILK, MK-2, IKK-2, Cdc7, Nek, Cdk/cyclin kinase family,
more particularly Aurora 2, IGF-1R and ALK activity, and ROS1 activity, and further more
particularly ALK activity and/or ROS1 activity, which comprises administering to a mammal in
need thereof an effective amount of a substituted indazole compound represented by formula (I) or
formula 2.(I) as defined above.
Some embodiments of the present invention are to treat a disease caused by
and/or associated with dysregulated protein kinase activity selected from the group consisting of
cancer and cell proliferative disorders.
Some embodiments of the present invention, are to treat specific types of cancer
including carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid
lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system,
melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, angiosarcoma,
glioblastoma, holangiocarcinoma, inflammatory myofibroblastic tumor, epitheloid
17426518_1 (GHMatters) P41939NZ00
hemangioendothelioma, astrocytoma, meningioma, angiosarcoma, epitheloid hemangiothelioma,
keratocanthomas, thyroid follicular cancer, Kaposi's sarcoma, and Pancreatic cancer.
Some embodiments of the present invention, are to treat specific types of cancer
such as, but not restricted to, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian
cancer, endometrial cancer, gastric cancer, clear cell renal cell carcinoma, invasive ductal
carcinoma (breast), uveal melanoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma,
Kaposi's sarcoma, Pancreatic cancer, and medulloblastoma.
Some embodiments of the present invention, are to treat ALK+ Anaplastic Large
Cell Lymphomas (ALCL) and possibly other indications in which the ALK activity might play a
role, like Neuroblastoma, Rhabdomyosarcoma, Glioblastoma, Inflammatory Myofibroblastic
Tumor, and some kind of Melanomas, Breast Carcinomas, Ewings sarcomas, Retinoblastomas and
Non Small Cell Lung Carcinomas (NSCLC).
Some embodiments of the present invention, are to treat, reduce the symptoms of,
ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address Pancreatic
cancer and possibly other indications in which a defect in the modulation of ROS1 activity, or
upregulation, misregulation or deletion thereof might play a role by administering a molecule of
Formula (I) as disclosed herein, such as N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazin
yl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide.
Some embodiments of the present invention, are to treat, reduce the symptoms of,
ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address Pancreatic
cancer and possibly other indications in which a defect in the modulation of ROS1 activity, or
upregulation, misregulation or deletion thereof might play a role by administering a molecule
disclosed in US 8,299,057, such as N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, which patent issued October
, 2012, the entirety of which is hereby incorporated by reference. Some embodiments of the
present invention, are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset
of, or otherwise pharmaceutically address Pancreatic cancer and possibly other indications in which
a defect in the modulation of ROS1 activity, or upregulation, misregulation or deletion thereof
might play a role by administering a molecule disclosed in US 8,114,865, such as N-[5-(3,5-
17426518_1 (GHMatters) P41939NZ00
difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-
piperazinyl) benzamide, which patent issued February 14, 2012, the entirety of which is hereby
incorporated by reference.
Some embodiments of the present invention, are to treat, reduce the symptoms of,
ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address Pancreatic
cancer and possibly other indications in which a defect in the modulation of ALK, ROS1, TrkA,
TrkB, or TrkC activity, or a combination thereof, or upregulation, misregulation or deletion thereof
might play a role by administering a molecule disclosed in US 8,299,057, such as N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide
or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide, which patent issued October 30, 2012, the entirety of which is hereby
incorporated by reference. Some embodiments of the present invention, are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ALK, ROS1,
TrkA, TrkB, or TrkC activity, or a combination thereof, or upregulation, misregulation or deletion
thereof might play a role by administering a molecule disclosed in US 8,114,865, such as N-[5-(3,5-
difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-
piperazinyl) benzamide, which patent issued February 14, 2012, the entirety of which is hereby
incorporated by reference.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazin-
1-yl)(tetrahydro-2H-pyranylamino) benzamide. In some embodiments, methods of the present
invention are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset of, or
otherwise pharmaceutically address Pancreatic cancer and possibly other indications in which a
defect in the modulation of ROS1 activity, or upregulation, misregulation or deletion thereof might
play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(piperazinyl)(tetrahydro-2H-pyranylamino) benzamide. In some embodiments, methods of
17426518_1 (GHMatters) P41939NZ00
the present invention are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the
onset of, or otherwise pharmaceutically address Pancreatic cancer and possibly other indications in
which a defect in the modulation of ROS1 activity, or upregulation, misregulation or deletion
thereof might play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ALK, ROS1,
TrkA, TrkB, or TrkC activity, or a combination thereof, or upregulation, misregulation or deletion
thereof might play a role by administering a molecule of US 8,299,057, issued October 30, 2012, the
entirety of which is hereby incorporated by reference. In some embodiments, methods of the
present invention are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset
of, or otherwise pharmaceutically address Pancreatic cancer and possibly other indications in which
a defect in the modulation of ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof,
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule of US 8,114,865, issued February 14, 2012, the entirety of which is hereby incorporated by
reference.
In some embodiments, methods of the present invention are treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1,
TrkA, TrkB, or TrkC activity, or a combination thereof, activity, or upregulation, misregulation or
deletion thereof might play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide. In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1,
TrkA, TrkB, or TrkC activity, or a combination thereof, activity, or upregulation, misregulation or
deletion thereof might play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide. In some
embodiments, methods of the present invention are to treat, reduce the symptoms of, ameliorate the
17426518_1 (GHMatters) P41939NZ00
symptoms of, delay the onset of, or otherwise pharmaceutically address Pancreatic cancer and
possibly other indications in which a defect in the modulation of ROS1, TrkA, TrkB, or TrkC
activity, or a combination thereof, activity, or upregulation, misregulation or deletion thereof might
play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer associated with a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion by identifying a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion in a cancer or precancerous pancreatic cell in an individual, and administering
to the individual a molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide. In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer associated with a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion by identifying a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion in a cancer or precancerous pancreatic cell in an individual, and administering
to the individual a molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)-
2-(tetrahydro-2H-pyranylamino) benzamide. In some embodiments, methods of the present
invention are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset of, or
otherwise pharmaceutically address Pancreatic cancer associated with a ROS1 down-regulation
defect, for example a null mutation such as a ROS1 deletion by identifying a ROS1 down-regulation
defect, for example a null mutation such as a ROS1 deletion in a cancer or precancerous pancreatic
cell in an individual, and administering to the individual a molecule which is N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer associated with a ALK, ROS1, TrkA, TrkB, or TrkC down-regulation defect, for
example a null mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion by identifying a ALK,
17426518_1 (GHMatters) P41939NZ00
ROS1, TrkA, TrkB, or TrkC down-regulation defect, for example a null mutation such as a ALK,
ROS1, TrkA, TrkB, or TrkC deletion in a cancer or precancerous pancreatic cell in an individual,
and administering to the individual a molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide
or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide.
In some embodiments identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous pancreatic cell in an individual comprises assaying for ROS1 activity in a cell extract
from a pancreatic cancerous or precancerous cell population. In some embodiments identifying a
ROS1 modulation defect such as an upregulation defect or a down-regulation defect, for example a
null mutation such as a ROS1 deletion or a ROS1 chimeric locus encoding a constitutively active
ROS1 kinase in a cancer or precancerous pancreatic cell in an individual comprises assaying for
ROS1 transcript accumulation in an RNA population from a pancreatic cancerous or precancerous
cell population. In some embodiments identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous pancreatic cell in an individual comprises determining the nucleic acid sequence such
as the genomic deoxyribonucleic acid sequence in a cell or cells or a cell population comprising a
cell or cells from a pancreatic cancerous or precancerous cell population.
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC
modulation defect such as an upregulation defect or a down-regulation defect, for example a null
mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or
TrkC chimeric locus encoding a constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a
cancer or precancerous pancreatic cell in an individual comprises assaying for ALK, ROS1, TrkA,
TrkB, or TrkC activity in a cell extract from a pancreatic cancerous or precancerous cell population.
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ALK, ROS1,
TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or TrkC chimeric locus encoding a
constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a cancer or precancerous
17426518_1 (GHMatters) P41939NZ00
pancreatic cell in an individual comprises assaying for ALK, ROS1, TrkA, TrkB, or TrkC transcript
accumulation in an RNA population from a pancreatic cancerous or precancerous cell population.
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ALK, ROS1,
TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or TrkC chimeric locus encoding a
constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a cancer or precancerous
pancreatic cell in an individual comprises determining the nucleic acid sequence such as the
genomic deoxyribonucleic acid sequence in a cell or cells or a cell population comprising a cell or
cells from a pancreatic cancerous or precancerous cell population.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ALK, ROS1,
TrkA, TrkB, or TrkC activity, or a combination thereof, or upregulation, misregulation or deletion
thereof might play a role by administering a molecule of US 8,299,057, issued October 30, 2012, the
entirety of which is hereby incorporated by reference. In some embodiments, methods of the
present invention are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset
of, or otherwise pharmaceutically address Pancreatic cancer and possibly other indications in which
a defect in the modulation of ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof,
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule of US 8,114,865, issued February 14, 2012, the entirety of which is hereby incorporated by
reference.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1,
TrkA, TrkB, or TrkC activity, or a combination thereof, activity, or upregulation, misregulation or
deletion thereof might play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide. In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1,
17426518_1 (GHMatters) P41939NZ00
TrkA, TrkB, or TrkC activity, or a combination thereof, activity, or upregulation, misregulation or
deletion thereof might play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide. In some
embodiments, methods of the present invention are to treat, reduce the symptoms of, ameliorate the
symptoms of, delay the onset of, or otherwise pharmaceutically address Pancreatic cancer and
possibly other indications in which a defect in the modulation of ROS1, TrkA, TrkB, or TrkC
activity, or a combination thereof, activity, or upregulation, misregulation or deletion thereof might
play a role by administering a molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer associated with a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion by identifying a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion in a cancer or precancerous pancreatic cell in an individual, and administering
to the individual a molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide. In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer associated with a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion by identifying a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion in a cancer or precancerous pancreatic cell in an individual, and administering
to the individual a molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)-
2-(tetrahydro-2H-pyranylamino) benzamide. In some embodiments, methods of the present
invention are to treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset of, or
otherwise pharmaceutically address Pancreatic cancer associated with a ROS1 down-regulation
defect, for example a null mutation such as a ROS1 deletion by identifying a ROS1 down-regulation
defect, for example a null mutation such as a ROS1 deletion in a cancer or precancerous pancreatic
cell in an individual, and administering to the individual a molecule which is N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide.
17426518_1 (GHMatters) P41939NZ00
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
Pancreatic cancer associated with a ALK, ROS1, TrkA, TrkB, or TrkC down-regulation defect, for
example a null mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion by identifying a ALK,
ROS1, TrkA, TrkB, or TrkC down-regulation defect, for example a null mutation such as a ALK,
ROS1, TrkA, TrkB, or TrkC deletion in a cancer or precancerous pancreatic cell in an individual,
and administering to the individual a molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide
or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide.
In some embodiments identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous pancreatic cell in an individual comprises assaying for ROS1 activity in a cell extract
from a pancreatic cancerous or precancerous cell population. In some embodiments identifying a
ROS1 modulation defect such as an upregulation defect or a down-regulation defect, for example a
null mutation such as a ROS1 deletion or a ROS1 chimeric locus encoding a constitutively active
ROS1 kinase in a cancer or precancerous pancreatic cell in an individual comprises assaying for
ROS1 transcript accumulation in an RNA population from a pancreatic cancerous or precancerous
cell population. In some embodiments identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous pancreatic cell in an individual comprises determining the nucleic acid sequence such
as the genomic deoxyribonucleic acid sequence in a cell or cells or a cell population comprising a
cell or cells from a pancreatic cancerous or precancerous cell population.
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC
modulation defect such as an upregulation defect or a down-regulation defect, for example a null
mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or
TrkC chimeric locus encoding a constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a
cancer or precancerous pancreatic cell in an individual comprises assaying for ALK, ROS1, TrkA,
TrkB, or TrkC activity in a cell extract from a pancreatic cancerous or precancerous cell population.
17426518_1 (GHMatters) P41939NZ00
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ALK, ROS1,
TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or TrkC chimeric locus encoding a
constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a cancer or precancerous
pancreatic cell in an individual comprises assaying for ALK, ROS1, TrkA, TrkB, or TrkC transcript
accumulation in an RNA population from a pancreatic cancerous or precancerous cell population.
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ALK, ROS1,
TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or TrkC chimeric locus encoding a
constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a cancer or precancerous
pancreatic cell in an individual comprises determining the nucleic acid sequence such as the
genomic deoxyribonucleic acid sequence in a cell or cells or a cell population comprising a cell or
cells from a pancreatic cancerous or precancerous cell population.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
a condition selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma,
pancreatic cancer and colorectal cancer and possibly other indications in which a defect in the
modulation of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, or upregulation,
misregulation or deletion thereof might play a role by administering a molecule of US 8,299,057,
issued October 30, 2012, the entirety of which is hereby incorporated by reference. In some
embodiments, methods of the present invention are to treat, reduce the symptoms of, ameliorate the
symptoms of, delay the onset of, or otherwise pharmaceutically address Pancreatic cancer and
possibly other indications in which a defect in the modulation of ROS1, TrkA, TrkB, or TrkC
activity, or a combination thereof, activity, or upregulation, misregulation or deletion thereof might
play a role by administering a molecule of US 8,114,865, issued February 14, 2012, the entirety of
which is hereby incorporated by reference.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
a condition selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma,
pancreatic cancer and colorectal cancer and possibly other indications in which a defect in the
modulation of ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, activity, or
17426518_1 (GHMatters) P41939NZ00
upregulation, misregulation or deletion thereof might play a role by administering a molecule which
is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide. In some embodiments, methods of the present invention are to
treat, reduce the symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise
pharmaceutically address a condition selected from non-small cell lung cancer, papillary thyroid
cancer, neuroblastoma, pancreatic cancer and colorectal cancer and possibly other indications in
which a defect in the modulation of ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof,
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide. In some embodiments, methods of the present invention are to treat,
reduce the symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise
pharmaceutically address a condition selected from non-small cell lung cancer, papillary thyroid
cancer, neuroblastoma, pancreatic cancer and colorectal cancer and possibly other indications in
which a defect in the modulation of ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof,
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
a condition selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma,
pancreatic cancer and colorectal cancer associated with a ROS1 down-regulation defect, for
example a null mutation such as a ROS1 deletion by identifying a ROS1 down-regulation defect, for
example a null mutation such as a ROS1 deletion in a cancer or precancerous cell in an individual,
and administering to the individual a molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide
or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide. In some embodiments, methods of the present invention are treat, reduce
the symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically
address a condition selected from non-small cell lung cancer, papillary thyroid cancer,
neuroblastoma, pancreatic cancer and colorectal cancer associated with a ROS1 down-regulation
17426518_1 (GHMatters) P41939NZ00
defect, for example a null mutation such as a ROS1 deletion by identifying a ROS1 down-regulation
defect, for example a null mutation such as a ROS1 deletion in a cancer or precancerous cell in an
individual, and administering to the individual a molecule which is N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide. In some
embodiments, methods of the present invention are to treat, reduce the symptoms of, ameliorate the
symptoms of, delay the onset of, or otherwise pharmaceutically address a condition selected from
non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and
colorectal cancer associated with a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion by identifying a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion in a cancer or precancerous cell in an individual, and administering to the
individual a molecule which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazin
yl)(tetrahydro-2H-pyranylamino) benzamide.
In some embodiments, methods of the present invention are to treat, reduce the
symptoms of, ameliorate the symptoms of, delay the onset of, or otherwise pharmaceutically address
a condition selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma,
pancreatic cancer and colorectal cancer associated with a ALK, ROS1, TrkA, TrkB, or TrkC down-
regulation defect, for example a null mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion
by identifying a ALK, ROS1, TrkA, TrkB, or TrkC down-regulation defect, for example a null
mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion in a cancer or precancerous cell in an
individual, and administering to the individual a molecule of Formula (I) as disclosed herein, such
as N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide.
In some embodiments identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous cell in an individual comprises assaying for ROS1 activity in a cell extract from a
pancreatic cancerous or precancerous cell population. In some embodiments identifying a ROS1
modulation defect such as an upregulation defect or a down-regulation defect, for example a null
mutation such as a ROS1 deletion or a ROS1 chimeric locus encoding a constitutively active ROS1
kinase in a cancer or precancerous cell in an individual comprises assaying for ROS1 transcript
17426518_1 (GHMatters) P41939NZ00
accumulation in an RNA population from a cancerous or precancerous cell population. In some
embodiments identifying a ROS1 modulation defect such as an upregulation defect or a down-
regulation defect, for example a null mutation such as a ROS1 deletion or a ROS1 chimeric locus
encoding a constitutively active ROS1 kinase in a cancer or precancerous cell in an individual
comprises determining the nucleic acid sequence such as the genomic deoxyribonucleic acid
sequence in a cell or cells or a cell population comprising a cell or cells from a pancreatic cancerous
or precancerous cell population.
In some embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC
modulation defect such as an upregulation defect or a down-regulation defect, for example a null
mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or
TrkC chimeric locus encoding a constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a
cancer or precancerous cell in an individual comprises assaying for ALK, ROS1, TrkA, TrkB, or
TrkC activity in a cell extract from a cancerous or precancerous cell population. In some
embodiments identifying a ALK, ROS1, TrkA, TrkB, or TrkC modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ALK, ROS1,
TrkA, TrkB, or TrkC deletion or a ALK, ROS1, TrkA, TrkB, or TrkC chimeric locus encoding a
constitutively active ALK, ROS1, TrkA, TrkB, or TrkC kinase in a cancer or precancerous cell in an
individual comprises assaying for ALK, ROS1, TrkA, TrkB, or TrkC transcript accumulation in an
RNA population from a cancerous or precancerous cell population. In some embodiments
identifying a ALK, ROS1, TrkA, TrkB, or TrkC modulation defect such as an upregulation defect or
a down-regulation defect, for example a null mutation such as a ALK, ROS1, TrkA, TrkB, or TrkC
deletion or a ALK, ROS1, TrkA, TrkB, or TrkC chimeric locus encoding a constitutively active
ALK, ROS1, TrkA, TrkB, or TrkC kinase in a cancer or precancerous cell in an individual
comprises determining the nucleic acid sequence such as the genomic deoxyribonucleic acid
sequence in a cell or cells or a cell population comprising a cell or cells from a cancerous or
precancerous cell population.
In some embodiments, methods of the present invention are to treat cell
proliferative disorders such as, but not restricted to, benign prostate hyperplasia, familial
adenomatosis polyposis, neuro-fibromatosis, psoriasis, atherosclerosis and conditions involving
vascular smooth muscle proliferation or neointimal formation such as restenosis following
angioplasty or surgery, pulmonary fibrosis, arthritis, glomerulonephritis, retinopathies including
17426518_1 (GHMatters) P41939NZ00
diabetic and neonatal retinopathies and age related macular degeneration, graft vessel disease, such
as can occur following vessel or organ transplantation, acromegaly and disorders secondary to
acromegaly as well as other hypertrophic conditions in which IGF/IGF-1R signaling is implicated,
such as fibrotic lung disease, pathologies related to chronic or acute oxidative stress or hyperoxia
induced tissue damage, and metabolic disorders in which elevated IGF levels or IGF-1R activity are
implicated, such as obesity.
In addition, the method of the present invention also provides tumor angiogenesis
and metastasis inhibition.
In some embodiments, the method of the present invention further comprises
subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in
combination with at least one cytostatic or cytotoxic agent. Moreover the invention provides a
method for inhibiting the activity ALK protein which comprises contacting the said protein with an
effective amount of a compound of formula (I) or formula 2.(I).
In some embodiments, methods of the present invention are for inhibiting at least
one of ALK, ROS1, TrkA, TrkB, or TrkC kinase activity, or a combination thereof, in a cell,
comprising contacting said cell with an effective amount of a compound disclosed herein. Some
embodiments provide methods of inhibiting at least one of ALK, ROS1, TrkA, TrkB, or TrkC
kinase activity, or a combination thereof, in a cell, comprising contacting said cell with an effective
amount of a compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide. Some embodiments provide
methods of inhibiting at least one of ALK, ROS1, TrkA, TrkB, or TrkC kinase activity, or a
combination thereof, in a cell, comprising contacting said cell with an effective amount of a
compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide. Some embodiments provide methods of inhibiting at least one of
ALK, ROS1, TrkA, TrkB, or TrkC kinase activity, or a combination thereof, in a cell, comprising
contacting said cell with an effective amount of a compound which is N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide.
The present invention also provides a pharmaceutical composition comprising
one or more compounds of formula (I) or formula 2.(I) or a pharmaceutically acceptable salt thereof
and a pharmaceutically acceptable excipient, carrier or diluent. Some embodiments provide a
17426518_1 (GHMatters) P41939NZ00
pharmaceutical composition comprising one or more compounds selected from N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide
and N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide or a pharmaceutically acceptable salt thereof and a pharmaceutically
acceptable excipient, carrier or diluent. Some embodiments provide a pharmaceutical composition
comprising N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide or a pharmaceutically acceptable salt thereof and a pharmaceutically
acceptable excipient, carrier or diluent. Some embodiments provide a pharmaceutical composition
comprising N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable excipient, carrier or diluent.
Some embodiments provide methods of inhibiting ALK, ROS1, TrkA, TrkB, or
TrkC activity, or a combination thereof, in a patient, comprising administering to said patient an
effective amount of a compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-
(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-
methyl-piperazinyl) benzamide or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of inhibiting ALK, ROS1, TrkA, TrkB, or
TrkC activity, or a combination thereof, in a patient, comprising administering to said patient an
effective amount of a compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazin-
1-yl)(tetrahydro-2H-pyranylamino) benzamide or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of inhibiting ALK, ROS1, TrkA, TrkB, or
TrkC activity, or a combination thereof, in a patient, comprising administering to said patient an
effective amount of a compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-
piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt
thereof.
Some embodiments provide methods of inhibiting ALK, ROS1, TrkA, TrkB, or
TrkC activity, or a combination thereof, in a patient, comprising administering to said patient an
effective amount of a compound which is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]
17426518_1 (GHMatters) P41939NZ00
((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide or a pharmaceutically
acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient in need
thereof, the method comprising inhibiting ALK, ROS1, TrkA, TrkB, or TrkC activity, or a
combination thereof, in said patient, by administering to said patient an effective amount of a
compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-
benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazin-
1-yl) benzamide or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient in need
thereof, the method comprising inhibiting ALK, ROS1, TrkA, TrkB, or TrkC activity, or a
combination thereof, in said patient, by administering to said patient an effective amount of a
compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient in need
thereof, the method comprising inhibiting ALK, ROS1, TrkA, TrkB, or TrkC activity, or a
combination thereof, in said patient, by administering to said patient an effective amount of a
compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient in need
thereof, the method comprising inhibiting ALK, ROS1, TrkA, TrkB, or TrkC activity, or a
combination thereof, in said patient, by administering to said patient an effective amount of a
compound which is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxy
methyl-ethylamino)(4-methyl-piperazinyl) benzamide or a pharmaceutically acceptable salt
thereof.
Some embodiments provide methods of treating non-small cell lung cancer,
papillary thyroid cancer, neuroblastoma, pancreatic cancer or colorectal cancer in a patient,
comprising administering to said patient an effective amount of a compound selected from N-[5-
(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
17426518_1 (GHMatters) P41939NZ00
2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)-
2-methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide or a pharmaceutically
acceptable salt thereof.
Some embodiments provide methods of treating tumors in a patient, said methods
comprising administering to the patient an effective amount of a compound selected from N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide,
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxy-
1-methyl-ethylamino)(4-methyl-piperazinyl) benzamide or a pharmaceutically acceptable salt
thereof.
Some embodiments provide methods wherein the tumors are caused by the
presence of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer
or colorectal cancer in the patient. Some embodiments provide methods wherein one or more of the
cells comprising the tumors in the patient test positive for the presence of a gene that expresses at
least one of ALK, ROS1, TrkA, TrkB, or TrkC kinase or one or more of the cells comprising the
tumors in said patient demonstrates at least one of ALK, ROS1, TrkA, TrkB, or TrkC kinase
activity.
Some embodiments provide methods wherein one or more of the cells
comprising the tumors in the patient test positive for at least one gene rearrangement comprising the
gene, or a fragment thereof, that expresses at least one of ALK, ROS1, TrkA, TrkB, or TrkC kinase.
Some embodiments provide such methods wherein the cells test positive for at least one of ROS1,
TrkA, TrkB, or TrkC kinases. Some embodiments provide methods wherein the cells test positive
for ROS1 kinase. Some embodiments provide methods wherein the cells test positive for at least
one of TrkA, TrkB and TrkC kinase. Some embodiments provide methods wherein the cells test
positive for TrkA kinase. Some embodiments provide methods wherein the cells test positive for
TrkB kinase. Some embodiments provide such methods wherein the cells test positive for TrkC
kinase.
Some embodiments provide methods of treating cancer in a patient, the method
comprising: (1) testing one or more cells comprising the tumors in the patient for the presence of at
least one of ALK, ROS1, TrkA, TrkB, or TrkC kinase; and (2) administering to the patient an
effective amount of a compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
17426518_1 (GHMatters) P41939NZ00
(piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-
(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-
methyl-piperazinyl) benzamide, or a pharmaceutically acceptable salt thereof, if said one or more
cells tests positive for at least one of ALK, ROS1, TrkA, TrkB, or TrkC kinase.
Some embodiments provide methods of treating cancer in a patient, the method
comprising: (1) testing one or more cells comprising the tumors in the patient for the presence of at
least one of ROS1, TrkA, TrkB, or TrkC kinase; and (2) administering to the patient an effective
amount of a compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)-
2-(tetrahydro-2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-
benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazin-
1-yl) benzamide, or a pharmaceutically acceptable salt thereof, if said one or more cells tests
positive for at least one of ROS1, TrkA, TrkB, or TrkC kinase.
Some embodiments provide methods wherein the patient is administered an
effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof. Some embodiments
provide methods wherein the patient is administered an effective amount of N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, or a pharmaceutically acceptable salt thereof. Some embodiments provide methods
wherein the patient is administered an effective amount of N-[5-(3,5-difluoro-benzenesulfonyl)-1H-
indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient, wherein one
or more cancerous cells in said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase,
the method comprising administering to the patient an effective amount of a compound selected
from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-yl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof. Some embodiments provide methods of treating cancer in
17426518_1 (GHMatters) P41939NZ00
a patient, wherein one or more cancerous cells in said patient express at least one of ROS1, TrkA,
TrkB, or TrkC kinase, the method comprising administering to the patient an effective amount of a
compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient, wherein one
or more cancerous cells in said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase,
the method comprising administering to the patient an effective amount of a compound which is N-
[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, or a pharmaceutically acceptable salt thereof. Some embodiments provide
methods of treating cancer in a patient, wherein one or more cancerous cells in said patient express
at least one of ROS1, TrkA, TrkB, or TrkC kinase, the method comprising administering to the
patient an effective amount of a compound which is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-
indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient, wherein one
or more cancerous cells in said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase,
the method comprising administering to the patient an effective amount of a compound selected
from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-yl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof. Some embodiments provide methods of treating cancer in
a patient, wherein one or more cancerous cells in said patient express at least one of ROS1, TrkA,
TrkB, or TrkC kinase, the method comprising administering to the patient an effective amount of a
compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating cancer in a patient, wherein one
or more cancerous cells in said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase,
the method comprising administering to the patient an effective amount of a compound which is N-
[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, or a pharmaceutically acceptable salt thereof. Some embodiments provide
17426518_1 (GHMatters) P41939NZ00
methods of treating cancer in a patient, wherein one or more cancerous cells in said patient express
at least one of ROS1, TrkA, TrkB, or TrkC kinase, the method comprising administering to the
patient an effective amount of a compound which is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-
indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating a patient in which one or more
cancerous cells from said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase, the
method comprising administering to the patient an effective amount of a compound selected from
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)-
2-methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof. Some embodiments provide methods of treating a patient in which one or
more cancerous cells from said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase,
the method comprising administering to the patient an effective amount of a compound which is N-
[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, or a pharmaceutically acceptable salt thereof. Some embodiments provide methods of
treating a patient in which one or more cancerous cells from said patient express at least one of
ROS1, TrkA, TrkB, or TrkC kinase, the method comprising administering to the patient an effective
amount of a compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazin-
1-yl)(tetrahydro-2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide methods of treating a patient in which one or more cancerous cells
from said patient express at least one of ROS1, TrkA, TrkB, or TrkC kinase, the method comprising
administering to the patient an effective amount of a compound which is N-[5-(3,5-difluoro-
benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazin-
1-yl) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide a method of treating cancer, comprising
administering to a patient in which one or more cancerous cells from said patient express at least
one of ROS1, TrkA, TrkB, or TrkC kinase an effective amount of a compound selected from N-[5-
(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
17426518_1 (GHMatters) P41939NZ00
2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)-
2-methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof. Some embodiments provide methods wherein said compound is N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, or a pharmaceutically acceptable salt thereof. Some embodiments provide methods
wherein said compound is N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxy-
1-methyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically acceptable salt
thereof.
Some emobodiments provide a method for treating a patient having cancer,
wherein tumors from said patient are ROS1, TrkA, TrkB, or TrkC positive, a combination thereof,
the method comprising administering to the patient an effective amount of a compound selected
from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-yl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof.
Some embodiments provide a method for treating a patient having ROS1, TrkA,
TrkB, or TrkC positive cancer, or a combination thereof, the method comprising administering to
the patient an effective amount of a compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazol-
3-yl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-
[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-
methyl-piperazinyl) benzamide, or a pharmaceutically acceptable salt thereof.
Some embodiments provide a method of treating a cancer patient, comprising (a)
acquiring knowledge of the presence of at least one genetic alteration in at least one target gene in
the cancer patient, wherein the at least one target gene is selected from ALK1, BDNF, NGF, NGFR,
NTF3, NTF4, ROS1, SORT1, NTRK1, NTRK2, and NTRK3; (b) selecting a compound selected
from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-yl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
17426518_1 (GHMatters) P41939NZ00
pharmaceutically acceptable salt thereof, as a treatment for the cancer patient, based on the
recognition that said compound is effective in treating cancer patients having said at least one
genetic alteration in said at least one target gene; and (c) administering a therapeutically effective
amount of said compound to said cancer patient.
Some embodiments provide a method of treating a cancer patient, comprising
administering to said cancer patient a therapeutically effective amount of a compound selected from
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)-
2-methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof, wherein prior to said administration of said compound, said cancer patient is
known to possess at least one genetic alteration in at least one target gene selected from ALK1,
BDNF, NGF, NGFR, NTF3, NTF4, ROS1, SORT1, NTRK1, NTRK2, and NTRK3.
Some embodiments provide a method of treating cancer in a patient, comprising
administering to said cancer patient known to possess at least one genetic alteration in at least one
target gene selected from ALK1, BDNF, NGF, NGFR, NTF3, NTF4, ROS1, SORT1, NTRK1,
NTRK2, and NTRK3 a therapeutically effective amount of a compound selected from N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide,
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxy-
1-methyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically acceptable salt
thereof.
Some embodiments provide a method of treating a cancer patient, wherein said
cancer patient is known to possess at least one genetic alteration in at least one target gene,
comprising administering to said cancer patient a therapeutically effective amount of a compound
selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-yl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof, and wherein said target gene is selected from ALK1,
BDNF, NGF, NGFR, NTF3, NTF4, ROS1, SORT1, NTRK1, NTRK2, and NTRK3.
17426518_1 (GHMatters) P41939NZ00
Some embodiments provide a method of treating a cancer patient, wherein prior
to said treatment said patient is known to possess at least one genetic alteration in at least one target
gene, comprising administering to said cancer patient a therapeutically effective amount of a
compound selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-
benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-methyl-piperazin-
1-yl) benzamide, or a pharmaceutically acceptable salt thereof, and wherein said target gene is
selected from ALK1, BDNF, NGF, NGFR, NTF3, NTF4, ROS1, SORT1, NTRK1, NTRK2, and
NTRK3.
Some embodiments provide a method of treating a cancer patient, comprising
administering to said cancer patient a therapeutically effective amount of a compound selected from
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)-
2-methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof, and wherein prior to said compound being admininstered to said patient,
said patient is known to possess at least one genetic alteration in at least one target gene selected
from ALK1, BDNF, NGF, NGFR, NTF3, NTF4, ROS1, SORT1, NTRK1, NTRK2, and NTRK3.
Some embodiments provide a method for treating a cancer patient, comprising
(a) acquiring knowledge of the presence of at least one genetic alteration in at least one target gene
selected from ALK1, BDNF, NGF, NGFR, NTF3, NTF4, ROS1, SORT1, NTRK1, NTRK2, and
NTRK3; and (b) administering to said patient a therapeutically effective amount of a compound
selected from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-yl]((R)methoxymethyl-ethylamino)(4-methyl-piperazinyl) benzamide, or a
pharmaceutically acceptable salt thereof.
Some embodiments provide any of the methods described herein wherein the
patient or subject is suffering from cancer and the cancer is selected from at least one of non-small
cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.
17426518_1 (GHMatters) P41939NZ00
Some embodiments provide a pharmaceutical composition comprising a
compound of formula (I) or formula 2.(I) in combination with one or more chemotherapeutic agents
or radiotherapy, such as radiotherapy as commonly administered to treat, ameliorate the symptoms
of, or prevent or delay the onset of cancer. Such agents can include, but are not limited to,
antihormonal agents such as antiestrogens, antiandrogens and aromatase inhibitors, topoisomerase I
inhibitors, topoisomerase II inhibitors, agents that target microtubules, platin-based agents,
alkylating agents, DNA damaging or intercalating agents, antineoplastic antimetabolites, other
kinase inhibitors, other anti-angiogenic agents, inhibitors of kinesins, therapeutic monoclonal
antibodies, inhibitors of mTOR, histone deacetylase inhibitors, farnesyl transferase inhibitors, and
inhibitors of hypoxic response.
Some embodiments provide a product or kit comprising a compound of formula
(I) or formula 2.(I) or a pharmaceutically acceptable salt thereof, as defined above, or
pharmaceutical compositions thereof and one or more chemotherapeutic agents, as a combined
preparation for simultaneous, separate or sequential use in anticancer therapy. Some embodiments
provide a product or kit comprising a compound selected from N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide and N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions thereof
and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or
sequential use in anticancer therapy.
Some embodiments provide a product or kit comprising a compound which is N-
[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide, or a pharmaceutically acceptable salt thereof, or pharmaceutical compositions thereof
and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or
sequential use in anticancer therapy. Some embodiments provide a product or kit comprising a
compound which is N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof, or
pharmaceutical compositions thereof and one or more chemotherapeutic agents, as a combined
preparation for simultaneous, separate or sequential use in anticancer therapy.
Some embodiments provide a compound of formula (I) or formula 2.(I) or a
pharmaceutically acceptable salt thereof, as defined above, for use as a medicament.
17426518_1 (GHMatters) P41939NZ00
Some embodiments provide the use of a compound of formula (I) or formula 2.(I)
or a pharmaceutically acceptable salt thereof, as defined above, in the manufacture of a medicament
with antitumor activity.
Some embodiments provide a compound of formula (I) or formula 2.(I) or a
pharmaceutically acceptable salt thereof, as defined above, for use in a method of treating cancer.
Some embodiments may be further summarized by reference to the numerically listed embodiments
recited below:
1. A method of treating, ameliorating the symptoms of, delaying the
onset of or delaying the progression of cancer comprising the steps of
determining whether modulation of ROS1 activity is defective in a cell
population of an individual, and if said modulation of ROS1 activity is defective,
administering a molecule of a selected from the list consisting of formula
(I) and formula 2.(I) to said individual,
thereby treating, ameliorating the symptoms of, delaying the onset of or
delaying the progression of cancer.
2. The method of embodiment 1, wherein said determining whether
modulation of ROS1 activity is defective comprises assaying for ROS1 kinase
activity in an extract of a cell population of said individual.
3. The method of embodiment 1, wherein said determining whether
modulation of ROS1 activity is defective comprises assaying for transcript
accumulation in an extract comprising RNA of a cell population of said
individual.
4. The method of embodiment 1, wherein said determining whether
modulation of ROS1 activity is defective comprises sequencing a ROS1 locus in
the genomic DNA of a cell population of said individual.
. The method of embodiment 4, wherein said defective modulation
of ROS1 activity comprises upregulation of ROS1 activity.
6. The method of embodiment 5, wherein a fusion of a coding region
of a second protein at the ROS1 locus indicates upregulation of ROS1 kinase
activity.
17426518_1 (GHMatters) P41939NZ00
7. The method of embodiment 4, wherein said defective modulation
of ROS1 activity comprises a reduction of ROS1 activity to a lower level.
8. The method of embodiment 7, wherein a null mutation of said
ROS1 locus indicates that ROS1 activity is reduced.
9. The method of embodiment 7, wherein said null mutation
comprises an insertion.
. The method of embodiment 7, wherein said null mutation
comprises a frame shift of a coding region encoding ROS1.
11. The method of embodiment 7, wherein said null mutation
comprises a deletion within the locus encoding ROS1.
12. The method of embodiment 7, wherein said null mutation
comprises a deletion of the nucleic acid sequence spanning the ROS1 locus.
13. The method of embodiment 7, wherein a mutation affecting
accumulation of ROS1 mRNA indicates that ROS1 activity is reduced.
14. The method of any of embodiments 1-13, wherein said molecule is
a molecule of formula (I).
. The method of any of embodiments 1-13, wherein said molecule is
a molecule of formula 2.(I).
16. The method of any of embodiments 1-13, wherein said molecule is
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide
17. The method of any of embodiments 1-13, wherein said molecule is
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide.
18. The method of any of embodiments 1-13, wherein said molecule is
N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxy
methyl-ethylamino)(4-methyl-piperazinyl) benzamide.
19. The method of any of embodiments 1-18, wherein said cancer
comprises pancreatic cancer.
. The method of any of embodiments 1-19, further comprising
administering radiotherapy to said individual.
17426518_1 (GHMatters) P41939NZ00
Some additional embodiments may be further summarized by reference to the
numerically listed embodiments recited below:
1. The use of a compound selected from the group consisting of N-
[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-
(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof, for preparing a medicament for treating cancer in a
patient, wherein said cancer patient has at least one genetic alteration in at least
one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3.
2. Use according to embodiment 1, wherein said at least one target
gene is ROS1.
3. Use according to embodiment 1, wherein said at least one target
gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.
4. Use according to embodiment 1, wherein said compound is N-[5-
(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof.
. Use according to embodiment 4, wherein said at least one target
gene is ROS1.
6. Use according to embodiment 4, wherein said at least one target
gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.
7. Use according to embodiment 1, wherein said compound is N-[5-
(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof.
8. Use according to embodiment 7, wherein said at least one target
gene is ROS1.
9. Use according to embodiment 7, wherein said at least one target
gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.
. Use according to embodiment 1, wherein said compound is N-[5-
(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
17426518_1 (GHMatters) P41939NZ00
ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof.
11. Use according to embodiment 10, wherein said at least one target
gene is ROS1.
12. Use according to embodiment 10, wherein said at least one target
gene is selected from the group consisting of NTRK1, NTRK2, and NTRK3.
13. Use according to embodiment 1, wherein said cancer is selected
from the group consisting of non-small cell lung cancer, papillary thyroid cancer,
neuroblastoma, pancreatic cancer and colorectal cancer.
14. Use according to embodiment 1, wherein said compound is N-[5-
(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran-
4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof, and said
cancer is selected from the group consisting of non-small cell lung cancer,
papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.
. Use according to embodiment 14, wherein said cancer is selected
from the group consisting of non-small cell lung cancer, neuroblastoma and
colorectal cancer.
16. Use according to embodiment 1, wherein said compound is N-[5-
(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof,
and said cancer is selected from the group consisting of non-small cell lung
cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal
cancer.
17. Use according to embodiment 16, wherein said cancer is selected
from the group consisting of non-small cell lung cancer, neuroblastoma and
colorectal cancer.
18. Use according to embodiment 1, wherein said compound is N-[5-
(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof, and said cancer is selected from the group consisting of
17426518_1 (GHMatters) P41939NZ00
non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic
cancer and colorectal cancer.
19. Use according to embodiment 18, wherein said cancer is selected
from the group consisting of non-small cell lung cancer, neuroblastoma and
colorectal cancer.
. A compound selected from the group consisting of N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-
piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-[5-(3,5-
difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof, for use in method of treating cancer in a patient having at
least one genetic alteration in at least one target gene selected from the group
consisting of ROS1, NTRK1, NTRK2, and NTRK3, wherein said method
comprises the steps of:
a) determining whether said patient has at least one genetic alteration in at
least one target gene selected from the group consisting of ROS1, NTRK1,
NTRK2, and NTRK3; and
b) administering a therapeutically effective amount of said compound to
said cancer patient.
21. A compound for use according to embodiment 20, wherein said
cancer is selected from the group consisting of non-small cell lung cancer,
papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.
22. A method of treating cancer in a patient, wherein said patient is
known to possess at least one genetic alteration in at least one target gene
selected from ROS1, NTRK1, NTRK2, and NTRK3, comprising administering to
said cancer patient a therapeutically effective amount of a compound selected
from N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-
2H-pyranylamino) benzamide, N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide, and N-
[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
17426518_1 (GHMatters) P41939NZ00
ethylamino)(4-methyl-piperazinyl) benzamide, or a pharmaceutically
acceptable salt thereof.
Some embodiments include any of the methods described herein, wherein said
cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma,
pancreatic cancer and colorectal cancer. Some embodiments are any of the methods described
herein wherein said cancer is non-small cell lung cancer. Some embodiments include any of the
methods described herein, wherein said cancer is said cancer is papillary thyroid cancer. Some
embodiments include any of the methods described herein, wherein said cancer is wherein said
cancer is neuroblastoma. Some embodiments include any of the methods described herein, wherein
said cancer is wherein said cancer is pancreatic cancer. Some embodiments include any of the
methods described herein, wherein said cancer is wherein said cancer is colorectal cancer.
Some embodiments include any of the methods described herein, wherein any of
the compounds described herein are administered to said individual in an amount ranging from
2 2 2 2
about 200 mg/m to about 1600 mg/m , or from about 200 mg/m to about 1200 mg/m , or from
2 2 2 2
about 200 mg/m to about 1000 mg/m , or from about 400 mg/m to about 1200 mg/m , or from
2 2 2 2
about 400 mg/m to about 1000 mg/m , or from about 800 mg/m to about 1000 mg/m , or from
2 2 2 2
about 800 mg/m to about 1200 mg/m , or from about 800 mg/m to about 1200 mg/m , or from
about 800 mg/m to about 1600 mg/m . Some embodiments include any of the methods described
herein, wherein any of the compounds described herein are administered to said individual in an
2 2 2 2
amount of about 200 mg/m , about 300 mg/m , about 400 mg/m , about 500 mg/m , about 600
2 2 2 2 2
mg/m , about 700 mg/m , about 800 mg/m , about 900 mg/m , about 1000 mg/m , about 1100
2 2 2 2 2
mg/m , about 1200 mg/m , about 1300 mg/m , about 1400 mg/m , about 1500 mg/m , about 1600
2 2 2 2 2
mg/m , about 1700 mg/m , about 1800 mg/m , about 1900 mg/m , or about 2000 mg/m .
Some embodiments relate to the use of any of the compounds as described
herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the
treatment of abnormal cell growth in a mammal. The present invention further relates to the use of
any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, in the
manufacture of a medicament for the treatment of abnormal cell growth in a mammal wherein the
abnormal cell growth is cancerous or non-cancerous. In some embodiments, the abnormal cell
growth is cancerous. In another embodiment, the abnormal cell growth is non-cancerous.
17426518_1 (GHMatters) P41939NZ00
Some embodiments relate to any of the compounds described herein, or
pharmaceutically acceptable salts thereof, for use as a medicament. Some embodiments relate to the
use of any of the compounds described above, or pharmaceutically acceptable salts thereof, for the
manufacture of a medicament for the treatment of abnormal cell growth.
As used herein "cancer" refers to any malignant and/or invasive growth or tumor
caused by abnormal cell growth. As used herein "cancer" refers to solid tumors named for the type
of cells that form them, cancer of blood, bone marrow, or the lymphatic system. Examples of solid
tumors include but are not limited to sarcomas and carcinomas. Examples of cancers of the blood
include but are not limited to leukemias, lymphomas and myeloma. The term "cancer" includes but
is not limited to a primary cancer that originates at a specific site in the body, a
metastatic cancer that has spread from the place in which it started to other parts of the body, a
recurrence from the original primary cancer after remission, and a second primary cancer that is a
new primary cancer in a person with a history of previous cancer of different type from latter one.
Some embodiments relate to compositions comprising a compound of Formula I
or a pharmaceutically acceptable salt thereof (e.g., pharmaceutical compositions). Accordingly, in
some embodiments, the invention relates to a pharmaceutical composition comprising a compound
of Formula I, or a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier and,
optionally, at least one additional medicinal or pharmaceutical agent. In some embodiments, the at
least one additional medicinal or pharmaceutical agent is an anti-cancer agent as described below.
The pharmaceutically acceptable carrier may comprise a conventional
pharmaceutical carrier or excipient. Suitable pharmaceutical carriers include inert diluents or fillers,
water and various organic solvents (such as hydrates and solvates). The pharmaceutical
compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients
and the like. Thus for oral administration, tablets containing various excipients, such as citric acid
may be employed together with various disintegrants such as starch, alginic acid and certain
complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally,
lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for
tableting purposes. Solid compositions of a similar type may also be employed in soft and hard
filled gelatin capsules. Non-limiting examples of materials, therefore, include lactose or milk sugar
and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired
for oral administration the active compound therein may be combined with various sweetening or
17426518_1 (GHMatters) P41939NZ00
flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents,
together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
The pharmaceutical composition may, for example, be in a form suitable for oral
administration as a tablet, capsule, pill, powder, sustained release formulations, solution suspension,
for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an
ointment or cream or for rectal administration as a suppository.
Exemplary parenteral administration forms include solutions or suspensions of
active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose
solutions. Such dosage forms may be suitably buffered, if desired.
The pharmaceutical composition may be in unit dosage forms suitable for single
administration of precise dosages.
In some embodiments, the composition comprises a therapeutically effective
amount of a compound as disclosed herein and a pharmaceutically acceptable carrier.
The compounds of the present invention may be formulated into pharmaceutical
compositions as described below in any pharmaceutical form recognizable to the skilled artisan as
being suitable. Pharmaceutical compositions of the invention comprise a therapeutically effective
amount of at least one compound disclosed herein and an inert, pharmaceutically acceptable carrier
or diluent.
To treat or prevent diseases or conditions mediated by ALK, ROS1, TrkA, TrkB,
or TrkC, or a combination thereof, a pharmaceutical composition of the invention is administered in
a suitable formulation prepared by combining a therapeutically effective amount (i.e., a ALK,
ROS1, TrkA, TrkB, or TrkC modulating, regulating, or inhibiting amount effective to achieve
therapeutic efficacy) of at least one compound of the present invention (as an active ingredient) with
one or more pharmaceutically suitable carriers, which may be selected, for example, from diluents,
excipients and auxiliaries that facilitate processing of the active compounds into the final
pharmaceutical preparations.
The pharmaceutical carriers employed may be either solid or liquid. Exemplary
solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid
and the like. Exemplary liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly,
the inventive compositions may include time-delay or time-release material known in the art, such
as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose,
17426518_1 (GHMatters) P41939NZ00
hydroxypropylmethylcellulose, methylmethacrylate or the like. Further additives or excipients may
be added to achieve the desired formulation properties. For example, a bioavailability enhancer,
such as Labrasol, Gelucire or the like, or formulator, such as CMC (carboxy-methylcellulose), PG
(propyleneglycol), or PEG (polyethyleneglycol), may be added. Gelucire®, a semi-solid vehicle that
protects active ingredients from light, moisture and oxidation, may be added, e.g., when preparing a
capsule formulation.
If a solid carrier is used, the preparation can be tableted, placed in a hard gelatin
capsule in powder or pellet form, or formed into a troche or lozenge. The amount of solid carrier
may vary, but generally will be from about 25 mg to about 1 g. If a liquid carrier is used, the
preparation may be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or
suspension in an ampoule or vial or non-aqueous liquid suspension. If a semi-solid carrier is used,
the preparation may be in the form of hard and soft gelatin capsule formulations. The inventive
compositions are prepared in unit-dosage form appropriate for the mode of administration, e.g.
parenteral or oral administration.
To obtain a stable water-soluble dose form, a salt of a compound of the present
invention may be dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3 M
solution of succinic acid or citric acid. If a soluble salt form is not available, the agent may be
dissolved in a suitable co-solvent or combinations of co-solvents. Examples of suitable co-solvents
include alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in
concentrations ranging from 0 to 60% of the total volume. In an exemplary embodiment, a
compound of the present invention is dissolved in DMSO and diluted with water. The composition
may also be in the form of a solution of a salt form of the active ingredient in an appropriate
aqueous vehicle such as water or isotonic saline or dextrose solution.
Proper formulation is dependent upon the route of administration selected. For
injection, the agents of the compounds of the present invention may be formulated into aqueous
solutions, preferably in physiologically compatible buffers such as Hanks solution, Ringer's solution,
or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the compounds can be formulated by combining the
active compounds with pharmaceutically acceptable carriers known in the art. Such carriers enable
the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels,
17426518_1 (GHMatters) P41939NZ00
syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with
the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture
of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable
excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and
cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin,
gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or
polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as crosslinked
polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated
sugar solutions may be used, which may optionally contain gum arabic, polyvinyl pyrrolidone,
Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic
solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings
for identification or to characterize different combinations of active agents.
Pharmaceutical preparations that can be used orally include push-fit capsules
made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or
sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as
lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and,
optionally, stabilizers. In soft capsules, the active agents may be dissolved or suspended in suitable
liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may
be added. All formulations for oral administration should be in dosages suitable for such
administration. For buccal administration, the compositions may take the form of tablets or lozenges
formulated in conventional manner.
For administration intranasally or by inhalation, the compounds for use according
to the present invention may be conveniently delivered in the form of an aerosol spray presentation
from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by
providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an
inhaler or insufflator and the like may be formulated containing a powder mix of the compound and
a suitable powder base such as lactose or starch.
17426518_1 (GHMatters) P41939NZ00
The compounds may be formulated for parenteral administration by injection,
e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit-
dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The
compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous
vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing
agents.
Pharmaceutical formulations for parenteral administration include aqueous
solutions of the active compounds in water-soluble form. Additionally, suspensions of the active
agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or
vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the
viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility
of the compounds to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a
suitable vehicle, e.g. sterile pyrogen-free water, before use.
In addition to the formulations described above, the compounds of the present
invention may also be formulated as a depot preparation. Such long-acting formulations may be
administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with suitable polymeric or
hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or
as sparingly soluble derivatives, for example, as a sparingly soluble salt. A pharmaceutical carrier
for hydrophobic compounds is a co-solvent system comprising benzyl alcohol, a non-polar
surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be
a VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the non-polar
surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute
ethanol. The VPD co-solvent system (VPD: 5 W) contains VPD diluted 1:1 with a 5% dextrose in
water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces
low toxicity upon systemic administration. The proportions of a co-solvent system may be suitably
varied without destroying its solubility and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other low-toxicity non-polar surfactants may be
17426518_1 (GHMatters) P41939NZ00
used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other
biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other
sugars or polysaccharides may be substituted for dextrose.
Alternatively, other delivery systems for hydrophobic pharmaceutical compounds
may be employed. Liposomes and emulsions are known examples of delivery vehicles or carriers for
hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed,
although usually at the cost of greater toxicity due to the toxic nature of DMSO. Additionally, the
compounds may be delivered using a sustained-release system, such as semipermeable matrices of
solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials
have been established and are known by those skilled in the art. Sustained-release capsules may,
depending on their chemical nature, release the compounds for a few weeks up to over 100 days.
Depending on the chemical nature and the biological stability of the therapeutic reagent, additional
strategies for protein stabilization may be employed.
The pharmaceutical compositions also may comprise suitable solid- or gel-phase
carriers or excipients. These carriers and excipients may provide marked improvement in the
bioavailability of poorly soluble drugs. Examples of such carriers or excipients include calcium
carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as
polyethylene glycols. Furthermore, additives or excipients such as Gelucire®, Capryol®, Labrafil®,
Labrasol®, Lauroglycol®, Plurol®, Peceol®, Transcutol® and the like may be used.
Further, the pharmaceutical composition may be incorporated into a skin patch
for delivery of the drug directly onto the skin.
It will be appreciated that the actual dosages of the agents of this invention will
vary according to the particular agent being used, the particular composition formulated, the mode
of administration, and the particular site, host, and disease being treated. Those skilled in the art
using conventional dosage-determination tests in view of the experimental data for a given
compound may ascertain optimal dosages for a given set of conditions. For oral administration, an
exemplary daily dose generally employed will be from about 0.001 to about 1000 mg/kg of body
weight, with courses of treatment repeated at appropriate intervals.
Furthermore, the pharmaceutically acceptable formulations of the present
invention may contain a compound of the present invention, or a salt or solvate thereof, in an
amount of about 10 mg to about 2000 mg, or from about 10 mg to about 1500 mg, or from about 10
17426518_1 (GHMatters) P41939NZ00
mg to about 1000 mg, or from about 10 mg to about 750 mg, or from about 10 mg to about 500 mg,
or from about 25 mg to about 500 mg, or from about 50 to about 500 mg, or from about 100 mg to
about 500 mg. Furthermore, the pharmaceutically acceptable formulations of the present invention
may contain a compound of the present invention, or a salt or solvate thereof, in an amount of about
50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg,
about 400 mg, about 450 mg, or about 500 mg.
Additionally, the pharmaceutically acceptable formulations of the present
invention may contain a compound of the present invention, or a salt or solvate thereof, in an
amount from about 0.5 w/w % to about 95 w/w %, or from about 1 w/w % to about 95 w/w %, or
from about 1 w/w % to about 75 w/w %, or from about 5 w/w % to about 75 w/w %, or from about
w/w % to about 75 w/w %, or from about 10 w/w % to about 50 w/w %.
The compounds of the present invention, or salts or solvates thereof, may be
administered to a mammal suffering from abnormal cell growth, such as a human, either alone or as
part of a pharmaceutically acceptable formulation, once a day, twice a day, three times a day, or
four times a day, or even more frequently.
Those of ordinary skill in the art will understand that with respect to the
compounds of the present invention, the particular pharmaceutical formulation, the dosage, and the
number of doses given per day to a mammal requiring such treatment, are all choices within the
knowledge of one of ordinary skill in the art and can be determined without undue experimentation.
Administration of the compounds disclosed herein may be effected by any
method that enables delivery of the compounds to the site of action. These methods include oral
routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous,
intramuscular, intravascular or infusion), topical, and rectal administration.
Dosage regimens may be adjusted to provide the optimum desired response. For
example, a single bolus may be administered, several divided doses may be administered over time
or the dose may be proportionally reduced or increased as indicated by the exigencies of the
therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage
unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein,
refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated;
each unit containing a predetermined quantity of active compound calculated to produce the desired
therapeutic effect in association with the required pharmaceutical carrier. The specification for the
17426518_1 (GHMatters) P41939NZ00
dosage unit forms of the invention are dictated by and directly dependent on (a) the unique
characteristics of the chemotherapeutic agent and the particular therapeutic or prophylactic effect to
be achieved, and (b) the limitations inherent in the art of compounding such an active compound for
the treatment of sensitivity in individuals.
Thus, the skilled artisan would appreciate, based upon the disclosure provided
herein, that the dose and dosing regimen is adjusted in accordance with methods well-known in the
therapeutic arts. That is, the maximum tolerable dose can be readily established, and the effective
amount providing a detectable therapeutic benefit to a patient may also be determined, as can the
temporal requirements for administering each agent to provide a detectable therapeutic benefit to
the patient. Accordingly, while certain dose and administration regimens are exemplified herein,
these examples in no way limit the dose and administration regimen that may be provided to a
patient in practicing the present invention.
It is to be noted that dosage values may vary with the type and severity of the
condition to be alleviated, and may include single or multiple doses. It is to be further understood
that for any particular subject, specific dosage regimens should be adjusted over time according to
the individual need and the professional judgment of the person administering or supervising the
administration of the compositions, and that dosage ranges set forth herein are exemplary only and
are not intended to limit the scope or practice of the claimed composition. For example, doses may
be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include clinical
effects such as toxic effects and/or laboratory values. Thus, the present invention encompasses intra-
patient dose-escalation as determined by the skilled artisan. Determining appropriate dosages and
regimens for administration of the chemotherapeutic agent are well-known in the relevant art and
would be understood to be encompassed by the skilled artisan once provided the teachings disclosed
herein.
The compounds, compositions and methods provided herein are useful for the
treatment of cancers including but not limited to cancers of the: circulatory system, for example,
heart (sarcoma [angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma], myxoma,
rhabdomyoma, fibroma, lipoma and teratoma), mediastinum and pleura, and other intrathoracic
organs, vascular tumors and tumor-associated vascular tissue; respiratory tract, for example, nasal
cavity and middle ear, accessory sinuses, larynx, trachea, bronchus and lung such as small cell
lung cancer (SCLC), non-small cell lung cancer (NSCLC), bronchogenic carcinoma (squamous cell,
17426518_1 (GHMatters) P41939NZ00
undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar)
carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma,
mesothelioma; gastrointestinal system, for example, esophagus (squamous cell carcinoma,
adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma),
gastric, pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors,
vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma,
leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular
adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract, for example, kidney
(adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and/or urethra
(squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma,
sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma,
sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); liver, for
example, hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma,
angiosarcoma, hepatocellular adenoma, hemangioma, pancreatic endocrine tumors (such as
pheochromocytoma, insulinoma, vasoactive intestinal peptide tumor, islet cell tumor and
glucagonoma); bone, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant
fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell
sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma
(osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid
osteoma and giant cell tumors; nervous system, for example, neoplasms of the central nervous
system (CNS), primary CNS lymphoma, skull cancer (osteoma, hemangioma, granuloma,
xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis),
brain cancer (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma],
glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
spinal cord neurofibroma, meningioma, glioma, sarcoma); reproductive system, for example,
gynecological, uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical
dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma,
unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma,
malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma,
fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma
(embryonal rhabdomyosarcoma), fallopian tubes (carcinoma) and other sites associated with female
17426518_1 (GHMatters) P41939NZ00
genital organs; placenta, penis, prostate, testis, and other sites associated with male genital
organs; hematologic system, for example, blood (myeloid leukemia [acute and chronic], acute
lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple
myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant
lymphoma]; oral cavity, for example, lip, tongue, gum, floor of mouth, palate, and other parts of
mouth, parotid gland, and other parts of the salivary glands, tonsil, oropharynx, nasopharynx,
pyriform sinus, hypopharynx, and other sites in the lip, oral cavity and pharynx; skin, for example,
malignant melanoma, cutaneous melanoma, basal cell carcinoma, squamous cell carcinoma,
Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids; adrenal
glands: neuroblastoma; and other tissues including connective and soft tissue, retroperitoneum and
peritoneum, eye, intraocular melanoma, and adnexa, breast, head or/and neck, anal region, thyroid,
parathyroid, adrenal gland and other endocrine glands and related structures, secondary and
unspecified malignant neoplasm of lymph nodes, secondary malignant neoplasm of respiratory and
digestive systems and secondary malignant neoplasm of other sites.
More specifically, examples of "cancer" when used herein in connection with the
present invention include cancer selected from lung cancer (NSCLC and SCLC), cancer of the head
or neck, ovarian cancer, colon cancer, rectal cancer, prostate cancer, cancer of the anal region,
stomachcancer, breast cancer, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the
renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, non-
Hodgkins's lymphoma, spinal axis tumors, or a combination of one or more of the foregoing
cancers.
In some embodiments, the compounds and the compositions disclosed herein are
useful for the treatment of cancers, including Spitz melanoma, perineural invasion, pulmonary large
cell neuroendocrine carcinoma, uterine carcinoma, juvenile breast cancer, nasopharyngeal
carcinoma, adenoid cystic cancer, meduallary thyroid cancer, salivary cancer, congenital infantile
fibrosarcoma, mesoblastic nephroma, esophageal cancer (squamous), diffuse large B-cell
lymphoma, papillary thyroid cancer, and mammary analogue secretory carcinoma.
In some embodiments, the compounds disclosed herein may be used in
combination with one or more additional anti-cancer agents which are described below. When a
combination therapy is used, the one or more additional anti-cancer agents may be administered
sequentially or simultaneously with the compound of the invention. In some embodiments, the
17426518_1 (GHMatters) P41939NZ00
additional anti-cancer agent is administered to a mammal (e.g., a human) prior to administration of
the compound of the invention. In some embodiments, the additional anti-cancer agent is
administered to the mammal after administration of the compound of the invention. In some
embodiments, the additional anti-cancer agent is administered to the mammal (e.g., a human)
simultaneously with the administration of the compound disclosed herein.
Some embodiments also relate to a pharmaceutical composition for the treatment
of abnormal cell growth in a mammal, including a human, which comprises an amount of a
compound disclosed herein, as defined above (including hydrates, solvates and polymorphs of said
compound or pharmaceutically acceptable salts thereof), in combination with one or more
(preferably one to three) anti-cancer agents selected from the group consisting of anti-angiogenesis
agents and signal transduction inhibitors and a pharmaceutically acceptable carrier, wherein the
amounts of the active agent and the combination anti-cancer agents when taken as a whole is
therapeutically effective for treating said abnormal cell growth.
In some embodiments, the anti-cancer agent used in conjunction with a
compound disclosed herein and pharmaceutical compositions described herein is an anti-
angiogenesis agent (e.g., an agent that stops tumors from developing new blood vessels). Examples
of anti-angiogenesis agents include for example VEGF inhibitors, VEGFR inhibitors, TIE-2
inhibitors, PDGFR inhibitors, angiopoetin inhibitors, PKC.beta. inhibitors, COX-2 (cyclooxygenase
II) inhibitors, integrins (alpha-v/beta-3), MMP-2 (matrix-metalloprotienase 2) inhibitors, and MMP-
9 (matrix-metalloprotienase 9) inhibitors. Preferred anti-angiogenesis agents include sunitinib
(Sutent®), bevacizumab (Avastin®), axitinib (AG 13736), SU 14813 (Pfizer), and AG 13958
(Pfizer).
Additional anti-angiogenesis agents include vatalanib (CGP 79787), Sorafenib
(Nexavar®), pegaptanib octasodium (Macugen®), vandetanib (Zactima®), PF-0337210 (Pfizer), SU
14843 (Pfizer), AZD 2171 (AstraZeneca), ranibizumab (Lucentis®), Neovastat® (AE 941),
tetrathiomolybdata (Coprexa®), AMG 706 (Amgen), VEGF Trap (AVE 0005), CEP 7055 (Sanofi-
Aventis), XL 880 (Exelixis), telatinib (BAY 57-9352), and CP-868,596 (Pfizer).
Other anti-angiogenesis agents include enzastaurin (LY 317615), midostaurin
(CGP 41251), perifosine (KRX 0401), teprenone (Selbex®) and UCN 01 (Kyowa Hakko).
Other examples of anti-angiogenesis agents which can be used in conjunction
with a compound of Disclosed herein and pharmaceutical compositions described herein include
17426518_1 (GHMatters) P41939NZ00
celecoxib (Celebrex®), parecoxib (Dynastat®), deracoxib (SC 59046), lumiracoxib (Preige®),
valdecoxib (Bextra®), rofecoxib (Vioxx®), iguratimod (Careram®), IP 751 (Invedus), SC-58125
(Pharmacia) and etoricoxib (Arcoxia®).
Other anti-angiogenesis agents include exisulind (Aptosyn®), salsalate
(Amigesic®), diflunisal (Dolobid®), ibuprofen (Motrin®), ketoprofen (Orudis®) nabumetone
(Relafen®), piroxicam (Feldene®), naproxen (Aleve®, Naprosyn®) diclofenac (Voltaren®),
indomethacin (Indocin®), sulindac (Clinoril®), tolmetin (Tolectin®), etodolac (Lodine®),
ketorolac (Toradol®), and oxaprozin (Daypro®).
Other anti-angiogenesis agents include ABT 510 (Abbott), apratastat (TMI 005),
AZD 8955 (AstraZeneca), incyclinide (Metastat®), and PCK 3145 (Procyon).
Other anti-angiogenesis agents include acitretin (Neotigason®), plitidepsin
(Aplidine®), cilengtide (EMD 121974), combretastatin A4 (CA4P), fenretinide (4 HPR),
halofuginone (Tempostatin®), Panzem® (2-methoxyestradiol), PF-03446962 (Pfizer), rebimastat
(BMS 275291), catumaxomab (Removab®), lenalidomide (Revlimid®) squalamine (EVIZON®),
thalidomide (Thalomid®), Ukrain® (NSC 631570), Vitaxin® (MEDI 522), and zoledronic acid
(Zometa®)
In some embodiments, the anti-cancer agent is a so called signal transduction
inhibitor (e.g., inhibiting the means by which regulatory molecules that govern the fundamental
processes of cell growth, differentiation, and survival communicated within the cell). Signal
transduction inhibitors include small molecules, antibodies, and antisense molecules. Signal
transduction inhibitors include for example kinase inhibitors (e.g., tyrosine kinase inhibitors or
serine/threonine kinase inhibitors) and cell cycle inhibitors. More specifically signal transduction
inhibitors include, for example, ALK inhibitors, ROS1 inhibitors, TrkA inhibitors, TrkB inhibitors,
TrkC inhibitors, farnesyl protein transferase inhibitors, EGF inhibitor, ErbB-1 (EGFR), ErbB-2, pan
erb, IGF1R inhibitors, MEK, c-Kit inhibitors, FLT-3 inhibitors, K-Ras inhibitors, PI3 kinase
inhibitors, JAK inhibitors, STAT inhibitors, Raf kinase inhibitors, Akt inhibitors, mTOR inhibitor,
P70S6 kinase inhibitors, inhibitors of the WNT pathway and so called multi-targeted kinase
inhibitors.
Preferred signal transduction inhibitors include gefitinib (Iressa®), cetuximab
(Erbitux®), erlotinib (Tarceva®), trastuzumab (Herceptin®), sunitinib (Sutent®) imatinib
(Gleevec®), and PD325901 (Pfizer).
17426518_1 (GHMatters) P41939NZ00
Additional examples of signal transduction inhibitors which may be used in
conjunction with a compound of Disclosed herein and pharmaceutical compositions described
herein include BMS 214662 (Bristol-Myers Squibb), lonafarnib (Sarasar®), pelitrexol (AG 2037),
matuzumab (EMD 7200), nimotuzumab (TheraCIM h-R3®), panitumumab (Vectibix®),
Vandetanib (Zactima®), pazopanib (SB 786034), ALT 110 (Alteris Therapeutics), BIBW 2992
(Boehringer Ingelheim), and Cervene® (TP 38).
Other examples of signal transduction inhibitor include PF-2341066 (Pfizer), PF-
299804 (Pfizer), canertinib (CI 1033), pertuzumab (Omnitarg®), Lapatinib (Tycerb®), pelitinib
(EKB 569), miltefosine (Miltefosin®), BMS 599626 (Bristol-Myers Squibb), Lapuleucel-T
(Neuvenge®), NeuVax® (E75 cancer vaccine), Osidem® (IDM 1), mubritinib (TAK-165), CP-
724,714 (Pfizer), panitumumab (Vectibix®), lapatinib (Tycerb®), PF-299804 (Pfizer), pelitinib
(EKB 569), and pertuzumab (Omnitarg®).
Other examples of signal transduction inhibitors include ARRY 142886 (Array
Biopharm), everolimus (Certican®), zotarolimus (Endeavor®), temsirolimus (Torisel®), AP 23573
(ARIAD), and VX 680 (Vertex).
Additionally, other signal transduction inhibitors include XL 647 (Exelixis),
sorafenib (Nexavar®), LE-AON (Georgetown University), and GI-4000 (GlobeImmune).
Other signal transduction inhibitors include ABT 751 (Abbott), alvocidib
(flavopiridol), BMS 387032 (Bristol Myers), EM 1421 (Erimos), indisulam (E 7070), seliciclib
(CYC 200), BIO 112 (One Bio), BMS 387032 (Bristol-Myers Squibb), PD 0332991 (Pfizer), AG
024322 (Pfizer), LOXO-101 (Loxo Oncology), crizotinib, and ceritinib.
In some embodiments, the compounds of disclosed herein are used together with
classical antineoplastic agents. Classical antineoplastic agents include but are not limited to
hormonal modulators such as hormonal, anti-hormonal, androgen agonist, androgen antagonist and
anti-estrogen therapeutic agents, histone deacetylase (HDAC) inhibitors, gene silencing agents or
gene activating agents, ribonucleases, proteosomics, Topoisomerase I inhibitors, Camptothecin
derivatives, Topoisomerase II inhibitors, alkylating agents, antimetabolites, poly(ADP-ribose)
polymerase-1 (PARP-1) inhibitor, microtubulin inhibitors, antibiotics, plant derived spindle
inhibitors, platinum-coordinated compounds, gene therapeutic agents, antisense oligonucleotides,
vascular targeting agents (VTAs), and statins.
17426518_1 (GHMatters) P41939NZ00
Examples of classical antineoplastic agents used in combination therapy with a
compound of disclosed herein, optionally with one or more other agents include, but are not limited
to, glucocorticoids, such as dexamethasone, prednisone, prednisolone, methylprednisolone,
hydrocortisone, and progestins such as medroxyprogesterone, megestrol acetate (Megace),
mifepristone (RU-486), Selective Estrogen Receptor Modulators (SERMs; such as tamoxifen,
raloxifene, lasofoxifene, afimoxifene, arzoxifene, bazedoxifene, fispemifene, ormeloxifene,
ospemifene, tesmilifene, toremifene, trilostane and CHF 4227 (Cheisi)), Selective Estrogen-
Receptor Downregulators (SERD's; such as fulvestrant), exemestane (Aromasin), anastrozole
(Arimidex), atamestane, fadrozole, letrozole (Femara), gonadotropin-releasing hormone (GnRH;
also commonly referred to as luteinizing hormone-releasing hormone [LHRH]) agonists such as
buserelin (Suprefact), goserelin (Zoladex), leuprorelin (Lupron), and triptorelin (Trelstar), abarelix
(Plenaxis), bicalutamide (Casodex), cyproterone, flutamide (Eulexin), megestrol, nilutamide
(Nilandron), and osaterone, dutasteride, epristeride, finasteride, Serenoa repens, PHL 00801,
abarelix, goserelin, leuprorelin, triptorelin, bicalutamide, tamoxifen, exemestane, anastrozole,
fadrozole, formestane, letrozole, and combinations thereof.
Other examples of classical antineoplastic agents used in combination with
compounds of disclosed herein include but are not limited to suberolanilide hydroxamic acid
(SAHA, Merck Inc./Aton Pharmaceuticals), depsipeptide (FR901228 or FK228), G2M-777, MS-
275, pivaloyloxymethyl butyrate and PXD-101; Onconase (ranpirnase), PS-341 (MLN-341),
Velcade (bortezomib), 9-aminocamptothecin, belotecan, BN-80915 (Roche), camptothecin,
diflomotecan, edotecarin, exatecan (Daiichi), gimatecan, 10-hydroxycamptothecin, irinotecan HCl
(Camptosar), lurtotecan, Orathecin (rubitecan, Supergen), SN-38, topotecan, camptothecin, 10-
hydroxycamptothecin, 9-aminocamptothecin, irinotecan, SN-38, edotecarin, topotecan, aclarubicin,
adriamycin, amonafide, amrubicin, annamycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin,
etoposide, idarubicin, galarubicin, hydroxycarbamide, nemorubicin, novantrone (mitoxantrone),
pirarubicin, pixantrone, procarbazine, rebeccamycin, sobuzoxane, tafluposide, valrubicin, Zinecard
(dexrazoxane), nitrogen mustard N-oxide, cyclophosphamide, AMD-473, altretamine, AP-5280,
apaziquone, brostallicin, bendamustine, busulfan, carboquone, carmustine, chlorambucil,
dacarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine,
mafosfamide, mechlorethamine, melphalan, mitobronitol, mitolactol, mitomycin C, mitoxatrone,
nimustine, ranimustine, temozolomide, thiotepa, and platinum-coordinated alkylating compounds
17426518_1 (GHMatters) P41939NZ00
such as cisplatin, Paraplatin (carboplatin), eptaplatin, lobaplatin, nedaplatin, Eloxatin (oxaliplatin,
Sanofi), streptozocin, satrplatin, and combinations thereof.
In some embodiments, the compounds of disclosed herein are used together with
dihydrofolate reductase inhibitors (such as methotrexate and NeuTrexin (trimetresate glucuronate)),
purine antagonists (such as 6-mercaptopurine riboside, mercaptopurine, 6-thioguanine, cladribine,
clofarabine (Clolar), fludarabine, nelarabine, and raltitrexed), pyrimidine antagonists (such as 5-
fluorouracil (5-FU), Alimta (premetrexed disodium, LY231514, MTA), capecitabine (Xeloda®),
cytosine arabinoside, Gemzar® (gemcitabine, Eli Lilly), Tegafur (UFT Orzel or Uforal and
including TS-1 combination of tegafur, gimestat and otostat), doxifluridine, carmofur, cytarabine
(including ocfosfate, phosphate stearate, sustained release and liposomal forms), enocitabine, 5-
azacitidine (Vidaza), decitabine, and ethynylcytidine) and other antimetabolites such as eflornithine,
hydroxyurea, leucovorin, nolatrexed (Thymitaq), triapine, trimetrexate, N-(5-[N-(3,4-dihydro
methyloxoquinazolinylmethyl)-N-methylamino]-- 2-thenoyl)-L-glutamic acid, AG-014699
(Pfizer Inc.), ABT-472 (Abbott Laboratories), INO-1001 (Inotek Pharmaceuticals), KU-0687
(KuDOS Pharmaceuticals) and GPI 18180 (Guilford Pharm Inc) and combinations thereof.
Other examples of classical antineoplastic cytotoxic agents used in combination
therapy with a compound of disclosed herein, optionally with one or more other agents include, but
are not limited to, Abraxane (Abraxis BioScience, Inc.), Batabulin (Amgen), EPO 906 (Novartis),
Vinflunine (Bristol-Myers Squibb Company), actinomycin D, bleomycin, mitomycin C,
neocarzinostatin (Zinostatin), vinblastine, vincristine, vindesine, vinorelbine (Navelbine), docetaxel
(Taxotere), Ortataxel, paclitaxel (including Taxoprexin a DHA/paciltaxel conjugate), cisplatin,
carboplatin, Nedaplatin, oxaliplatin (Eloxatin), Satraplatin, Camptosar, capecitabine (Xeloda),
oxaliplatin (Eloxatin), Taxotere alitretinoin, Canfosfamide (Telcyta®), DMXAA (Antisoma),
ibandronic acid, L-asparaginase, pegaspargase (Oncaspar®), Efaproxiral (Efaproxyn®--radiation
therapy)), bexarotene (Targretin®), Tesmilifene (DPPE--enhances efficacy of cytotoxics)),
Theratope® (Biomira), Tretinoin (Vesanoid®), tirapazamine (Trizaone®), motexafin gadolinium
(Xcytrin®) Cotara® (mAb), and NBI-3001 (Protox Therapeutics), polyglutamate-paclitaxel
(Xyotax®) and combinations thereof.
Further examples of classical antineoplastic agents used in combination therapy
with a compound of disclosed herein, optionally with one or more other agents include, but are not
limited to, as Advexin (ING 201), TNFerade (GeneVec, a compound which express TNFalpha in
17426518_1 (GHMatters) P41939NZ00
response to radiotherapy), RB94 (Baylor College of Medicine), Genasense (Oblimersen, Genta),
Combretastatin A4P (CA4P), Oxi-4503, AVE-8062, ZD-6126, TZT-1027, Atorvastatin (Lipitor,
Pfizer Inc.), Provastatin (Pravachol, Bristol-Myers Squibb), Lovastatin (Mevacor, Merck Inc.),
Simvastatin (Zocor, Merck Inc.), Fluvastatin (Lescol, Novartis), Cerivastatin (Baycol, Bayer),
Rosuvastatin (Crestor, AstraZeneca), Lovostatin, Niacin (Advicor, Kos Pharmaceuticals), Caduet,
Lipitor, torcetrapib, and combinations thereof.
Some embodiments relate to a method for the treatment of breast cancer in a
human in need of such treatment, comprising administering to said human an amount of a
compound of disclosed herein, in combination with one or more (preferably one to three) anti-
cancer agents selected from the group consisting of trastuzumab, tamoxifen, docetaxel, paclitaxel,
capecitabine, gemcitabine, vinorelbine, exemestane, letrozole and anastrozole.
Some embodiments provide a method of treating colorectal cancer in a mammal,
such as a human, in need of such treatment, by administering an amount of a compound of disclosed
herein, in combination with one or more (preferably one to three) anti-cancer agents. Examples of
particular anti-cancer agents include those typically used in adjuvant chemotherapy, such as
FOLFOX, a combination of 5-fluorouracil (5-FU) or capecitabine (Xeloda), leucovorin and
oxaliplatin (Eloxatin). Further examples of particular anti-cancer agents include those typically used
in chemotherapy for metastatic disease, such as FOLFOX or FOLFOX in combination with
bevacizumab (Avastin); and FOLFIRI, a combination of 5-FU or capecitabine, leucovorin and
irinotecan (Camptosar). Further examples include 17-DMAG, ABX-EFR, AMG-706, AMT-2003,
ANX-510 (CoFactor), aplidine (plitidepsin, Aplidin), Aroplatin, axitinib (AG-13736), AZD-0530,
AZD-2171, bacillus Calmette-Guerin (BCG), bevacizumab (Avastin), BIO-117, BIO-145, BMS-
184476, BMS-275183, BMS-528664, bortezomib (Velcade), C-1311 (Symadex), cantuzumab
mertansine, capecitabine (Xeloda), cetuximab (Erbitux), clofarabine (Clofarex), CMD-193,
combretastatin, Cotara, CT-2106, CV-247, decitabine (Dacogen), E-7070, E-7820, edotecarin,
EMD-273066, enzastaurin (LY-317615) epothilone B (EPO-906), erlotinib (Tarceva), flavopyridol,
GCAN-101, gefitinib (Iressa), huA33, huC242-DM4, imatinib (Gleevec), indisulam, ING-1,
irinotecan (CPT-11, Camptosar) ISIS 2503, ixabepilone, lapatinib (Tykerb), mapatumumab (HGS-
ETR1), MBT-0206, MEDI-522 (Abregrin), Mitomycin, MK-0457 (VX-680), MLN-8054, NB-1011,
NGR-TNF, NV-1020, oblimersen (Genasense, G3139), OncoVex, ONYX 015 (CI-1042), oxaliplatin
(Eloxatin), panitumumab (ABX-EGF, Vectibix), pelitinib (EKB-569), pemetrexed (Alimta), PD-
17426518_1 (GHMatters) P41939NZ00
325901, PF-0337210, PF-2341066, RAD-001 (Everolimus), RAV-12, Resveratrol, Rexin-G, S-1
(TS-1), seliciclib, SN-38 liposome, Sodium stibogluconate (SSG), sorafenib (Nexavar), SU-14813,
sunitinib (Sutent), temsirolimus (CCI 779), tetrathiomolybdate, thalomide, TLK-286 (Telcyta),
topotecan (Hycamtin), trabectedin (Yondelis), vatalanib (PTK-787), vorinostat (SAHA, Zolinza),
WX-UK1, and ZYC300, wherein the amounts of the active agent together with the amounts of the
combination anticancer agents are effective in treating colorectal cancer.
Some embodiments provide methods for the treatment of renal cell carcinoma in
a human in need of such treatment, comprising administering to said human an amount of a
compound of disclosed herein, in combination with one or more (preferably one to three) anti-
cancer agents selected from the group consisting of capecitabine (Xeloda), interferon alpha,
interleukin-2, bevacizumab (Avastin), gemcitabine (Gemzar), thalidomide, cetuximab (Erbitux),
vatalanib (PTK-787), Sutent, AG-13736, SU-11248, Tarceva, Iressa, Lapatinib and Gleevec,
wherein the amounts of the active agent together with the amounts of the combination anticancer
agents is effective in treating renal cell carcinoma.
Some embodiments provide methods for the treatment of melanoma in a human
in need of such treatment, comprising administering to said human an amount of a compound of
disclosed herein, in combination with one or more (preferably one to three) anti-cancer agents
selected from the group consisting of interferon alpha, interleukin-2, temozolomide (Temodar),
docetaxel (Taxotere), paclitaxel, Dacarbazine (DTIC), carmustine (also known as BCNU),
Cisplatin, vinblastine, tamoxifen, PD-325,901, Axitinib, bevacizumab (Avastin), thalidomide,
sorafanib, vatalanib (PTK-787), Sutent, CpG-7909, AG-13736, Iressa, Lapatinib and Gleevec,
wherein the amounts of the active agent together with the amounts of the combination anticancer
agents is effective in treating melanoma.
Some embodiments provide methods for the treatment of lung cancer in a human
in need of such treatment, comprising administering to said human an amount of a compound
disclosed herein, in combination with one or more (preferably one to three) anti-cancer agents
selected from the group consisting of capecitabine (Xeloda), bevacizumab (Avastin), gemcitabine
(Gemzar), docetaxel (Taxotere), paclitaxel, premetrexed disodium (Alimta), Tarceva, Iressa,
Vinorelbine, Irinotecan, Etoposide, Vinblastine, and Paraplatin (carboplatin), wherein the amounts
of the active agent together with the amounts of the combination anticancer agents is effective in
treating lung cancer.
17426518_1 (GHMatters) P41939NZ00
DETAILED DESCRIPTION
Methods for treating, ameliorating the symptoms of, delaying the progression of,
delaying the onset of or otherwise addressing diseases caused by and/or associated with deregulated
protein kinase activity, particularly ROS family, PLK family, protein kinase C in different isoforms,
Met, PAK-4, PAK-5, ZC-1, STLK-2, DDR-2, Aurora 1, Aurora 2, Bub-1, Chk1, Chk2, HER2, raf1,
MEK1, MAPK, EGF-R, PDGF-R, FGF-R, FLT3, JAK2, IGF-R, ALK, PI3K, weel kinase, Src, Abl,
Akt, MAPK, ILK, MK-2, IKK-2, Cdc7, Nek, Cdk/cyclin kinase family, more particularly Aurora 2,
IGF-1R and ALK activity, and ROS1 activity, and further more particularly ALK activity and/or
ROS1 activity, which comprises administering to a mammal in need thereof an effective amount of
a substituted indazole compound represented by formula (I) or formula 2.(I) as defined below, are
disclosed herein.
Some embodiments provide methods for treating a disease caused by and/or
associated with dysregulated protein kinase activity selected from the group consisting of cancer and
cell proliferative disorders.
Some embodiments provide methods for treating specific types of cancer
including carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid
lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system,
melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, angiosarcoma,
glioblastoma, holangiocarcinoma, inflammatory myofibroblastic tumor, epitheloid
hemangioendothelioma, astrocytoma, meningioma, angiosarcoma, epitheloid hemangiothelioma,
keratocanthomas, thyroid follicular cancer, Kaposi's sarcoma, and Pancreatic cancer.
Some embodiments provide methods for treating specific types of cancer such as,
but not restricted to, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer,
endometrial cancer, gastric cancer, clear cell renal cell carcinoma, invasive ductal carcinoma
(breast), uveal melanoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's
sarcoma, Pancreatic cancer, and medulloblastoma.
Some embodiments provide methods for treating ALK+ Anaplastic Large Cell
Lymphomas (ALCL) and possibly other indications in which the ALK activity might play a role, like
Neuroblastoma, Rhabdomyosarcoma, Glioblastoma, Inflammatory Myofibroblastic Tumor, and
some kind of Melanomas, Breast Carcinomas, Ewings sarcomas, Retinoblastomas and Non Small
Cell Lung Carcinomas (NSCLC).
17426518_1 (GHMatters) P41939NZ00
Some embodiments provide methods for treating, reducing the symptoms of,
ameliorating the symptoms of, delaying the onset of, or otherwise pharmaceutically addressing
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(piperazinyl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide.
Some embodiments provide methods for treating, reducing the symptoms of,
ameliorating the symptoms of, delaying the onset of, or otherwise pharmaceutically addressing
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule of US 8,299,057, issued October 30, 2012, the entirety of which is hereby incorporated by
reference. Some embodiments provide methods for treating, reducing the symptoms of,
ameliorating the symptoms of, delaying the onset of, or otherwise pharmaceutically addressing
Pancreatic cancer and possibly other indications in which a defect in the modulation of ROS1
activity, or upregulation, misregulation or deletion thereof might play a role by administering a
molecule of US 8,114,865, issued February 14, 2012, the entirety of which is hereby incorporated by
reference.
Some embodiments provide methods for treating, reducing the symptoms of,
ameliorating the symptoms of, delaying the onset of, or otherwise pharmaceutically addressing
Pancreatic cancer associated with a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion by identifying a ROS1 down-regulation defect, for example a null mutation such
as a ROS1 deletion in a cancer or precancerous pancreatic cell in an individual, and administering
to the individual a molecule of Formula (I) as disclosed herein, such as N-[5-(3,5-difluorobenzyl)-
1H-indazolyl](piperazinyl)(tetrahydro-2H-pyranylamino) benzamide or N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide.
Some embodiments provide for identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous pancreatic cell in an individual comprises assaying for ROS1 activity in a cell extract
17426518_1 (GHMatters) P41939NZ00
from a pancreatic cancerous or precancerous cell population. In some embodiments identifying a
ROS1 modulation defect such as an upregulation defect or a down-regulation defect, for example a
null mutation such as a ROS1 deletion or a ROS1 chimeric locus encoding a constitutively active
ROS1 kinase in a cancer or precancerous pancreatic cell in an individual comprises assaying for
ROS1 transcript accumulation in an RNA population from a pancreatic cancerous or precancerous
cell population. In some embodiments identifying a ROS1 modulation defect such as an
upregulation defect or a down-regulation defect, for example a null mutation such as a ROS1
deletion or a ROS1 chimeric locus encoding a constitutively active ROS1 kinase in a cancer or
precancerous pancreatic cell in an individual comprises determining the nucleic acid sequence such
as the genomic deoxyribonucleic acid sequence in a cell or cells or a cell population comprising a
cell or cells from a pancreatic cancerous or precancerous cell population.
Some embodiments provide methods to treat cell proliferative disorders such as,
but not restricted to, benign prostate hyperplasia, familial adenomatosis polyposis, neuro-
fibromatosis, psoriasis, atherosclerosis and conditions involving vascular smooth muscle
proliferation or neointimal formation such as restenosis following angioplasty or surgery, pulmonary
fibrosis, arthritis, glomerulonephritis, retinopathies including diabetic and neonatal retinopathies
and age related macular degeneration, graft vessel disease, such as can occur following vessel or
organ transplantation, acromegaly and disorders secondary to acromegaly as well as other
hypertrophic conditions in which IGF/IGF-1R signaling is implicated, such as fibrotic lung disease,
pathologies related to chronic or acute oxidative stress or hyperoxia induced tissue damage, and
metabolic disorders in which elevated IGF levels or IGF-1R activity are implicated, such as obesity.
In addition, the method of the present invention also provides tumor angiogenesis
and metastasis inhibition.
Some embodiments further comprise subjecting the mammal in need thereof to a
radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic
agent. Moreover the invention provides a method for inhibiting the activity ALK protein which
comprises contacting the said protein with an effective amount of a compound of formula (I) or
formula 2.(I).
Formula I
The compounds of formula (I) may have one or more asymmetric centers, and
may therefore exist as individual optical isomers or racemic mixtures. Accordingly, all the possible
17426518_1 (GHMatters) P41939NZ00
isomers, and their mixtures, of the compounds of formula (I) are within the scope of the present
invention.
Derivatives of compounds of formula (I) originating from metabolism in a
mammal, and the pharmaceutically acceptable bio-precursors (otherwise referred to as pro-drugs) of
the compounds of formula (I) are also within the scope of the present invention.
In addition to the above, as known to those skilled in the art, the unsubstituted
nitrogen on the pyrazole ring of the compounds of formula (I) rapidly equilibrates in solution to
form a mixture of tautomers, as depicted below:
X, Ar, R, R1, R2 and R3 are as defined above.
Accordingly, in the present invention, where only one tautomer is indicated for
the compounds of formula (I), the other tautomer (Ia) is also within the scope of the present
invention, unless specifically noted otherwise.
The general terms as used herein, unless otherwise specified, have the meaning
reported below as applied to formula (I).
The term “straight or branched C1-C6 alkyl” refers to a saturated aliphatic
hydrocarbon radical, including straight chain and branched chain groups of from 1 to 6 carbon
atoms, e.g. methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl and the like. The
alkyl group may be substituted or unsubstituted. When substituted, the substituent groups are
preferably one to three, independently selected from the group consisting of halogen, C2-C6
alkenyl, C2-C6 alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10,
SO2R10, NHSOR10, NHSO2R10, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further
substituted C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are as
defined above.
17426518_1 (GHMatters) P41939NZ00
The term “C3-C6 cycloalkyl” refers to a 3- to 6-membered all-carbon monocyclic
ring, which may contain one or more double bonds but does not have a completely conjugated π-
electron system. Examples of cycloalkyl groups, without limitation, are cyclopropyl, cyclobutyl,
cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and cyclohexadienyl. A cycloalkyl group may
be substituted or unsubstituted. When substituted, the substituent groups are preferably one or two
substituents, independently selected from the group consisting of halogen, C2-C6 alkenyl, C2-C6
alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10,
NHSOR10, NHSO2R10, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further
substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4,
R5, R6, R7, R8, R9 and R10 are as defined above.
The term “heterocyclyl” refers to a 3- to 7-membered, saturated or partially
unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as
nitrogen, oxygen and sulfur. Not limiting examples of heterocyclyl groups are, for instance,
oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl,
dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, pyranyl, dihydropyranyl, tetrahydropyranyl,
tetrahydrothiopyranyl, piperidinyl, pyrazolinyl, isoxazolidinyl, isoxazolinyl, thiazolidinyl,
thiazolinyl, isothiazolinyl, dioxanyl, piperazinyl, morpholinyl, thiomorpholinyl,
examethyleneiminyl, homopiperazinyl and the like. A heterocyclyl group may be substituted or
unsubstituted. When substituted, the substituent groups are preferably one or two substituents,
independently selected from the group consisting of halogen, C2-C6 alkenyl, C2-C6 alkynyl, cyano,
nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10, NHSO2R10,
R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched
C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are
as defined above.
The term “aryl” refers to a mono-, bi- or poly-carbocyclic hydrocarbon with from
1 to 4 ring systems, optionally further fused or linked to each other by single bonds, wherein at least
one of the carbocyclic rings is “aromatic”, wherein the term “aromatic” refers to completely
conjugated pi-electron bond system. Non limiting examples of such aryl groups are phenyl, α- or β-
naphthyl or biphenyl groups.
The term “heteroaryl” refers to aromatic heterocyclic rings, typically 5- to 7-
membered heterocycles with from 1 to 3 heteroatoms selected among N, O or S; the heteroaryl ring
17426518_1 (GHMatters) P41939NZ00
can be optionally further fused or linked to aromatic and non-aromatic carbocyclic and heterocyclic
rings. Not limiting examples of such heteroaryl groups are, for instance, pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, phenyl-pyrrolyl, furyl,
phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl,
quinolinyl, isoquinolinyl, 1,2,3-triazolyl, 1-phenyl-1,2,3-triazolyl, 2,3-dihydroindolyl, 2,3-
dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl; benzopyranyl, 2,3-dihydrobenzoxazinyl, 2,3-
dihydroquinoxalinyl and the like.
The aryl and heteroaryl groups can be optionally substituted by one or more,
preferably one, two or three substituents independently selected from halogen, C2-C6 alkenyl, C2-
C6 alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10,
NHSOR10, NHSO2R10, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further
substituted straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4,
R5, R6, R7, R8, R9 and R10 are as defined above.
The term “halogen” indicates fluorine, chlorine, bromine or iodine.
The term “C2-C6 alkenyl” indicates an aliphatic C2-C6 hydrocarbon chain
containing at least one carbon-carbon double bond and which can be straight or branched.
Representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-
propenyl, 1- or 2-butenyl, and the like.
The term “C2-C6 alkynyl” indicates an aliphatic C2-C6 hydrocarbon chain
containing at least one carbon-carbon double bond and which can be straight or branched.
Representative examples include, but are not limited to, ethynyl, 1-propynyl, 2-
propynyl, 1- or 2-butynyl, and the like.
The term “cyano” indicates a —CN residue.
The term “nitro” indicates a —NO2 group.
The term “pharmaceutically acceptable salt” of compounds of formula (I) refers
to those salts that retain the biological effectiveness and properties of the parent compound.
Such salts include acid addition salts with inorganic acids such as hydrochloric,
hydrobromic, nitric, phosphoric, sulfuric, perchloric acid and the like, or with organic acids such as
acetic, trifluoroacetic, propionic, glycolic, lactic, (D) or (L) malic, maleic, methanesulfonic,
ethanesulfonic, benzoic, p-toluenesulfonic, salicylic, cinnamic, mandelic, tartaric, citric, succinic,
malonic acid and the like; salts formed when an acidic proton present in a compound of formula (I)
17426518_1 (GHMatters) P41939NZ00
is either replaced by a metal ion, e.g., an alkali metal ion such as sodium or potassium, or an
alkaline earth ion such as calcium or magnesium, or coordinates with an organic base such as
ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
Compounds of formula (I) wherein X is —CH2—, are represented by the general
formula (IA):
Compounds of formula (I) wherein X is —CH(OH)—, are represented by the
general formula (IB):
Compounds of formula (I) wherein X is —CH(OR′)—, are represented by the
general formula (IC):
17426518_1 (GHMatters) P41939NZ00
Compounds of formula (I) wherein X is —C(R′R″)—, are represented by the
general formula (ID):
In some embodiments, the class of compounds of formula (I) are the compounds
wherein: X is —CH2—, —CH(OH)—, —CH(OR′)— or —C(R′R″)—, wherein R′ is C1-C3 alkyl
and R″ is hydrogen or C1-C3 alkyl; R is an optionally substituted C3-C6 cycloalkyl, heterocyclyl,
aryl or heteroaryl, and R1, R2 and R3 are independently hydrogen, halogen or hydroxy.
In some embodiments, the class of compounds of formula (I) are the compounds
wherein: X is —CH2—, —CH(OH)—, —CH(OR′)— or —C(R′R″)—, wherein R′ is methyl and R″
is hydrogen or methyl, and R1, R2 and R3 are hydrogen.
In some embodiments, the class of compounds of formula (I) are the compounds
wherein R is an optionally substituted aryl or heteroaryl.
In some embodiments, the class of compounds of formula (I) are the compounds
wherein Ar is a group of formula:
17426518_1 (GHMatters) P41939NZ00
Ra, Rb and Rc are independently hydrogen, halogen, C2-C6 alkenyl, C2-C6 alkynyl, cyano,
nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10, NHSO2R10,
R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched
C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein R4, R5, R6, R7, R8, R9
and R10 are as defined above and R is an optionally substituted aryl.
In some embodiments, the class of compounds of formula (I) are the compounds
wherein: Ar is a group of formula:
Ra and Rb are as defined above.
In some embodiments, the class of compounds of formula (I) are the compounds
wherein: •Ar is a group of formula:
Ra is hydrogen, halogen, nitro, NHCOR4 or NR5R6 and Rb is hydrogen, nitro, NR5R6, OR7
or R8R9N—C1-C6 alkyl wherein R4, R5, R6, R7, R8 and R9 are as defined above.
Specific compounds (cpd.) of the invention are listed below:
17426518_1 (GHMatters) P41939NZ00
•1. N-(5-benzyl-1H-indazolyl)(4-methyl-piperazinyl)-benzamide;
•2. N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)-benzamide;
•3. N-[5-(2,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)benzamide;
•4. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)benzamide;
•5. N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)nitrobenzamide;
•6. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)nitro-
benzamide;
•7. 2-Amino-N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
•8. 2-Amino-N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
•9. N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-pyran-
4-ylamino)-benzamide;
•10. N-[5-(2,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
pyranylamino)-benzamide;
•11. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-
pyranylamino)-benzamide;
•12. N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)(1-methyl-
piperidinylamino)-benzamide;
•13. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)(1-methyl-
piperidinylamino)-benzamide;
•14. N-[5-(3-fluoro-benzyl)-1H-indazolyl](2-methoxymethoxymethyl-ethylamino)
(4-methyl-piperazinyl)-benzamide:
•15. N-[5-(2,5-difluoro-benzyl)-1H-indazolyl](2-methoxymethoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•16. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](2-methoxymethoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•17. 2-cyclohexylamino-N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazin
yl)-benzamide;
•18. 2-cyclohexylamino-N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazin-
1-yl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
•19. N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-hydroxy-cyclohexylamino)(4-methyl-
piperazinyl)-benzamide;
•20. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-hydroxy-cyclohexylamino)(4-
methyl-piperazinyl)-benzamide;
•21. N-[5-(3-fluoro-benzyl)-1H-indazolyl]isobutylamino(4-methyl-piperazinyl)-
benzamide;
•22. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]isobutylamino(4-methyl-piperazin
yl)-benzamide;
•23. 2-benzylamino-N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
•24. 2-benzylamino-N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
•25. N-[5-(3-fluoro-benzyl)-1H-indazolyl](2-methoxy-ethylamino)(4-methyl-
piperazinyl)-benzamide;
•26. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](2-methoxy-ethylamino)(4-methyl-
piperazinyl)-benzamide;
•27. N-[5-(3-fluoro-benzyl)-1H-indazolyl](2-methoxymethyl-ethylamino)(4-
methyl-piperazinyl)-benzamide;
•28. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](2-methoxymethyl-ethylamino)(4-
methyl-piperazinyl)-benzamide;
•29. N-[5-(3-fluoro-benzyl)-1H-indazolyl]((S)methoxymethyl-ethylamino)(4-
methyl-piperazinyl)-benzamide;
•30. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]((S)methoxymethyl-ethylamino)
(4-methyl-piperazinyl)-benzamide;
•31. N-[5-(3-fluoro-benzyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)(4-
methyl-piperazinyl)-benzamide;
•32. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]((R)methoxymethyl-ethylamino)
(4-methyl-piperazinyl)-benzamide;
•33. N-[5-(3-fluoro-benzyl)-1H-indazolyl](2-methoxy-1,1-dimethyl-ethylamino)(4-
methyl-piperazinyl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
•34. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](2-methoxy-1,1-dimethyl-ethylamino)
(4-methyl-piperazinyl)-benzamide;
•35. N-[5-(3-fluoro-benzyl)-1H-indazolyl](3-methoxy-propylamino)(4-methyl-
piperazinyl)-benzamide;
•36. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](3-methoxy-propylamino)(4-methyl-
piperazinyl)-benzamide;
•37. N-[5-(3-fluoro-benzyl)-1H-indazolyl](2-fluoro-ethylamino)(4-methyl-piperazin-
1-yl)-benzamide;
•38. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](2-fluoro-ethylamino)(4-methyl-
piperazinyl)-benzamide;
•39. N-[5-(3-fluoro-benzyl)-1H-indazolyl](3-fluoro-propylamino)(4-methyl-
piperazinyl)-benzamide;
•40. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](3-fluoro-propylamino)(4-methyl-
piperazinyl)-benzamide;
•41. N-[5-(3-fluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)phenylamino-
benzamide;
•42. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)
phenylamino-benzamide;
•43. 1H-pyrrolecarboxylic acid [2-[5-(3-fluoro-benzyl)-1H-indazolylcarbamoyl](4-
methyl-piperazinyl)-phenyl]-amide;
•44. 1H-pyrrolecarboxylic acid [2-[5-(3,5-difluoro-benzyl)-1H-indazolylcarbamoyl]
(4-methyl-piperazinyl)-phenyl]-amide;
•45. 1H-pyrrolecarboxylic acid [2-[5-(3-fluoro-benzyl)-1H-indazolylcarbamoyl](4-
methyl-piperazinyl)-phenyl]-amide;
•46. 1H-pyrrolecarboxylic acid [2-[5-(3,5-difluoro-benzyl)-1H-indazolylcarbamoyl]
(4-methyl-piperazinyl)-phenyl]-amide;
•47. N-[5-(3-fluoro-benzyl)-1H-indazolyl]methanesulfonylamino(4-methyl-
piperazinyl)-benzamide;
•48. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]methanesulfonylamino(4-methyl-
piperazinyl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
•49. 2-fluoro-N-[5-(3-fluoro-benzyl)-1H-indazolyl](tetrahydro-pyranylamino)-
benzamide;
•50. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]fluoro(tetrahydro-pyranylamino)-
benzamide;
•51. 2-fluoro-N-[5-(3-fluoro-benzyl)-1H-indazolyl](2-methoxy-ethylamino)-benzamide;
•52. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]fluoro(2-methoxy-ethylamino)-
benzamide;
•53. 4-[(3-dimethylamino-propyl)-methyl-amino]-N-[5-(3-ethoxy-benzyl)-1H-indazolyl]-
2-nitro-benzamide;
•54. 2-amino[(3-dimethylamino-propyl)-methyl-amino]-N-[5-(3-ethoxy-benzyl)-1H-
indazolyl]-benzamide;
•55. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl][(3-dimethylamino-propyl)-methyl-
amino](tetrahydro-pyranylamino)-benzamide;
•56. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl][(3-dimethylamino-propyl)-methyl-
amino](2-methoxymethoxymethyl-ethylamino)-benzamide;
•57. 2-amino-N-[5-(3,5-difluoro-benzyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino]-benzamide;
•58. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl][(3-dimethylamino-propyl)-methyl-
amino]-benzamide;
•59. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl][(3-dimethylamino-propyl)-methyl-
amino]nitro-benzamide;
•60. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(4-methyl-piperazin-
1-yl)(tetrahydro-pyranylamino)-benzamide;
•61. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(2-methoxy
methoxymethyl-ethylamino)(4-methyl-piperazinyl)-benzamide;
•62. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(4-methyl-piperazin-
1-yl)-benzamide;
•63. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(2-methoxy-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•64. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(3-methoxy-
propylamino)(4-methyl-piperazinyl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
•65. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(2-methoxy-1,1-
dimethyl-ethylamino)(4-methyl-piperazinyl)-benzamide;
•66. N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazolyl}(2-fluoro-ethylamino)-
4-(4-methyl-piperazinyl)-benzamide;
•67. N-{5-[(3-ethoxy-phenyl)-hydroxy-methyl]-1H-indazolyl}(4-methyl-piperazin
yl)nitro-benzamide;
•68. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(4-methyl-piperazin-
1-yl)(tetrahydro-pyranylamino)-benzamide;
•69. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(2-methoxy
methoxymethyl-ethylamino)(4-methyl-piperazinyl)-benzamide;
•70. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(4-methyl-piperazin-
1-yl)-benzamide;
•71. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(2-methoxy-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•72. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(3-methoxy-
propylamino)(4-methyl-piperazinyl)-benzamide;
•73. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(2-methoxy-1,1-
dimethyl-ethylamino)(4-methyl-piperazinyl)-benzamide;
•74. N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazolyl}(2-fluoro-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•75. N-{5-[1-(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
•76. N-{5-[1-(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(2-methoxymethoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•77. N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(4-methyl-piperazinyl)-
benzamide;
•78. N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(2-methoxy-ethylamino)(4-
methyl-piperazinyl)-benzamide;
•79. N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(3-methoxy-propylamino)(4-
methyl-piperazinyl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
•80. N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(2-methoxy-1,1-dimethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•81. N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazolyl}(2-fluoro-ethylamino)(4-
methyl-piperazinyl)-benzamide;
•82. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(4-methyl-piperazin-
1-yl)(tetrahydro-pyranylamino)-benzamide;
•83. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(2-methoxy
methoxymethyl-ethylamino)(4-methyl-piperazinyl)-benzamide;
•84. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(4-methyl-piperazin-
1-yl)-benzamide;
•85. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(2-methoxy-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•86. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(3-methoxy-
propylamino)(4-methyl-piperazinyl)-benzamide;
•87. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(2-methoxy-1,1-
dimethyl-ethylamino)(4-methyl-piperazinyl)-benzamide;
•88. N-{5-[1-(3,5-difluoro-phenyl)methyl-ethyl]-1H-indazolyl}(2-fluoro-
ethylamino)(4-methyl-piperazinyl)-benzamide;
•89. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-1,4-diazepanyl)
(tetrahydro-2H-pyranylamino)benzamide;
•90. N-[5-(3,5-Difluoro-benzyl)-1H-indazolyl][(2-dimethylamino-ethyl)-methyl-
amino](tetrahydro-pyranylamino)-benzamide;
•91. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][4-(dimethylamino)piperidinyl]
(tetrahydro-2H-pyranylamino)benzamide;
•92. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(2S)(pyrrolidinylmethyl)pyrrolidin-
1-yl](tetrahydro-2H-pyranylamino)benzamide;
•93. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methylpiperazinyl)benzamide;
•94. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2S)methylpyrrolidinyl]methoxy}-
2-(tetrahydro-2H-pyranylamino)benzamide;
•95. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(1-methylpiperidinyl)oxy]
(tetrahydro-2H-pyranylamino)benzamide;
17426518_1 (GHMatters) P41939NZ00
•96. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][2-(dimethylamino)ethoxy](tetrahydro-
2H-pyranylamino)benzamide;
•97. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(3S)methylpyrrolidinyl]oxy}
(tetrahydro-2H-pyranylamino)benzamide;
•98. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperazinyl)(tetrahydro-2H-pyran
ylamino)benzamide;
•99. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methylpiperazinyl){[cis
(trifluoromethyl)cyclohexyl]amino}benzamide;
•100. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methylpiperazinyl){[trans
(trifluoromethyl)cyclohexyl]amino}benzamide;
•101. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]fluoro(4-methylpiperazin
yl)benzamide;
•102. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](piperidinyl)-1H-pyrazole
carboxamide;
•103. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(cishydroxycyclohexyl)amino](4-
methylpiperazinyl)benzamide;
•104. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(transhydroxycyclohexyl)amino]
(4-methylpiperazinyl)benzamide;
•105. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(2-hydroxyethyl)amino](4-
methylpiperazinyl)benzamide;
•106. 2-[(azetidinylmethyl)amino]-N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methylpiperazinyl)benzamide;
•107. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(1-methylazetidinyl)methyl]amino}-
4-(4-methylpiperazinyl)benzamide;
•108. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(1-methylpiperidinyl)amino]
[tetrahydro-2H-pyranylamino]benzamide;
•109. 4-[(azetidinylmethyl)amino]-N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(tetrahydro-2H-pyranylamino)benzamide;
•110. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(1-methylpiperidin
yl)amino]benzamide;
17426518_1 (GHMatters) P41939NZ00
•111. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(1-methylpiperidinyl)amino]
(morpholinyl)benzamide;
•112. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]methoxy(4-methylpiperazin
yl)benzamide;
•113. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methylpiperazinyl)(tetrahydro-
2H-pyranylamino)pyridinecarboxamide;
•114. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methylpiperazinyl)(tetrahydro-
2H-pyranylamino)pyridinecarboxamide;
•115. 1-[4-{[5-(3,5-difluorobenzyl)-1H-indazolyl]carbamoyl}(tetrahydro-2H-pyran
ylamino)benzyl]piperidine;
•116. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2-
methoxyethyl)(methyl)amino]methyl}(tetrahydro-2H-pyranylamino)benzamide;
•117. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](pyrrolidinylmethyl)(tetrahydro-
2H-pyranylamino)benzamide;
•118. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](morpholinylmethyl)(tetrahydro-
2H-pyranylamino)benzamide;
•119. 4-(azetidinylmethyl)-N-[5-(3,5-difluorobenzyl)-1H-indazolyl](tetrahydro-2H-
pyranylamino)benzamide;
•120. N-[5-(3,5-Difluoro-benzyl)-1H-indazolyl]fluoro(4-methyl-piperazin
ylmethyl)-benzamide;
•121. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]fluoro{[(2S)(pyrrolidin
ylmethyl)pyrrolidinyl]methyl}benzamide;
•122. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]fluoro(morpholin
ylmethyl)benzamide;
•123. N-[5-(3,5-Difluoro-benzyl)-1H-indazolyl]fluoro((S)pyrrolidinylmethyl-
pyrrolidinecarbonyl)-benzamide;
•124. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2R)(pyrrolidin
ylmethyl)pyrrolidinyl]carbonyl}benzamide;
•125. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2S)(pyrrolidin
ylmethyl)pyrrolidinyl]carbonyl}benzamide;
17426518_1 (GHMatters) P41939NZ00
•126. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[4-(pyrrolidinyl)piperidin
yl]carbonyl}benzamide;
•127. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2S)(pyrrolidin
ylmethyl)pyrrolidinyl]carbonyl}(tetrahydro-2H-pyranylamino)benzamide;
•128. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2R)(pyrrolidin
ylmethyl)pyrrolidinyl]carbonyl}(tetrahydro-2H-pyranylamino)benzamide;
•129. N1-[5-(3,5-difluorobenzyl)-1H-indazolyl]-N4-[2-(dimethylamino)ethyl]-N4-methyl-
2-(tetrahydro-2H-pyranylamino)benzene-1,4-dicarboxamide;
•130. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[4-(propanyl)piperazin
yl]carbonyl}(tetrahydro-2H-pyranylamino)benzamide;
•131. N1-[5-(3,5-difluorobenzyl)-1H-indazolyl]-N4-[2-(dimethylamino)ethyl]
(tetrahydro-2H-pyranylamino)benzene-1,4-dicarboxamide;
•132. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(4-methylpiperazinyl)carbonyl]
(tetrahydro-2H-pyranylamino)benzamide;
•133. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[4-(dimethylamino)piperidin
yl]carbonyl}(tetrahydro-2H-pyranylamino)benzamide;
•134. N1-[5-(3,5-difluorobenzyl)-1H-indazolyl]-N4-(1-methylpiperidinyl)
(tetrahydro-2H-pyranylamino)benzene-1,4-dicarboxamide;
•135. N-[5-(2-methylfluoro-benzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
•136. 4-(4-methylpiperazinyl)-N-[5-(pyridinylmethyl)-1H-indazolyl](tetrahydro-
2H-pyranylamino)benzamide;
•137. N-[5-benzyl-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-pyran
ylamino)-benzamide;
•138. ethyl 4-{[2-{[5-(3,5-difluorobenzyl)-1H-indazolyl]carbamoyl}(4-
methylpiperazinyl)phenyl]amino}piperidinecarboxylate;
•139. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methylpiperazinyl)(piperidin
ylamino)benzamide;
•140. ethyl 5-(3,5-difluorobenzyl)({[4-(4-methylpiperazinyl)(tetrahydro-2H-pyran
ylamino)phenyl]carbonyl}amino)-1H-indazolecarboxylate;
17426518_1 (GHMatters) P41939NZ00
•141. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]((S)methoxymethyl-ethylamino)-
4-(4-methyl-piperazinyl)-benzamide;
•142. N-[5-(3,5-difluorobenzyl)-1H-indazolyl][(2R)(pyrrolidin
ylmethyl)pyrrolidinyl](tetrahydro-2H-pyranylamino)benzamide;
•143. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(2R)methylpyrrolidin
yl]methoxy}(tetrahydro-2H-pyranylamino)benzamide;
•144. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]{[(3R)methylpyrrolidinyl]oxy}
(tetrahydro-2H-pyranylamino)benzamide;
•145. N-[5-(3,5-difluorobenzyl)-1H-indazolyl]fluoro{[(2R)(pyrrolidin
ylmethyl)pyrrolidinyl]methyl}benzamide, and
•146. N-[5-(3,5-difluoro-benzyl)-1H-indazolyl]fluoro((R)pyrrolidinylmethyl-
pyrrolidinecarbonyl)-benzamide.
In some embodiments, the compound of the invention is: N-[5-(3,5-difluoro-
benzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-pyranylamino)-benzamide.
The synthesis of the compounds of formula (I), is described in US Patent No
8,299,057, issued October 30, 2012, which is hereby incorporated by reference in its entirety.
Formula 2.(I).
The compounds of formula 2.(I) may have one or more asymmetric centers, and
may therefore exist as individual optical isomers or racemic mixtures. Accordingly, all the possible
isomers, and their mixtures, of the compounds of formula 2.(I) are within the scope of the present
invention.
Derivatives of compounds of formula 2.(I) originating from metabolism in a
mammal, and the pharmaceutically acceptable bio-precursors (otherwise referred to as pro-drugs) of
the compounds of formula 2.(I) are also within the scope of the present invention.
In addition to the above, as known to those skilled in the art, the pyrazole ring of
the compounds of formula 2.(I) rapidly equilibrates in solution to form a mixture of tautomers, as
depicted below:
17426518_1 (GHMatters) P41939NZ00
wherein Ar, R, R1, R2 and R3 are as defined above.
Accordingly, in the present invention, where only one tautomer is indicated for
the compounds of formula 2.(I), the other tautomer 2.(Ia) is also within the scope of the present
invention, unless specifically noted otherwise.
The general terms as used herein, unless otherwise specified, have the meaning
reported below as applied to formula 2.(I).
The term “straight or branched C1-C6 alkyl” refers to a saturated aliphatic
hydrocarbon radical, including straight chain and branched chain groups of from 1 to 6 carbon
atoms, e.g. methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl and the like. The
alkyl group may be substituted or unsubstituted. When substituted, the substituent groups are
preferably one to three, independently selected from the group consisting of halogen, alkenyl,
alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10,
NHSOR10, NHSO2R10, R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further
substituted C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are as
defined above.
The term “C3-C6 cycloalkyl” refers to a 3- to 6-membered all-carbon monocyclic
ring, which may contain one or more double bonds but does not have a completely conjugated π-
electron system. Examples of cycloalkyl groups, without limitation, are cyclopropyl, cyclobutyl,
17426518_1 (GHMatters) P41939NZ00
cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and cyclohexadienyl. A cycloalkyl group may
be substituted or unsubstituted. When substituted, the substituent groups are preferably one or two
substituents, independently selected from the group consisting of halogen, alkenyl, alkynyl, cyano,
nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10, NHSO2R10,
R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched
C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are
as defined above.
The term “heterocyclyl” refers to a 3- to 7-membered, saturated or partially
unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms. These
heteroatoms can include, but are not limited to, nitrogen, oxygen and sulfur. Not limiting examples
of heterocyclyl groups are, for instance, oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, pyranyl,
dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, pyrazolinyl, isoxazolidinyl,
isoxazolinyl, thiazolidinyl, thiazolinyl, isothiazolinyl, dioxanyl, piperazinyl, morpholinyl,
thiomorpholinyl, hexamethyleneiminyl, homopiperazinyl and the like. A heterocyclyl group may be
substituted or unsubstituted. When substituted, the substituent groups are preferably one or two
substituents, independently selected from the group consisting of halogen, alkenyl, alkynyl, cyano,
nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10, NHS2R10,
R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched
C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are
as defined above.
The term “aryl” refers to a mono-, bi- or poly-carbocyclic as well as a
heterocyclic system with from 1 to 4 rings, either fused or linked to each other by single bonds,
wherein at least one of the carbocyclic or heterocyclic rings is aromatic. Not limiting examples of
aryl groups are, for instance, phenyl, α- or β-naphthyl, 9,10-dihydroanthracenyl, indanyl, fluorenyl,
biphenyl, pyrrolyl, furoyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, indolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzopyrazolyl, benzoxazolyl,
benzo isoxazolyl, benzothiazolyl, benzo isothiazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl and the
like.
17426518_1 (GHMatters) P41939NZ00
The term “aryl” may also refer to aromatic carbocyclic or heterocyclic rings
further fused or linked to non-aromatic heterocyclic rings, typically 5- to 7-membered heterocycles.
Not limiting examples of such aryl groups are, for instance, 2,3-dihydroindolyl, 2,3-
dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, benzopyranyl, 2,3-dihydrobenzoxazinyl, 2,3-
dihydroquinoxalinyl and the like.
The aryl group can be optionally substituted by one or more, preferably one, two,
or three substituents independently selected from halogen, alkenyl, alkynyl, cyano, nitro, NHCOR4,
COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10, NHSO2R10, R8R9N—C1-
C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched C1-C6 alkyl,
C3-C6 cycloalkyl, heterocyclyl and aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are as defined
above.
The term “halogen” indicates fluorine, chlorine, bromine or iodine.
The term “alkenyl” indicates straight or branched C2-C6 alkyl groups bearing a
double bond. Representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-
propenyl, 1- or 2-butenyl, and the like.
The term “alkynyl” indicates straight or branched C2-C6 alkyl groups bearing a
triple bond. Representative examples include, but are not limited to, ethynyl, 1-propynyl, 2-
propynyl, 1- or 2-butynyl, and the like.
The term “cyano” indicates a —CN residue.
The term “nitro” indicates a —NO2 group.
References herein to “compounds” are meant to encompass, alternatively,
pharmaceutically acceptable salts of such compounds.
The term “pharmaceutically acceptable salt” of compounds of formula 2.(I) or
any other compounds referenced herein refers to those salts that retain the biological effectiveness
and properties of the parent compound. Such salts include:
Acid addition salts with inorganic acids such as hydrochloric, hydrobromic,
nitric, phosphoric, sulfuric, perchloric acid and the like, or with organic acids such as acetic,
trifluoroacetic, propionic, glycolic, lactic, (D) or (L) malic, maleic, methanesulfonic,
ethanesulfonic, benzoic, p-toluenesulfonic, salicylic, cinnamic, mandelic, tartaric, citric, succinic,
malonic acid and the like;
salts formed when an acidic proton present in a compound of formula 2.(I) is either replaced by a
17426518_1 (GHMatters) P41939NZ00
metal ion, e.g., an alkali metal ion such as sodium or potassium, or an alkaline earth ion such as
calcium or magnesium, or coordinates with an organic base such as ethanolamine, diethanolamine,
triethanolamine, tromethamine, N-methylglucamine, and the like.
In some embodiments, the class of compounds of formula 2.(I) are the
compounds wherein: R is an optionally further substituted C3-C6 cycloalkyl, heterocyclyl or aryl
and R1, R2 and R3 are independently hydrogen, halogen or hydroxy.
In some embodiments, the class of compounds of formula 2.(I) are the
compounds wherein: Ar is an optionally further substituted phenyl, pyridinyl, pyrimidinyl or
pyrazinyl.
In some embodiments, the compounds of formula 2.(I) are the compounds
wherein: R1, R2 and R3 are hydrogen.
In some embodiments, the class of compounds of formula 2.(I) are the
compounds wherein: Ar is an optionally further substituted phenyl or pyridinyl and R is an
optionally further substituted aryl.
In some embodiments, the class of compounds of formula 2.(I) are the
compounds wherein:
Ar is a group of formula:
wherein Ra, Rb and Rc are independently hydrogen, halogen, alkenyl, alkynyl, cyano, nitro,
NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO2R10, NHSOR10, NHSO2R10,
R8R9N—C1-C6 alkyl, R8O—C1-C6 alkyl, an optionally further substituted straight or branched
C1-C6 alkyl, C3-C6 cycloalkyl, heterocyclyl or aryl, wherein R4, R5, R6, R7, R8, R9 and R10 are as
defined above and
R is an optionally further substituted aryl.
17426518_1 (GHMatters) P41939NZ00
In some embodiments, the class of compounds of formula 2.(I) are the
compounds wherein: Ar is a group of formula:
Ra and Rb are as defined above and R is an optionally further substituted aryl.
In some embodiments, the class of compounds of formula 2.(I) are the
compounds wherein: Ar is a group of formula:
Ra is hydrogen, halogen, nitro, NHCOR4 or NR5R6 and Rb is hydrogen, nitro, NR5R6, OR7 or
R8R9N—C1-C6 alkyl wherein R4, R5, R6, R7, R8 and R9 are as defined above and R is an
optionally further substituted phenyl.
Some compounds (cpd.) of the invention are listed below:
1. N-(5-Benzenesulfonyl-1H-indazolyl)(4-methyl-piperazinyl)-benzamide;
2. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
3. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
4. N-(5-Benzenesulfonyl-1H-indazolyl)(4-methyl-piperazinyl)nitro-benzamide;
17426518_1 (GHMatters) P41939NZ00
. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)nitro-
benzamide;
6. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
nitro-benzamide;
7. 2-Amino-N-(5-benzenesulfonyl-1H-indazolyl)(4-methyl-piperazinyl)-benzamide;
8. 2-Amino-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)-
benzamide;
9. 2-Amino-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazin
yl)-benzamide;
. N-(5-Benzenesulfonyl-1H-indazolyl)(4-methyl-piperazinyl)(tetrahydro-pyran-
4-ylamino)-benzamide;
11. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
12. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
13. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]isobutylamino(4-methyl-
piperazinyl)-benzamide;
14. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]isobutylamino(4-methyl-
piperazinyl)-benzamide;
. 2-Cyclohexylamino-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-
piperazinyl)-benzamide;
16. 2-Cyclohexylamino-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-
piperazinyl)-benzamide;
17. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-hydroxy-cyclohexylamino)(4-
methyl-piperazinyl)-benzamide;
18. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-hydroxy-cyclohexylamino)-
4-(4-methyl-piperazinyl)-benzamide;
19. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
[(pyrrolidinylmethyl)-amino]-benzamide;
. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
[(pyrrolidinylmethyl)-amino]-benzamide;
17426518_1 (GHMatters) P41939NZ00
21. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
[(piperidinylmethyl)-amino]-benzamide;
22. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
[(piperidinylmethyl)-amino]-benzamide;
23. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)[(1-
methyl-pyrrolidinylmethyl)-amino]-benzamide;
24. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)[(1-
methyl-pyrrolidinylmethyl)-amino]-benzamide;
. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(piperidinylamino)-benzamide;
26. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(piperidinylamino)-benzamide;
27. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(piperidinylamino)-benzamide;
28. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(piperidinylamino)-benzamide;
29. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-thiopyranylamino)-benzamide;
. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-thiopyranylamino)-benzamide;
31. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl][(furanylmethyl)-amino](4-
methyl-piperazinyl)-benzamide;
32. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(furanylmethyl)-amino]
(4-methyl-piperazinyl)-benzamide;
33. 1H-Pyrrolecarboxylic acid [2-(5-benzenesulfonyl-1H-indazolylcarbamoyl)(4-
methyl-piperazinyl)-phenyl]-amide;
34. 1H-Pyrrolecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
. 1H-Pyrrolecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
17426518_1 (GHMatters) P41939NZ00
36. (S)-Tetrahydro-furancarboxylic acid [2-(5-benzenesulfonyl-1H-indazol
ylcarbamoyl)(4-methyl-piperazinyl)-phenyl]-amide;
37. (S)-Tetrahydro-furancarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
38. (S)-Tetrahydro-furancarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
39. 1H-Pyrrolecarboxylic acid [2-(5-benzenesulfonyl-1H-indazolylcarbamoyl)(4-
methyl-piperazinyl)-phenyl]-amide;
40. 1H-Pyrrolecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
41. 1H-Pyrrolecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
42. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]isobutyrylamino(4-methyl-
piperazinyl)-benzamide;
43. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]isobutyrylamino(4-methyl-
piperazinyl)-benzamide;
44. 2-(Cyclobutanecarbonyl-amino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-
methyl-piperazinyl)-benzamide;
45. 2-(Cyclobutanecarbonyl-amino)-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]
(4-methyl-piperazinyl)-benzamide;
46. 2-(2-Amino-acetylamino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-
methyl-piperazinyl)-benzamide;
47. 2-(2-Amino-acetylamino)-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl](4-
methyl-piperazinyl)-benzamide;
48. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-methylamino-acetylamino)(4-
methyl-piperazinyl)-benzamide;
49. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-methylamino-acetylamino)-
4-(4-methyl-piperazinyl)-benzamide;
50. 2-(2-Dimethylamino-acetylamino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]
(4-methyl-piperazinyl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
51. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-dimethylamino-
acetylamino)(4-methyl-piperazinyl)-benzamide;
52. 2-((S)Amino-propionylamino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-
methyl-piperazinyl)-benzamide;
53. 2-((S)Amino-propionylamino)-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]-
4-(4-methyl-piperazinyl)-benzamide;
54. (S)-Pyrrolidinecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
55. (S)-Pyrrolidinecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
56. Piperidinecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
57. Piperidinecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
58. Piperidinecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
59. Piperidinecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
60. Piperidinecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
61. Piperidinecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
62. (R)-Tetrahydro-furancarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
63. Tetrahydro-furancarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
64. Tetrahydro-pyrancarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
65. Pyridinecarboxylic acid [2-(5-benzenesulfonyl-1H-indazolylcarbamoyl)(4-
methyl-piperazinyl)-phenyl]-amide;
17426518_1 (GHMatters) P41939NZ00
66. Pyridinecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazolylcarbamoyl]-
-(4-methyl-piperazinyl)-phenyl]-amide;
67. Pyridinecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
68. 3H-Imidazolecarboxylic acid [2-(5-benzenesulfonyl-1H-indazolylcarbamoyl)(4-
methyl-piperazinyl)-phenyl]-amide;
69. 3H-Imidazolecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
70. 3H-Imidazolecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
71. 1-Methyl-1H-pyrrolecarboxylic acid [2-(5-benzenesulfonyl-1H-indazol
ylcarbamoyl)(4-methyl-piperazinyl)-phenyl]-amide;
72. 1-Methyl-1H-pyrrolecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
73. 1-Methyl-1H-pyrrolecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-
3-ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
74. Furancarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazolylcarbamoyl]
(4-methyl-piperazinyl)-phenyl]-amide;
75. Furancarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
76. 5-Methyl-isoxazolecarboxylic acid [2-(5-benzenesulfonyl-1H-indazolylcarbamoyl)-
-(4-methyl-piperazinyl)-phenyl]-amide;
77. 5-Methyl-isoxazolecarboxylic acid [2-[5-(3-fluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
78. 5-Methyl-isoxazolecarboxylic acid [2-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol
ylcarbamoyl](4-methyl-piperazinyl)-phenyl]-amide;
79. N-(5-Benzenesulfonyl-1H-indazolyl)benzoylamino(4-methyl-piperazinyl)-
benzamide;
80. 2-Benzoylamino-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-
piperazinyl)-benzamide;
17426518_1 (GHMatters) P41939NZ00
81. 2-Benzoylamino-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-
piperazinyl)-benzamide;
82. N-[5-(3-Chloro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
83. N-[5-(3-M ethoxy-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
84. N-[5-(3,5-Dichloro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
85. N-[5-(3-Fluoromethoxy-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazin
yl)(tetrahydro-pyranylamino)-benzamide;
86. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyranylamino)-
benzamide;
87. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyranylamino)-
benzamide;
88. 4-Fluoro-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyran
ylamino)-benzamide;
89. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]fluoro(tetrahydro-pyran
ylamino)-benzamide;
90. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]methoxy(tetrahydro-pyran
ylamino)-benzamide;
91. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]methoxy(tetrahydro-pyran
ylamino)-benzamide;
92. 4-Dimethylamino-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyran-
4-ylamino)-benzamide;
93. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]dimethylamino(tetrahydro-
pyranylamino)-benzamide;
94. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]morpholinyl(tetrahydro-pyran-
4-ylamino)-benzamide;
95. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]morpholinyl(tetrahydro-
pyranylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
96. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]piperazinyl(tetrahydro-pyran-
4-ylamino)-benzamide;
97. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]piperazinyl(tetrahydro-
pyranylamino)-benzamide;
98. 4-(4-Ethyl-piperazinyl)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]
(tetrahydro-pyranylamino)-benzamide;
99. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-ethyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
100. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-propyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
101. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-propyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
102. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-isopropyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
103. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-isopropyl-piperazinyl)
(tetrahydro-pyranylamino)-benzamide;
104. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-[1,4]diazepanyl)
(tetrahydro-pyranylamino)-benzamide;
105. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-[1,4]diazepanyl)-
2-(tetrahydro-pyranylamino)-benzamide;
106. 4-(4-Ethyl-[1,4]diazepanyl)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]
(tetrahydro-pyranylamino)-benzamide;
107. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-ethyl-[1,4]diazepanyl)
(tetrahydro-pyranylamino)-benzamide;
108. 4-(2-Dimethylamino-ethoxy)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]
(tetrahydro-pyranylamino)-benzamide;
109. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-dimethylamino-ethoxy)
(tetrahydro-pyranylamino)-benzamide;
110. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-pyrrolidinyl-ethoxy)
(tetrahydro-pyranylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
111. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-pyrrolidinyl-ethoxy)
(tetrahydro-pyranylamino)-benzamide;
112. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](1-methyl-piperidinyloxy)
(tetrahydro-pyranylamino)-benzamide;
113. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](1-methyl-piperidinyloxy)-
2-(tetrahydro-pyranylamino)-benzamide;
114. 4-Dimethylaminomethyl-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]
(tetrahydro-pyranylamino)-benzamide;
115. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]dimethylaminomethyl
(tetrahydro-pyranylamino)-benzamide;
116. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]pyrrolidinylmethyl
(tetrahydro-pyranylamino)-benzamide;
117. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]pyrrolidinylmethyl
(tetrahydro-pyranylamino)-benzamide;
118. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]piperidinylmethyl
(tetrahydro-pyranylamino)-benzamide;
119. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]piperidinylmethyl
(tetrahydro-pyranylamino)-benzamide;
120. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]morpholinylmethyl
(tetrahydro-pyranylamino)-benzamide;
121. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]morpholinylmethyl
(tetrahydro-pyranylamino)-benzamide;
122. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](1-methyl-piperidinylamino)
(tetrahydro-pyranylamino)-benzamide;
123. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](1-methyl-piperidin
ylamino)(tetrahydro-pyranylamino)-benzamide;
124. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]-2,4-bis-(tetrahydro-pyran
ylamino)-benzamide;
125. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]-2,4-bis-(tetrahydro-pyran
ylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
126. 4-(2-Dimethylaminomethyl-ethylamino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](tetrahydro-pyranylamino)-benzamide;
127. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-dimethylaminomethyl-
ethylamino)(tetrahydro-pyranylamino)-benzamide;
128. 4-(2-Diethylaminomethyl-ethylamino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazol-
3-yl](tetrahydro-pyranylamino)-benzamide;
129. 4-(2-Diethylaminomethyl-ethylamino)-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-
indazolyl](tetrahydro-pyranylamino)-benzamide;
130. 4-(2-Dimethylamino-ethylamino)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]
(tetrahydro-pyranylamino)-benzamide;
131. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-dimethylamino-
ethylamino)(tetrahydro-pyranylamino)-benzamide;
132. 4-[(2-Dimethylamino-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](tetrahydro-pyranylamino)-benzamide;
133. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
methyl-amino](tetrahydro-pyranylamino)-benzamide;
134. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]{[2-(isopropyl-methyl-amino)-
ethyl]-methyl-amino}(tetrahydro-pyranylamino)-benzamide;
135. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]{[2-(isopropyl-methyl-amino)-
ethyl]-methyl-amino}(tetrahydro-pyranylamino)-benzamide;
136. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl][methyl-(2-piperidinyl-ethyl)-
amino](tetrahydro-pyranylamino)-benzamide;
137. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][methyl-(2-piperidinyl-
ethyl)-amino](tetrahydro-pyranylamino)-benzamide;
138. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl][methyl-(2-morpholinyl-ethyl)-
amino](tetrahydro-pyranylamino)-benzamide;
139. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][methyl-(2-morpholinyl-
ethyl)-amino](tetrahydro-pyranylamino)-benzamide;
140. 4-[(2-Dimethylamino-ethyl)-ethyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazol-
3-yl](tetrahydro-pyranylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
141. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
ethyl-amino](tetrahydro-pyranylamino)-benzamide;
142. 4-[(3-Dimethylamino-propyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](tetrahydro-pyranylamino)-benzamide;
143. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino](tetrahydro-pyranylamino)-benzamide;
144. 4-(4-Dimethylamino-piperidinyl)-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl]-
2-(tetrahydro-pyranylamino)-benzamide;
145. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-dimethylamino-piperidin
yl)(tetrahydro-pyranylamino)-benzamide;
146. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-pyrrolidinyl-piperidinyl)-
2-(tetrahydro-pyranylamino)-benzamide;
147. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-pyrrolidinyl-piperidin
yl)(tetrahydro-pyranylamino)-benzamide;
148. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl][methyl-(1-methyl-pyrrolidin
yl)-amino](tetrahydro-pyranylamino)-benzamide;
149. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][methyl-(1-methyl-pyrrolidin-
3-yl)-amino](tetrahydro-pyranylamino)-benzamide;
150. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-methoxy-ethylamino)(4-
methyl-piperazinyl)-benzamide;
151. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-methoxy-ethylamino)(4-
methyl-piperazinyl)-benzamide;
152. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
methyl-amino](2-methoxy-ethylamino)-benzamide;
153. 4-[(2-Dimethylamino-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](2-methoxy-ethylamino)-benzamide;
154. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino](2-methoxy-ethylamino)-benzamide;
155. 4-[(3-Dimethylamino-propyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](2-methoxy-ethylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
156. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylaminomethyl-
ethyl)-methyl-amino](2-methoxy-ethylamino)-benzamide;
157. 4-[(2-Dimethylaminomethyl-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-
1H-indazolyl](2-methoxy-ethylamino)-benzamide;
158. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-methoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
159. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-methoxymethyl-ethylamino)-
4-(4-methyl-piperazinyl)-benzamide;
160. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
methyl-amino](2-methoxymethyl-ethylamino)-benzamide;
161. 4-[(2-Dimethylamino-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](2-methoxymethyl-ethylamino)-benzamide;
162. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino](2-methoxymethyl-ethylamino)-benzamide;
163. 4-[(3-Dimethylamino-propyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](2-methoxymethyl-ethylamino)-benzamide;
164. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylaminomethyl-
ethyl)-methyl-amino](2-methoxymethyl-ethylamino)-benzamide;
165. 4-[(2-Dimethylaminomethyl-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-
1H-indazolyl](2-methoxymethyl-ethylamino)-benzamide;
166. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]dimethylaminomethyl(2-
methoxymethyl-ethylamino)-benzamide;
167. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]((S)methoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
168. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]((S)methoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
169. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
methyl-amino]((S)methoxymethyl-ethylamino)-benzamide;
170. 4-[(2-Dimethylamino-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl]((S)methoxymethyl-ethylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
171. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino]((S)methoxymethyl-ethylamino)-benzamide;
172. 4-[(3-Dimethylamino-propyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl]((S)methoxymethyl-ethylamino)-benzamide;
173. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylaminomethyl-
ethyl)-methyl-amino]((S)methoxymethyl-ethylamino)-benzamide;
174. 4-[(2-Dimethylaminomethyl-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-
1H-indazolyl]((S)methoxymethyl-ethylamino)-benzamide;
175. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
176. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
177. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
methyl-amino]((R)methoxymethyl-ethylamino)-benzamide;
178. 4-[(2-Dimethylamino-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl]((R)methoxymethyl-ethylamino)-benzamide;
179. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino]((R)methoxymethyl-ethylamino)-benzamide;
180. 4-[(3-Dimethylamino-propyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl]((R)methoxymethyl-ethylamino)-benzamide;
181. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylaminomethyl-
ethyl)-methyl-amino]((R)methoxymethyl-ethylamino)-benzamide;
182. 4-[(2-Dimethylaminomethyl-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-
1H-indazolyl]((R)methoxymethyl-ethylamino)-benzamide;
183. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-methoxymethoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
184. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-methoxymethoxymethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
185. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylamino-ethyl)-
methyl-amino](2-methoxymethoxymethyl-ethylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
186. 4-[(2-Dimethylamino-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](2-methoxymethoxymethyl-ethylamino)-benzamide;
187. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino](2-methoxymethoxymethyl-ethylamino)-benzamide;
188. 4-[(3-Dimethylamino-propyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-1H-
indazolyl](2-methoxymethoxymethyl-ethylamino)-benzamide;
189. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(2-dimethylaminomethyl-
ethyl)-methyl-amino](2-methoxymethoxymethyl-ethylamino)-benzamide;
190. 4-[(2-Dimethylaminomethyl-ethyl)-methyl-amino]-N-[5-(3-fluoro-benzenesulfonyl)-
1H-indazolyl](2-methoxymethoxymethyl-ethylamino)-benzamide;
191. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-methoxy-1,1-dimethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
192. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-methoxy-1,1-dimethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
193. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
propylamino)(4-methyl-piperazinyl)-benzamide;
194. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
propylamino)(4-methyl-piperazinyl)-benzamide;
195. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
propylamino)(4-methyl-piperazinyl)-benzamide;
196. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]((R)methoxymethyl-
propylamino)(4-methyl-piperazinyl)-benzamide;
197. 2-Fluoro-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyran
ylamino)-benzamide;
198. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]fluoro(tetrahydro-pyran
ylamino)-benzamide;
199. 2-Fluoro-N-[5-(3-fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)-
6-(tetrahydro-pyranylamino)-benzamide;
200. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]fluoro(4-methyl-piperazin-
1-yl)(tetrahydro-pyranylamino)-benzamide;
17426518_1 (GHMatters) P41939NZ00
201. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyranylamino)-
isonicotinamide;
202. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyranylamino)-
isonicotinamide;
203. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-methoxymethyl-ethylamino)-
isonicotinamide;
204. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-methoxymethyl-
ethylamino)-isonicotinamide;
205. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyranylamino)-
nicotinamide;
206. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](tetrahydro-pyranylamino)-
nicotinamide;
207. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-nicotinamide;
208. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-pyranylamino)-nicotinamide;
209. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl][(1H-pyrrolecarbonyl)-amino]-
isonicotinamide;
210. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(1H-pyrrolecarbonyl)-
amino]-isonicotinamide;
211. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl][(1H-pyrrolecarbonyl)-amino]-
nicotinamide;
212. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(1H-pyrrolecarbonyl)-
amino]-nicotinamide;
213. 3-Amino-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl]-isonicotinamide;
214. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]fluoronitro-benzamide;
215. 2-Amino-N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl][methyl-(2-piperidin-
1-yl-ethyl)-amino]-benzamide;
216. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl][(3-dimethylamino-propyl)-
methyl-amino]isobutylamino-benzamide;
17426518_1 (GHMatters) P41939NZ00
217. N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazolyl][methyl-(2-piperidinyl-
ethyl)-amino]nitro-benzamide;
218. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl]nitro(tetrahydro-pyran
ylamino)-benzamide;
219. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](4-pyrrolidinyl-piperidine-
1-carbonyl)-benzamide;
220. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]((R)pyrrolidinylmethyl-
pyrrolidinecarbonyl)-benzamide;
221. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl]((S)pyrrolidinylmethyl-
pyrrolidinecarbonyl)-benzamide;
222. 1-Piperidinyl-1H-pyrazolecarboxylic acid [5-(3,5-difluoro-benzenesulfonyl)-1H-
indazolyl]-amide;
223. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-fluoro-ethylamino)(4-
methyl-piperazinyl)-benzamide;
224. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-fluoro-ethylamino)(4-
methyl-piperazinyl)-benzamide;
225. N-(5-Benzenesulfonyl-1H-indazolyl)(2-fluoro-ethylamino)(4-methyl-piperazin-
1-yl)-benzamide;
226. N-[5-(3,5-Difluoro-benzenesulfonyl)-1H-indazolyl](2-fluorofluoromethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide;
227. N-[5-(3-Fluoro-benzenesulfonyl)-1H-indazolyl](2-fluorofluoromethyl-
ethylamino)(4-methyl-piperazinyl)-benzamide and
228. N-(5-Benzenesulfonyl-1H-indazolyl)(2-fluorofluoromethyl-ethylamino)(4-
methyl-piperazinyl)-benzamide.
The present invention also provides a process for the preparation of a compound
of formula 2.(I)
The synthesis of the compounds of formula 2.(I), is described in US Patent No
8,114,865, issued February 14, 2012, which is hereby incorporated by reference in its entirety.
Pharmacology
The short forms and abbreviations used herein have the following meaning: Ci –
Curie; DMSO – dimethylsulfoxide; ID – identity; KDa – kiloDalton; microCi – microCurie; Mg –
17426518_1 (GHMatters) P41939NZ00
milligram; Microg – microgram; mL – milliliter; microL – microliter; M – molar; mM – millimolar;
microM – micromolar; nM – nanomolar.
Molecular Screening
Transcript accumulation levels, genomic locus screening methods, and protein
kinase activity assays for ROS1, ALK, TrkA, TrkB, TrkC, or or any kinase recited herein, or a
combination thereof, may be performed using methods known to one of skill in the art. Kinase
assays may be performed by providing a substrate to a protein extract comprising ROS1, ALK,
TrkA, TrkB, TrkC, or any kinase recited herein. ROS1, ALK, TrkA, TrkB, TrkC, or any kinase
recited herein locus sequencing may be performed using, for example, whole genome shotgun
sequencing, or targeted sequencing of the ROS1, ALK, TrkA, TrkB, TrkC, or any kinase recited
herein locus, for example through targeted amplification of the locus or a region spanning the locus
wholly or in part, using PCR techniques know to one of skill in the art and primers generated
through means known to one of skill in the art, followed by sequencing of any generated amplicons.
Molecular alterations can be detected by next generation sequencing (NGS), quantitative reverse-
transcription polymerase chain reaction DNA amplification reactions (qPCR), fluorescence in situ
hybridization (FISH), and/or immunohistochemistry (IHC) and are inclusive of gene
rearrangements, single-nucleotide polymorphisms (SNPs), insertions, deletions, splice variants, gene
amplifications, and aberrant RNA/protein expression.
Copy number variations (CNVs), point mutations (SNPs/SNVs), insertions,
deletions, gene rearrangements, RNA/protein over expression, and constitutive phosphorylation are
measurable alterations that can result in oncogenic perturbation of ROS1, ALK, TrkA, TrkB, TrkC,
or any kinase recited herein, such as misregulation, upregulation, or downregulation through and
including downregulation to complete loss of activity. A DNA-based test can detect CNVs, SNPs,
insertions, deletions, and gene rearrangements. An RNA-based test can detect over expression,
under expression (up to and including complete loss of expression) or misexpression of ROS1,
ALK, TrkA, TrkB, TrkC, or any kinase recited herein mRNA and many of the alterations detected in
the DNA-based test. Protein-based tests allow one to measure the over expression, under expression
(through and including complete loss of expression) or misexpression of ROS1, ALK, TrkA, TrkB,
TrkC, or any kinase recited herein protein; constitutive phosphorylation, constitutive
dephosphorylation or misphosphorylation of the ROS1, ALK, TrkA, TrkB, TrkC, or any kinase
17426518_1 (GHMatters) P41939NZ00
recited herein protein; and increase, decrease (through and including complete loss) or altered
activity pattern of ROS1, ALK, TrkA, TrkB, TrkC, or any kinase recited herein kinase activity.
Preparation of formulation and dosage forms comprising N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide.
Hard gelatin capsules comprising 50 mg, 100 mg, and 200 mg of N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide were prepared as follows.
The required amounts of active ingredient and excipients are weighed into the
warehouse dispensing area. The weight of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-
piperazinyl)(tetrahydro-2H-pyranylamino) benzamide and the mannitol are adjusted
according to the active desired potency of the dosage form. (1) Manually pre-mix N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide and colloidal silicon dioxide into a polyethylene (PE) bag. (2) The resulting mixture
from step 1 is passed through a 0.500 mm screen size sieve, along with a portion of the
pregelatinized starch and mannitol and the resulting materials are collected in a blender. (3) The
resulting mixture from step 2 is further mixed for about 20 minutes at 20 - 25 rpm. (4) The
pregelatinized starch and magnesium stearate and are pre-mixed together and are passed through a
0.500 mm screen size sieve. (5) The material from step 4 are mixed together with the materials from
step 3 and mixed for about 20 minutes at 20 - 25 rpm. (6) The blend resulting from step 5 is filled
into hard gelatin capsules using an automatic capsule filling machine. Representative formulations
of capsules comprising 50 mg, 100 mg or 200 mg of N-[5-(3,5-difluorobenzyl)-1H-indazolyl]
(4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide are shown below.
50 mg capsule representative batch formulation
Batch formula 50 Amount per capsule
Components Function
mg (6,000 capsules) 50 mg
N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl- Active
300 g 50 mg
piperazinyl)(tetrahydro-2H- ingredient
pyranylamino) benzamide
Mannitol Filler 255.00 g 42.50 mg
Pregelatinized starch Filler 102.75 g 17.125 mg
17426518_1 (GHMatters) P41939NZ00
Colloidal silicon dioxide Glidant 10.50 g 1.750 mg
Magnesium sterate Lubricant 6.75 g 1.125 mg
Total 675.00 g 112.50 mg
100 mg capsule representative batch formulation
Batch formula 100 Amount per capsule
Components Function
mg (3,600 capsules) 100 mg
N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl- Active
360.0 g 100.00 mg
piperazinyl)(tetrahydro-2H- ingredient
pyranylamino) benzamide
Mannitol Filler 306.00 g 85.00 mg
Pregelatinized starch Filler 123.30 g 34.25 mg
Colloidal silicon dioxide Glidant 12.60 g 3.50 mg
Magnesium sterate Lubricant 8.10 g 2.25 mg
Total 810.00 g 225.00 mg
200 mg capsule representative batch formulation
Batch formula 200 Amount per capsule
Components Function
mg (4,100 capsules) 200 mg
N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-
Active 820.00 g 200.00 mg
piperazinyl)(tetrahydro-2H-
ingredient
pyranylamino) benzamide
Mannitol Filler 697.00 g 170.00 mg
Pregelatinized starch Filler 280.85 g 68.50 mg
Colloidal silicon dioxide Glidant 28.70 g 7.00 mg
Magnesium sterate Lubricant 18.45 g 4.50 mg
Total 1845.00 g 450.00 mg
A dose escalation study of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide was conducted in human
patients with advanced solid tumors. N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-
piperazinyl)(tetrahydro-2H-pyranylamino) benzamide was dosed orally once/day in a 4 day
on, 3 day off schedule for 3 weeks, followed by a 7 day rest period, in continuous 28-day cycles
(Schedule A); once/day in continuous 28-day cycles (Schedule B); and once/day in a 4 day on, 3 day
off schedule without interruption in continuous 28-day cycles (Schedule C). A minimum of 3
17426518_1 (GHMatters) P41939NZ00
patients were enrolled at each dose level. Endpoints include safety, PK, and tumor response by
response evaluation criteria in solid tumors (RECIST).
Schedule A evaluated ascending oral doses of N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide once daily
(fasted state) in a 4-day on, 3-day off schedule for 3 weeks, followed by a 7-day rest period, in
continuous 28-day cycles. Dose escalation was conducted according to the standard ‘3 + 3’ scheme.
Schedule B evaluated ascending oral doses of N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide once daily
(fed state) without rest, in continuous 28-day cycles.
Schedule C evaluated ascending oral doses of N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide once daily
(fed state) in a 4-day on, 3-day off schedule for 4 weeks without rest, in continuous 28-day cycles.
Patients on each dosing schedule and at each dose
Schedule Cohort Daily Dose Level # of Patients
1 100 mg/m 3
2 200 mg/m 3
3 400 mg/m 4
4 800 mg/m 3
1200 mg/m 3
6 1600 mg/m 3
B 1 200 mg/m 3
C 1 400 mg/m 3
Patient cancer diagnosis and associated molecular alterations
Number of
Primary Diagnosis Molecular Alteration
patients
ALK rearrangement
ROS1 6 rearrangements 8*
NSCLC
1 deletion 8
1 copy number gain
17426518_1 (GHMatters) P41939NZ00
CRC TrkA rearrangement 1
ROS1 deletion 1
ALK mutation 2
Neuroblastoma ROS1 rearrangement 1
TrkA overexpression 1
Glioblastoma None** 1
Pancreatic ROS1 deletion 1
Leiomyosarcoma ALK deletion 1
Steady state pK profile of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide in patients on dosing
Schedule A
17426518_1 (GHMatters) P41939NZ00
Exposure to N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazin
yl)(tetrahydro-2H-pyranylamino) benzamide in patients on dosing Schedule A increased in an
approximate dose proportional manner up to doses of 800 mg/m . The mean plasma half-life was
17 – 44 hours following administration. The most common adverse events (AEs) (mainly grade 1-2)
considered possibly treatment-related included nausea, paresthesia, vomiting, diarrhea, asthenia,
myalgia, arthralgia, and dysgeusia. There was one possibly treatment-related grade 3 AE of
asthenia.
17426518_1 (GHMatters) P41939NZ00
Adverse Event G1 (%) G2 (%) Total (%)**
Nausea 14 (56) 2 (8) 16 (64)
Paresthesia 15 (60) 0 (0) 15 (60)
Asthenia 9 (36) 3 (12) 13 (52)
Vomiting 7 (28) 2 (8) 9 (36)
Diarrhea 6 (24) 2 (8) 8 (32)
Myalgia 6 (24) 1 (4) 7 (28)
Abdominal pain 4 (16) 2 (8) 6 (24)
Back Pain 5 (20) 1 (4) 6 (24)
Arthralgia 3 (12) 3 (12) 6 (24)
Headache 6 (24) 0 (0) 6 (24)
Dyspnea 3 (12) 1 (4) 6 (24)
Pyrexia 6 (24) 0 (0) 6 (24)
Dysgeusia 6 (24) 0 (0) 6 (24)
Cough 4 (16) 1 (4) 5 (20)
Results
Non-small cell lung cancer (NSCLC) patients (N=4).
A 46 year old female, with a ROS1 rearrangement, s/p 2 cycles of chemotherapy,
achieved complete response after 2 cycles of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-
methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide (400 mg/m2/day, Schedule
C). Complete response is ongoing (patient is currently in cycle 2).
A 63 year old female with metastatic adenocarcinoma, ALK rearrangement, s/p 4
cycles of chemotherapy, crizotinib, achieved partial response after 4 cycles of N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide (1200 mg/m2/day, Schedule A). Partial response is ongoing (patient is currently in cycle
).
17426518_1 (GHMatters) P41939NZ00
A 44 year old female with metastatic disease (CNS metastases), ROS1
rearrangement, s/p 3 cycles of chemotherapy, erlotinib, s/p surgery/XRT to brain, achieved partial
response after 2 cycles of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide (1200 mg/m /day, Schedule A). The patient exhibited a
partial response that is ongoing (patient currently in cycle 9).
A 63 year old male, ROS1 rearrangement, s/p 3 cycles of chemotherapy, achieved
partial response after 1 cycle of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazin-
1-yl)(tetrahydro-2H-pyranylamino) benzamide (400 mg/m2/day, Schedule C). Partial response
is ongoing (patient currently in cycle 3).
Colorectal cancer (CRC) (N=1).
A 75 year old female with metastatic CRC, TrkA rearrangement, s/p 3 cycles of
chemotherapy, cetuximab, achieved partial response after 1 cycle of N-[5-(3,5-difluorobenzyl)-1H-
indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide (1600
mg/m , Schedule A). Partial response lasted for 4 cycles before progressive disease.
Neuroblastoma (NB) (N=1).
A 22 year old female with metastatic NB, ALK mutation, s/p 4 cycles of
chemotherapy, achieved partial response after 12 cycles of N-[5-(3,5-difluorobenzyl)-1H-indazol
yl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino) benzamide (started at 200
mg/m /day and had subsequent dose escalations to1200 mg/m /day, Schedule A). Partial response is
ongoing (the patient is currently in cycle 21).
A total of 25 patients were evaluated across 3 different dosing schedules in this
trial of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-
pyranylamino) benzamide.
There was a complete response in a patient with non-small cell lung cancer
(NSCLC) with a ROS1 molecular alteration. There were 5 partial responses (3 of these durable >9
cycles) across multiple tumor types (NSCLC, CRC and NB) in patients with TrkA, ROS1, and ALK
molecular alterations; moreover, there were 2 patients with prolonged stable disease (11+ cycles)
with NSCLC and pancreatic adenocarcinoma.
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide was well tolerated in all dosing schedules tested,
including intermittent and daily continuous administration.
17426518_1 (GHMatters) P41939NZ00
Most common AEs (mainly grade 1-2) considered possibly drug-related were
nausea, paresthesia, vomiting, diarrhea, asthenia, myalgia, arthralgia, and dysgeusia.
Only 1 possibly drug-related Grade >3 AE was observed: asthenia (Grade 3 in
one patient).
No drug limiting toxicities, study discontinuations due to adverse events, or drug-
related serious adverse events were reported.
Schedule A was terminated at 1600 mg/m2/day due to a plateau of N-[5-(3,5-
difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)(tetrahydro-2H-pyranylamino)
benzamide exposure and the data were presented previously.
N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl)
(tetrahydro-2H-pyranylamino) benzamide was well tolerated in all dosing schedules tested (both
on an intermittent and daily continuous basis). Most AEs ≤ Grade 2.
Only 1 possibly drug-related Grade >3 AE has been observed: asthenia (1200
mg/m , Schedule A), that subsided with dose reduction to 800 mg/m /day.
No DLTs, study discontinuations due to AEs, or drug-related SAEs were reported
in any dosing schedule.
Exposure to N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazin
yl)(tetrahydro-2H-pyranylamino) benzamide increased in an approximate dose proportional
manner up to doses of 800 mg/m with mean plasma half-life of 17 to 44 hours.
Responders tended to have higher exposure than non-responders throughout the
entire dosing cycle in Schedule A.
The term “comprising” as used herein is synonymous with “including,”
“containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional,
unrecited elements or method steps.
The term “wild-type” as used herein refers to the protein, nucleic acid sequence,
allele, locus, or activity level of a protein in a disease-free cell of a healthy individual with respect
to a disease in question. For example, a wild-type ROS1 activity level corresponds to an activity
level of ROS1 in a healthy cell of an individual lacking a ROS1-related disease or pre-disease
condition.
All numbers expressing quantities of ingredients, reaction conditions, and so
forth used in the specification are to be understood as being modified in all instances by the term
17426518_1 (GHMatters) P41939NZ00
“about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are
approximations that may vary depending upon the desired properties sought to be obtained. At the
very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope
of any claims in any application claiming priority to the present application, each numerical
parameter should be construed in light of the number of significant digits and ordinary rounding
approaches.
The above description discloses several methods and materials of the present
invention. This invention is susceptible to modifications in the methods and materials, as well as
alterations in the fabrication methods and equipment. Such modifications will become apparent to
those skilled in the art from a consideration of this disclosure or practice of the invention disclosed
herein. Consequently, it is not intended that this invention be limited to the specific embodiments
disclosed herein, but that it cover all modifications and alternatives coming within the true scope
and spirit of the invention.
All references cited herein, including but not limited to published and
unpublished applications, patents, and literature references, are incorporated herein by reference in
their entirety and are hereby made a part of this specification. To the extent publications and
patents or patent applications incorporated by reference contradict the disclosure contained in the
specification, the specification is intended to supersede and/or take precedence over any such
contradictory material.
17426518_1 (GHMatters) P41939NZ00
Claims (14)
1. Use of N-[5-(3,5-difluorobenzyl)-1H-indazolyl](4-methyl-piperazinyl) (tetrahydro-2H-pyranylamino) benzamide, or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3.
2. The use according to claim 1, wherein said cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.
3. The use according to claim 1 or 2, wherein said cancer is selected from non-small cell lung cancer, neuroblastoma and colorectal cancer.
4. The use according to claim 1 or 2, wherein said cancer is papillary thyroid cancer.
5. The use according to claim 1 or 2, wherein said cancer is pancreatic cancer.
6. The use according to any one of claims 1 to 3, wherein said cancer is colorectal cancer.
7. The use according to any one of claims 1 to 3, wherein said cancer is non-small cell lung cancer.
8. The use according to claim 1, wherein said cancer is mammary analogue secretory carcinoma.
9. The use according to claim 1, wherein said cancer is sarcoma.
10. The use according to any one of claims 1 to 9, wherein said at least one target gene is ROS1.
11. The use according to any one of claims 1 to 9, wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3.
12. The use according to any one of claims 1 to 9 or 11, wherein said at least one target gene is NTRK1.
13. The use according to any one of claims 1 to 9 or 11, wherein said at least one target gene is NTRK2.
14. The use according to any one of claims 1 to 9 or 11, wherein said at least one target gene is NTRK3. 17426518_1 (GHMatters) P41939NZ00
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461942287P | 2014-02-20 | 2014-02-20 | |
US61/942,287 | 2014-02-20 | ||
US201462052994P | 2014-09-19 | 2014-09-19 | |
US62/052,994 | 2014-09-19 | ||
US201462055450P | 2014-09-25 | 2014-09-25 | |
US62/055,450 | 2014-09-25 | ||
US201462069999P | 2014-10-29 | 2014-10-29 | |
US62/069,999 | 2014-10-29 | ||
PCT/EP2015/053544 WO2015124697A1 (en) | 2014-02-20 | 2015-02-19 | Compounds for treating patients with ros1 mutant cancer cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ722405A NZ722405A (en) | 2021-03-26 |
NZ722405B2 true NZ722405B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10682348B2 (en) | Molecules for administration to ROS1 mutant cancer cells | |
US20210113555A1 (en) | Combinations for the treatment of cancer | |
US20190224200A1 (en) | Combinations for the treatment of cancer | |
US10799503B2 (en) | Methods for the treatment of cancer | |
WO2018026663A1 (en) | Combinations for the treatment of cancer | |
EP3758753A1 (en) | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor | |
NZ722405B2 (en) | Compounds for treating patients with ros1 mutant cancer cells |